Document:

Amended and Restated Distribution and License Agreement

 Exhibit 10.35 
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
 AMENDED AND RESTATED DISTRIBUTION AND LICENSE AGREEMENT 
 This Amended and Restated Distribution and License Agreement (hereinafter, the “Restated License
Agreement”), which amends and restates the Distribution and License Agreement, dated as of the 1st day of December, 2005 (hereinafter, as amended to date pursuant to that certain First Amendment, dated as of the 15
th day of May, 2009, the “Original
Agreement”), between XenoPort, Inc., a Delaware corporation having a place of business at 3410 Central Expressway, Santa Clara, CA 95051, United States of America (“XenoPort”), and Astellas Pharma Inc., a Japanese
corporation having a place of business at 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, 103-8411, Japan (“Astellas”), is entered into and made effective as of the 31st day of October, 2009 (the “Restatement Effective
Date”). Each of XenoPort and Astellas shall be a “Party” and, together, the “Parties.” 
 RECITALS 
 A. XenoPort is developing a Transported ProdrugTM of gabapentin (as further defined
below, the “Product”) in the United States, for the treatment of restless legs syndrome (“RLS”) and the management of neuropathic pain; 
 B. Astellas desires to further develop and commercialize the Product in Japan and certain other countries (as further described below, the “Territory”), and XenoPort desires to have the
Product developed and commercialized in the Territory by Astellas, in accordance with this Agreement; 
 C. The Parties have
previously entered into the Original Agreement, pursuant to which XenoPort has granted to Astellas certain exclusive distribution and license rights for the Product in the Territory; 
 D. Astellas now wishes to be responsible for the manufacture of clinical and commercial supplies of the Compound and/or Product and the
Product Formulation (as further defined below) for the development and commercialization of the Product in the Territory; and 
 E. The Parties now wish to amend and restate in its entirety the Original Agreement with this Restated License Agreement. 

 NOW, THEREFORE, the Parties hereby agree as follows: 
 AGREEMENT 
 1. DEFINITIONS 
 1.1 “Affiliates” shall mean, in the case of a subject entity, another
entity that controls, is controlled by or is under common control with the subject entity, for so long as such control exists. For purposes of this definition only, “control” shall mean beneficial ownership (direct or indirect) of at least
fifty percent (50%) of the shares of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, in the election of the corresponding managing authority).
“Subsidiaries” of a subject entity shall mean Affiliates that are controlled by such entity. 
 1.2
“Agreement” shall mean the Original Agreement, as in effect from the Effective Date until the Restatement Effective Date, together with the Restated License Agreement, which replaces the Original Agreement in its entirety as of the
Restatement Effective Date. 
 1.3 “Astellas Know-How” shall mean any and all scientific, medical, technical
and/or regulatory information relating to the Compound and/or the Product and Data, which are owned or Controlled by Astellas as of the Effective Date or during the term of this Agreement, which are needed by or reasonably useful to XenoPort in
order to develop and/or commercialize the Product outside the Territory. Astellas Know-How shall include any developments and improvements relating to the Compound and/or the Product made by Astellas during the term of this Agreement.
Notwithstanding the foregoing, Astellas Know-How shall not include Astellas Manufacturing Know-How. 
 1.4 “Astellas
Manufacturing Know-How” shall mean any and all scientific, medical, technical and/or regulatory information and Data relating to manufacture of the Compound, the Material and/or the Product, which are owned or Controlled by Astellas as of
the Effective Date or during the term of this Agreement, which are needed by or reasonably useful to XenoPort in order to manufacture the Product outside the Territory. Astellas Manufacturing Know-How shall include any developments and improvements
relating to manufacture of the Compound, the Material and/or the Product made by Astellas during the term of this Agreement. 
 1.5 “Batch” means a specific quantity of Compound comprised of a number of units as set forth in the applicable master batch record(s), and that (a) is intended to have uniform character and quality within its
specifications and (b) is produced according to a single production order during the same cycle of production. 
 1.6
“Competitive Compound” shall mean any compound having as a primary mechanism of action [... * ...], other than the Compound. For avoidance of doubt, Competitive Compound shall not include any compound that has a
mechanism of action [... * ...]; provided, however, that such compound [... * ...] by either Party, including without limitation RLS and painful diabetic neuropathy. 
 1.7 “Compound” shall mean that certain compound, referred to internally at XenoPort as XP13512, the structure of which is
set forth in Exhibit A, and all isomers and/or mixtures of isomers thereof. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 1.8 “Control” shall mean possession of the ability to grant a license
or sublicense, of or within the scope set forth in this Agreement, without violating the terms of any agreement or other arrangement with any Third Party. 
 1.9 “Data” shall mean all preclinical data, clinical data, clinical pharmacology data and all regulatory filings and approvals submitted or obtained, together with its supporting data and
regulatory correspondence and rights to reference the same, in each case pertaining to the Compound and/or the Product, which are Controlled by each Party as of the Effective Date or during the term of this Agreement. 
 1.10 “Diligent Efforts” shall mean the level of efforts required to carry out a particular task or obligation in a
sustained manner, consistent with the efforts generally used by a Party with respect to its own compounds, with the same level of peak sales potential, for which Marketing Approval is being sought as expeditiously as practicable or for which
Marketing Approval has been obtained, as the case may be. 
 1.11 “Effective Date” shall mean December 1,
2005, the effective date of the Original Agreement. 
 1.12 “First Commercial Sale” shall mean the first
bona fide, arm’s length sale of a Product in a country following receipt of Marketing Approval of such Product in such country; provided that where such a first sale has occurred in a country for which government pricing or government
reimbursement approval is needed and Astellas chooses to apply for such approval, then such sales shall not be deemed a First Commercial Sale until such pricing or reimbursement approval has been obtained.
 1.13 “Field” shall mean any and all indications for human use. 
 1.14 “GSK” shall mean Glaxo Group Limited, a company existing under the laws of England and Wales (d/b/a GlaxoSmithKline),
having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, and its Affiliates. 
 1.15 “GSK Agreement” shall mean the License and Services Agreement dated September 24, 2009 between Astellas and GSK. 
 1.16 “IND” shall mean an Investigational New Drug application filed with the U.S. Food and Drug Administration (“FDA”), or a comparable filing in the Territory.

 1.17 “Lonza” shall mean Lonza Ltd., a company existing under the laws of Switzerland, having a place of
business at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland, and its Affiliates, including Lonza Japan Ltd. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 1.18 “MAA” shall mean a New Drug Application filed with the FDA (or, in the
Territory, a marketing authorization application comparable to such New Drug Application), including all supporting documentation and data required for such application to be accepted for review, filed with the FDA or counterpart health regulatory
agency, requesting approval for commercialization of a product for a particular indication in such country. 
 1.19
“Marketing Approval” shall mean, with respect to the United States or in the Territory, approval by the health regulatory agency in such country that is the counterpart of the FDA of the MAA for a product filed in such country. It
is understood that, as used herein, Marketing Approval does not include pricing or reimbursement approval. 
 1.20
“Material” shall mean analogues, metabolites, impurities, degradates and radio-labeled compounds and standard materials, i.e., defined, highly purified compound for the purposes of conducting analytical, release and other studies.

 1.21 “Net Sales” shall mean the gross amounts invoiced or otherwise received for sales of the Product by
Astellas, its Affiliates and Subdistributors to Third Parties (but not including sales among Astellas, its Affiliates and their respective Subdistributors) less deductions for: (a) customary trade, quantity and cash discounts allowed and
actually taken; (b) credits to customers on account of return of Product; (c) [... * ...] of such gross amount to cover outbound transportation charges, including insurance, freight and packaging; and (d) sales and excise
taxes and duties and any other similar governmental charges imposed upon the sale of Product to the customer. Notwithstanding the foregoing, the amounts described in (c) and (d) above shall be deducted only to the extent they are stated
separately on the invoice and included within gross amounts received from sales of the Product. If a Product is sold for consideration other than solely cash, the monetary value of such other consideration shall be included in the calculation of Net
Sales. 
 1.22 “Patheon” shall mean Patheon Pharmaceuticals Inc, a Delaware corporation, having a place of
business at 2110 East Galbraith Road, Cincinnati, Ohio 45237-1625. 
 1.23 “Phase III Trial” shall mean human
clinical trial(s), the principal purpose of which is to establish safety and efficacy of the Product against the disease being studied as required in 21 C.F.R. §312.21(c) or a similar clinical study in a country other than the United States.
For clarity, a Phase III Trial shall also include any other human clinical trial intended as a pivotal trial for filing an MAA, whether or not such trial is a traditional Phase III Trial. 
 1.24 “Product” shall mean (a) the pharmaceutical product containing the Compound that is the subject of IND Nos.
68,341 and 71,352 (the “Existing Product”), and (b) any changes to the formulation, dosage form or other aspects of the Existing Product established by the Parties pursuant to Section 4.3 or otherwise, provided that the
result remains a pharmaceutical product containing the Compound, alone or in combination with other active ingredients. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 1.25 “Product Formulation” shall mean all processes and activities
typically engaged in by a person or entity in the pharmaceutical industry for formulation and packaging of: (a) placebo tablets; and (b) the Product from the Compound; including, without limitation, vendor selection, contract negotiation,
vendor management, scheduling, manufacturing process and formulation development, validation and scale-up, coating, packaging, labeling and shipping, storage, quality control and assurance, release testing, process improvement and support for
inspections. 
 1.26 “Product Trademark” shall mean the trademark identified by XenoPort for the Product in the
Territory, or another mutually agreed trademark for the Product.
 1.27 “Regulatory Authority” shall mean any
national (e.g., the FDA or MHLW), supra-national (e.g., the European Commission, the Council of the European Union or the EMEA), or other governmental entity in any jurisdiction of the world involved in the granting of Marketing Approval for
pharmaceutical products. 
 1.28 “Subdistributor” shall mean an entity to whom Astellas has granted directly or
indirectly the right to market, distribute and/or promote, a Product in the Territory in accordance with Section 2.3. For avoidance of doubt, “Subdistributor” shall not include a wholesaler who is not primarily responsible for
marketing and promoting the Product for its respective territory or customer group. 
 1.29 “Territory” shall
mean Indonesia, Japan, Korea, Philippines, Taiwan and Thailand. 
 1.30 “Third Party” shall mean any person or
entity other than Astellas, XenoPort and their Affiliates.
 1.31 “Valid Claim” means (a) a claim of any
issued, unexpired patent rights which has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken
within the time allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; and (b) a claim in any patent application pending with an administrative patent
authority unless the application has been (i) abandoned, or (ii) rejected by the relevant patent authority and all options for appeal to the relevant administrative patent authority for further prosecution of such claim have been
exhausted. 
 1.32 “XenoPort Patent Rights” shall mean all issued, unexpired patents and all reissues,
renewals, re-examinations and extensions thereof, and patent applications therefor, and any divisions or continuations, in whole or in part, thereof, including those patents and applications set forth in Exhibit B, which would, but for the license
granted hereunder, be infringed by use, development, manufacture, formulation, packaging, import, sale, distribution, promotion or marketing of the Compound and/or the Product by

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
Astellas, any of its Affiliates or Subdistributors in the Territory (and countries outside the Territory, to the extent the Compound and/or the Product is manufactured, formulated or packaged
pursuant to Section 2.2 in such countries, or where Astellas conducts or, requests XenoPort to conduct, development activities in such countries pursuant to Section 4.7), to the extent Controlled by XenoPort as of the Effective Date or
during the term of this Agreement. 
 1.33 “XenoPort Know-How” shall mean any and all scientific, medical,
technical and/or regulatory information relating to the Compound and/or the Product and Data, which are owned or Controlled by XenoPort as of the Effective Date or during the term of this Agreement, which are needed by or reasonably useful to
Astellas in order for Astellas to perform its obligations under this Agreement. XenoPort Know-How shall include any developments and improvements relating to the Compound and/or the Product made by XenoPort during the term of this Agreement.

 In addition, the following terms shall have the meaning described in the corresponding section of this Agreement. Other terms
may be defined throughout the Agreement. 
  

									
	 Term
	  	 Section
	  	 	  	 Term
	  	 Section

	accepted	  	6.2.3	  		  	Infringement Action	  	10.3
	Acquisition	  	2.4.2	  		  	Infringing Product	  	10.4
	Affected Area	  	16.2	  		  	JAMS	  	17.2
	Annual Net Sales	  	7.1	  		  	Joint Development Committee, JDC	  	3.2
	Astellas	  	Preamble	  		  	Joint Steering Committee, JSC	  	3.1
	Astellas Development Plan	  	4.2.2	  		  	Liabilities	  	14.1
	Astellas Indemnitees	  	14.2	  		  	M&A Acquired Product	  	2.4.2
	Change of Control	  	2.4.2	  		  	[... * ...]	  	
	[... * ...]	  		  		  	[... * ...]	  	
	Commercialization Plan	  	5.1.1	  		  	[... * ...]	  	
	completion	  	6.2.2	  		  	Original Agreement	  	Preamble
	Confidential Information	  	12.1	  		  	Party, Parties	  	Preamble
	CMC Information	  	13.2.4	  		  	Panel	  	17.2.1
	Damages	  	10.3	  		  	Product Liability Claim	  	14.4
	DMF	  	4.5	  		  	Product Materials	  	16.2.5
	Enforcement Action	  	10.4	  		  	Recall Costs	  	8.2
	Existing Product	  	1.24	  		  	[... * ...]	  	
	Fault of Astellas	  	8.2	  		  	Restated License Agreement	  	Preamble
	Fault of XenoPort	  	8.2	  		  	Restatement Effective Date	  	Preamble
	FDA	  	1.16	  		  	RLS	  	Preamble
	Force Majeure	  	18.2	  		  	Royalty Rate	  	7.1
	Generic Product	  	7.3.3	  		  	second indication	  	6.2.7(a)
	Improvements	  	10.1	  		  	Subsidiaries	  	1.1
	Indemnitee, Indemnitor	  	14.3	  		  	third indication	  	6.2.7(b)
	Third Party Claim	  	14.1	  		  	Written Disclosure	  	12.4
	Third Party IP	  	2.5	  		  	XenoPort	  	Preamble
	Third Party Royalties	  	7.3.1	  		  	XenoPort Indemnitees	  	14.1
	Wind-down Period	  	16.2.1(b)	  		  	[... * ...]	  	

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 2. GRANT OF DISTRIBUTION RIGHTS AND LICENSE 
 2.1 Appointment. During the term of this Agreement, XenoPort appoints Astellas, and Astellas hereby accepts such appointment, as
the exclusive (even as to XenoPort) distributor and marketer of the Product in the Territory. 
 2.2 License. Subject to
the terms and conditions of this Agreement, XenoPort hereby grants to Astellas an exclusive license during the term of this Agreement under the XenoPort Patent Rights and XenoPort Know-How to: (a) formulate, have formulated, package and have
packaged the Product using the Compound; and (b) develop, make, have made, use, market, import, export, sell, distribute and promote the Compound and the Product; in each case for use in the Field. Such license shall be limited solely to the
Territory, except that Astellas has the non-exclusive right to make, have made, formulate and have formulated the Compound, formulate and have formulated the Product, and package and have packaged the Product, outside the Territory, in each case
solely for sale of the resulting Product within the Territory. The rights and licenses in Section 2.2(a) and 2.2(b) shall be exclusive even as to XenoPort, except with respect to [... * ...] in accordance with [... *
...] 
 2.3 Subdistributors. Astellas shall have the right to engage its Subsidiaries as Subdistributors of the
Product, and may grant sublicenses under Section 2.2 to such Subsidiaries solely for such purposes, solely for as long as such entity remains a Subsidiary. Astellas may otherwise engage Subdistributors and grant sublicenses only upon the
approval of XenoPort, which approval shall not be unreasonably withheld or delayed. In any event, Astellas shall ensure that all of its Subdistributors are bound by a written agreement containing provisions as protective of the Product and XenoPort
as this Agreement. Without limiting the foregoing, in the event that Products supplied by Astellas to a Subdistributor are being directly or indirectly sold or used outside the Territory, Astellas agrees that, upon becoming aware of such sale or use
or otherwise upon the request of XenoPort, it shall not supply further quantities of Products to such Subdistributor. 
 2.4
No Conflict.
 2.4.1 Competitive Compounds. In the event that Astellas and its Affiliates shall, by themselves or
through any Third Party(ies): (a) [... * ...] (b) [... * ...], prior to [... * ...] anywhere in the world [... * ...] regarding a product containing Competitive Compound(s), [... *
...] with the Product, [... * ...] XenoPort under this Section 2.4.1 and XenoPort shall [... * ...]. 
 2.4.2 Notice of M&A Acquired Product. In the event of a Change of Control or Acquisition, whereby [... * ...] prior to such Change of Control [... * ...] and whether
Astellas or its Affiliate [... * ...] above. In the event Astellas [... * ...] as the case may be, shall not apply with respect to [... * ...]. However, in such event, unless XenoPort and Astellas [... *
...] upon written notice,

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
which shall be [... * ...] and XenoPort shall [... * ...]. In the event Astellas [... * ...] fully apply with respect to [... * ...]. As used
herein, “Change of Control” means (a) a merger involving Astellas, in which the shareholders of Astellas immediately prior to such merger cease to control (as defined in Section 1.1) Astellas after such merger, (b) a
sale of all or substantially all of the assets of Astellas to an acquiring entity or (c) a sale of a controlling (as defined in Section 1.1) interest of Astellas to an acquiring entity. As used herein, “Acquisition” means
(a) a merger involving Astellas, in which the shareholders of Astellas immediately prior to such merger does not cease to control (as defined in Section 1.1) Astellas after such merger, or a merger involving an Affiliate of Astellas in
which the resulting entity remains an Affiliate of Astellas after such merger, (b) an acquisition of all or substantially all of the assets of an acquired entity by Astellas or an Affiliate or (c) a sale of a controlling (as defined in
Section 1.1) interest of an acquired entity to Astellas or an Affiliate. 
 2.4.3 Ex-Territory; No Exploitation except
as Licensed. Except as provided in Section 2.2, neither Astellas nor its Affiliates will develop, file for Marketing Approval with respect to, use, make, have made, market, import, export, distribute, promote or sell the Compound and/or
Product anywhere in the world, except in the Territory, and, within the Territory, only in accordance with and under this Agreement. Astellas agrees that it and its Affiliates shall not use nor otherwise exploit XenoPort Patent Rights, XenoPort
Know-How and the Product Trademark, except as licensed in this Agreement. 
 2.4.4 Sale of Compounds Only as Part of
Products. Astellas agrees that it shall not, and shall ensure that its Affiliates and Subdistributors do not, sell or otherwise make commercially available the Compound, other than as part of a Product. This Section 2.4.4 shall not,
however, prohibit sales of Compounds among Astellas, its Affiliates and/or Subdistributors, provided that such Compounds will be incorporated into Products for resale by such entities, nor prohibit Astellas, its Affiliates and/or Subdistributors
from exercising their rights under Section 2.2 to “have” formulated or “have” packaged the Compound. 
 2.4.5 Wind-down Period. For avoidance of doubt, Sections 2.4.1 and 2.4.2 shall not apply during the Wind-down Period with respect to the Affected Area. 
 2.5 XenoPort IP Acquired after the Effective Date. If, after the Effective Date, XenoPort acquires from a Third Party subject matter within the XenoPort Patent Rights and XenoPort Know-How
(“Third Party IP”) that is subject to royalty or other payment obligations to such Third Party, then the following shall apply. The licenses granted under Section 2.2 above with respect to such Third Party IP shall be subject
to Astellas promptly reimbursing XenoPort for any milestones, royalties or other amounts that become owing to such third party by reason of Astellas’ exercise of rights granted in this Agreement with respect to the Third Party IP. Upon request
by Astellas, XenoPort shall disclose to Astellas a true, complete and correct written description of such payment obligations, and Astellas’ obligation to reimburse such amounts following such request shall be limited to those payment
obligations

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
as so disclosed by XenoPort. In the event Astellas does not promptly reimburse XenoPort for such amounts upon request, then such Third Party IP shall thereafter be deemed excluded from the
XenoPort Patent Rights and XenoPort Know-How hereunder. The reimbursement made by Astellas to XenoPort under this Section 2.5 may then be treated by Astellas as Third Party Royalty payments under Section 7.3.1 below. 
 2.6 No Other Rights; No License to Other Therapeutically Active Components. Except for the rights and licenses expressly granted in
this Agreement, each Party retains all rights under its intellectual property, and no additional rights shall be deemed granted to the other Party by implication, estoppel or otherwise. The licenses and rights granted in this Agreement shall not be
construed to convey any licenses or rights under the XenoPort Patent Rights with respect to any active ingredients other than the Compound. 
 3. GOVERNANCE 
 3.1 Joint Steering Committee. The Parties
shall establish a committee (the “Joint Steering Committee” or “JSC”) to oversee the Party’s collaboration relating to the Product in the Territory. The JSC will consist of two (2) representatives from
each Party, each of whom shall be a senior executive of a Party. In case a representative of a Party is unavailable for a scheduled JSC meeting, upon reasonable notice to the other Party, such Party may substitute in place of such representative for
such meeting, a competent person who is authorized by such Party to act on matters that will be presented to the JSC at such meeting. 
 3.1.1 Meetings. The JSC shall meet at least once annually during the term of this Agreement, unless otherwise agreed by the Parties. Such meeting(s) shall be in person at least once per year, alternating between the facilities of
each Party unless otherwise mutually agreed, and the other meetings may be through telephone or video conference or other mutually agreeable means. At the discretion of each Party, other representatives of XenoPort or Astellas may attend JSC
meetings as non-voting observers. Each Party shall bear its own personnel and travel costs and expenses relating to JSC meetings. 
 3.1.2 Responsibility. The JSC will (a) serve as a forum for keeping each Party informed as to material matters in connection with the development, manufacturing and commercialization of the Product in and outside of the
Territory, (b) provide strategic direction to the JDC, (c) resolve any disputed matters submitted to the JSC by the JDC under Section 3.2.3 below, (d) review and discuss the Commercialization Plan, any updates, modifications and
additions thereto submitted to the JSC pursuant to Section 5.1.1 below, and the progress of Astellas thereunder and (e) undertake and/or approve such other matters as are provided for the JSC under this Agreement, or otherwise agreed by
the Parties. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 3.1.3 Decisions. The objective of the JSC shall be [... * ...] on the
JSC. If the JSC cannot reach agreement on any determination or decision for which it is responsible within [... * ...] after the date such matter was initially referred to the JSC, the dispute shall be referred to [... *
...] to resolve the dispute. If, [... * ...] deciding vote with respect to [... * ...], unless the matter (a) would materially adversely affect [... * ...], (b) would change [... *
...], (c) would involve [... * ...] or [... * ...], or (d) involves [... * ...] for the Compound and/or Product in the Territory. It is understood that the JSC shall [... * ...].
If the Parties are unable to resolve a dispute with respect to matters described in Sections 3.1.3(a), (b), (c) or (d), the Parties shall [... * ...] and until such resolution, neither Party shall proceed with a course of action
that is claimed to fall within Sections 3.1.3(a) through (d) above. 
 3.2 Joint Development Committee. The
Parties shall establish a committee (the “Joint Development Committee” or “JDC”) to oversee the development efforts relating to the Product in the Territory. The JDC will consist of three (3) representatives
from each Party, at least one of whom shall be a senior executive of each Party. In case a representative of a Party is unavailable for a scheduled JDC meeting, upon reasonable notice to the other Party, such Party may substitute in place of such
representative for such meeting, a competent person who is authorized by such Party to act on matters that will be presented to the JDC at such meeting. 
 3.2.1 Meetings. The JDC shall meet once each calendar quarter until the first filing of MAA with respect to the Product in the Territory, and twice annually thereafter, during the term of this
Agreement, unless otherwise agreed by the Parties. Such meetings shall be in person at least twice per year until the first filing of MAA with respect to the Product in the Territory, alternating between the facilities of each Party unless otherwise
mutually agreed, and the other meetings may be through telephone or video conference or other mutually agreeable means. With the consent of the JDC members, other representatives of XenoPort or Astellas may attend JDC meetings as non-voting
observers. Each Party shall bear its own personnel and travel costs and expenses relating to JDC meetings. 
 3.2.2
Responsibility. The JDC will (a) review and approve the Astellas Development Plan, including the initial Astellas Development Plan pursuant to Section 4.2.2 and any updates, modifications or additions thereto submitted to the JDC
pursuant to Section 4.2.3 below, (b) oversee the implementation of the Astellas Development Plan, (c) review and approve protocols for any clinical trials of Product in the Territory, (d) review and approve the translated
summaries of any regulatory filings for Products in the Territory (including the precise wording of the label), which shall be provided by Astellas to the JDC in the English language, (e) facilitate the exchange of Data and other information
and/or materials between the Parties, (f) review and approve manufacturing plans for the Compound and the Product and (g) undertake and/or approve such other matters as are provided for the JDC under this Agreement or otherwise agreed by
the Parties. 
 3.2.3 Decisions. Decisions of the JDC shall be by unanimous approval of its members, with at least one
(1) representative of each of Astellas and XenoPort voting on the matter; provided, however, if the JDC cannot reach agreement on a matter within [... * ...] after the date such matter was initially referred to the JDC, the dispute
shall be referred to the JSC who shall meet promptly and negotiate in good faith to resolve the dispute in accordance with Section 3.1.3 above. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 3.3 Limited Authority. Notwithstanding the creation of the JSC and JDC, each
Party shall retain the rights, powers and discretion granted to it hereunder, and the JSC and JDC shall not be delegated or vested with such rights, powers or discretion unless such delegation or vesting is expressly provided herein or the Parties
expressly so agree in writing. The JSC and JDC shall not have the power to amend or modify this Agreement, and its decisions shall not be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be
formally decided by the JSC and JDC are only those specific issues that are expressly provided in this Agreement to be decided by the JSC and JDC. 
 4. DEVELOPMENT 
 4.1 Development. 
 4.1.1 Subject to oversight by the JDC, Astellas shall be responsible for: (a) conducting, and shall use Diligent Efforts to conduct,
such clinical trials and to obtain such regulatory approvals, including Marketing Approvals and pricing and/or reimbursement approval, as may be necessary to commercialize the Product in each country in the Territory, in accordance with the Astellas
Development Plan; and (b) manufacturing, and shall use Diligent Efforts to manufacture, Compound and Product necessary to support such clinical trials and regulatory approvals, including Marketing Approvals and pricing and/or reimbursement
approval, as may be necessary to commercialize the Product in each country in the Territory. Without limiting the foregoing, Astellas agrees to use Diligent Efforts to conduct such clinical trials and to obtain, as soon as practical, Marketing
Approval of the Product for RLS and painful diabetic neuropathy in the Territory. Astellas agrees to keep XenoPort reasonably informed as to the progress of its clinical development, manufacturing and regulatory activities relating to the Product in
the Territory, including its correspondence and meetings with regulatory agencies, by way of updates to the JDC at its meetings and as otherwise reasonably requested by XenoPort. Astellas agrees to reasonably consider and promptly respond to any
comments provided by XenoPort with respect to such clinical development and regulatory activities. It is understood and agreed that all development and manufacturing efforts for the Product in the Territory shall be at the sole cost and expense of
Astellas, and shall be conducted in accordance with the Astellas Development Plan described below. 
 4.1.2 XenoPort or its
licensee(s) shall be responsible for all development, manufacturing and regulatory activities of the Product outside the Territory. XenoPort agrees to keep Astellas reasonably informed as to the progress of its and/or [... * ...] its
other licensees’ clinical development, manufacturing and regulatory activities relating to the Product outside the Territory, including their correspondence and meetings with regulatory agencies, by way of updates to the JDC at its meetings and
as otherwise

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
reasonably requested by Astellas. XenoPort agrees to reasonably consider and promptly respond to any comments provided by Astellas with respect to such clinical development, manufacturing and
regulatory activities. It is understood and agreed that all development efforts for Product outside the Territory shall be at the sole cost and expense of XenoPort, its Affiliates or its other licensee(s), provided that any development efforts
conducted for the Territory requested by Astellas pursuant to Section 4.7 shall be at the sole cost and expense of Astellas. 
 4.2 Astellas Development Plan. 
 4.2.1 An initial, preliminary development plan for Astellas’ development
of the Product in the Territory is set forth in Exhibit C. For avoidance of doubt, such initial, preliminary development plan is not intended to create or constitute any legally binding obligation among the Parties. 
 4.2.2 Within [... * ...] after the Effective Date, the JDC shall discuss and approve the plan for Astellas’ development
of the Product in the Territory (the “Astellas Development Plan”). Astellas acknowledges and agrees that each Party desires that Astellas commit to conduct development of the Compound and/or Product in the Territory for both the RLS
and painful diabetic neuropathy indications, in a manner to be described by the JDC in the Astellas Development Plan; and the JDC shall, during the discussion of such development, take into account an expected selling price of the Product, expected
launch time for respective indications, communications with the Regulatory Authority in the Territory, advice of the experts in the Territory, possibility of bridging use of the Data obtained by XenoPort from its pre-clinical studies and/or clinical
trials of the Product outside the Territory for development in the Territory and any other relevant regulatory and business matters. 
 4.2.3 Astellas agrees to provide to the JDC for its review and approval, which approval shall not be unreasonably withheld or delayed, updated versions of the Astellas Development Plan at least annually, and any modification or addition to
the Astellas Development Plan within a reasonable period of time prior to adoption and implementation thereof. 
 4.3 Change
in Formulation. Before modifying or creating a new formulation or dosage form of the Product, or developing the Compound in combination with another active ingredient, Astellas shall discuss the proposed modifications or development with
XenoPort at the JSC and obtain the approval of the JSC, which approval shall not be unreasonably withheld or delayed. Subject to Section 3.1.3(b), XenoPort agrees that Astellas may conduct formulation studies on the Compound that were so
discussed and approved by the JSC for the purpose of developing and commercializing pharmaceutical formulations of the Compound as a sole active ingredient. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 4.4 Exchange of Data and Know-How. Promptly after the Effective Date, XenoPort shall
provide Astellas with any and all XenoPort Know-How that XenoPort considers as necessary or reasonably useful for Astellas to develop and/or commercialize the Product in the Territory, including but not limited to, any and all Data from any and all
clinical trials and preclinical studies of the Compound and/or Product that are completed as of the Effective Date. During the term of this Agreement, each Party shall provide to the other Party all Data (and, in case of XenoPort, any and all
additional XenoPort Know-How, and in the case of Astellas, any and all Astellas Know-How and Astellas Manufacturing Know-How) Controlled by such Party, (a) that such Party considers as necessary or reasonably useful for the other Party to
develop and/or commercialize the Product in the Territory (in the case of Astellas) or outside the Territory (in the case of XenoPort), in a timely fashion and as promptly as possible or (b) upon the reasonable request of the other Party; in
each case, for use by such other Party in accordance with this Section 4.4. Promptly after May 15, 2009, XenoPort shall disclose to Astellas any and all undisclosed Data and XenoPort Know-How relating to manufacture of the Compound, the
Material and the Product and Product Formulation that is Controlled by XenoPort (the “XenoPort Manufacturing Know-How”). XenoPort shall grant Astellas, its Affiliates or Third Parties the right to use the XenoPort Manufacturing
Know-How for the sole purpose of developing and commercializing the Product in the Territory and under reasonable and customary confidentiality restrictions. 
 4.4.1 Use; Disclosure. Astellas will use and disclose Data, XenoPort Know-How and XenoPort Manufacturing Know-How to its Affiliates or Third Parties only as required to obtain Marketing
Approval for the Product in the Territory and/or as may be necessary in performing its obligations and exercising its rights under this Agreement (including, but not limited to, the use of such Data, XenoPort Know-How and XenoPort Manufacturing
Know-How to manufacture clinical and commercial supplies of Compound and/or Product pursuant to Section 8 and to design development activities outside the Territory for Section 4.7), in each case solely to the extent necessary for
development and commercialization of the Product in the Territory and under reasonable and customary confidentiality restrictions. Astellas may not use any Data, XenoPort Know-How or XenoPort Manufacturing Know-How (or permit any Affiliates or Third
Party to use Data, XenoPort Know-How or XenoPort Manufacturing Know-How) outside the Territory (other than pursuant to Sections 4.7 and 8.1), nor for any products other than the Product. XenoPort may only use, and disclose to Affiliates and Third
Parties, Data, Astellas Know-How and Astellas Manufacturing Know-How provided by Astellas as is reasonably necessary or useful for developing, manufacturing and/or commercializing the Product outside the Territory, including for cross-referencing
drug master files or other regulatory filings by XenoPort, its Affiliates or Third Parties, provided that the disclosure of such Data, Astellas Know-How and Astellas Manufacturing Know-How to a non-governmental Third Party is made under reasonable
and customary confidentiality restrictions, and complies with Section 4.4.2 below. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 4.4.2 Other Licensee(s). XenoPort shall [... * ...] under this
Section 4.4 [... * ...] to the extent that [... * ...]. It is understood that [... * ...], shall not be [... * ...]. However, XenoPort agrees [... * ...] except to the extent
[... * ...]. Promptly after May 15, 2009, XenoPort shall use [... * ...] that is [... * ...] and under [... * ...]. Promptly after the Restatement Effective Date, XenoPort shall use [...
* ...] that are [... * ...] and under [... * ...]. It is understood that [... * ...], shall not be [... * ...]. 
 4.5 Regulatory Matters. Subject to Section 16.2.2 below, all regulatory filings for the Product, including the MAA and Marketing Approvals, in the Territory shall be in the name of Astellas in
Japan, or its Affiliate(s) or Subdistributor(s) in countries other than Japan. Astellas shall, or shall cause its Affiliate(s) or its Subdistributor(s) to, be responsible for the filing thereof, the payment of fees and all other associated costs,
for monitoring clinical experiences and filing associated reports and fulfilling all of its regulatory obligations throughout the development and commercialization of the Product in the Territory. Notwithstanding the foregoing, XenoPort may, and if
elected by XenoPort shall be responsible to, file and keep a Drug Master File (“DMF”) in the Territory at its expense in its own name or in the name of its suppliers with respect to the bulk supply of the Compound and shall permit
Astellas, its Affiliates and its Subdistributors to cross-reference such DMF in their regulatory filings for the Product in the Territory. 
 4.6 Development within the Territory. Astellas shall commence, promptly after the Effective Date, its development of the Product in Japan in accordance with this Section 4. The Parties
recognize, however, that Astellas’ development and commercialization of the Product in countries of the Territory other than Japan may not be achieved, if ever, until a later date as is customary for pharmaceutical launches in Asia, and may
depend upon (a) whether the Data obtained by XenoPort and/or by Astellas from their respective pre-clinical studies and/or clinical trials of the Product may be used for obtaining Marketing Approval of the Product in such country(ies) and
(b) whether commercialization of the Product in such country(ies) would be commercially feasible under the terms and conditions of this Agreement. Subject to the foregoing, a decision by Astellas not to develop and/or commercialize a Product in
a country of the Territory other the Japan shall not by itself be deemed a breach of its obligations to use Diligent Efforts under this Agreement with respect to such country, provided that Astellas can and does promptly terminate this Agreement
with respect to such country pursuant to Section 15.2 below. 
 4.7 Cooperation in Development. The Parties
acknowledge that, from time to time, Astellas may, or may request XenoPort to, conduct activities outside the Territory (for example, to conduct certain clinical trials in the United States on Japanese subjects) for use in obtaining Marketing
Approval of the Product in the Territory. Any activities outside the Territory conducted or requested by Astellas pursuant to this Section 4.7 shall be subject to the consent of XenoPort, which consent shall not be unreasonably withheld or
delayed. Subject to such consent, XenoPort shall cooperate as mutually agreed to perform such activities, the cost of which shall be reimbursed by Astellas (including without limitation payment of the supply price of the clinical supplies used in
such activities, in accordance with any supply agreement between the Parties then in effect). 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 4.8 Astellas Know-How and Astellas Manufacturing Know-How. All results, data,
information, know-how and technology obtained by Astellas or its Affiliates in the course of development or manufacturing activities with respect to the Compound and/or the Product conducted by Astellas or any of its Affiliates shall be solely owned
by Astellas or such Affiliates. Subject to Section 2.3(a) of the GSK Agreement and Sections 4.4 and 10.1 of this Agreement, during the term of this Agreement, Astellas shall solely own or Control all right, title and interest in and to the
know-how and technology owned or Controlled by Astellas which Astellas may decide to use for manufacturing the Compound and Product or modifying or creating a new formulation or dosage form of the Product in accordance with Section 4.3.

 5. COMMERCIALIZATION 
 5.1 Commercialization.
 5.1.1 Subject to oversight by the JSC, Astellas
shall be responsible for: (a) launching and commercializing, and shall use Diligent Efforts to launch and commercialize, the Product in each country in the Territory in accordance with a commercialization plan submitted by Astellas to the JSC
(“Commercialization Plan”); and (b) manufacturing, and shall use Diligent Efforts to manufacture, the Compound and Product necessary to support the launching and commercialization of the Product in each country in the Territory
in accordance with the Commercialization Plan. Without limiting the foregoing, Astellas agrees to use Diligent Efforts to launch the Product as soon as practicable in the Territory, and thereafter to manufacture, market, promote and sell such
Product and to maximize the Net Sales of the Product in the Territory. Astellas agrees to provide to the JSC updated versions of the Commercialization Plan at least annually, and any material modification or addition to the Commercialization Plan
within a reasonable period of time prior to adoption and implementation thereof. Astellas shall keep XenoPort reasonably informed as to the progress of its launch, manufacturing and commercialization activities relating to the Product in the
Territory, by way of updates to the JSC at its meetings and as otherwise reasonably requested by XenoPort. It is understood and agreed that, subject to oversight by the JSC, and consistent with the other provisions of this Agreement, all
commercialization and manufacturing efforts for the Product in the Territory shall be at the sole discretion and expense of Astellas, its Affiliates or Subdistributors. 
 5.1.2 XenoPort or its licensee(s) shall be responsible for launching, manufacturing and commercializing the Product outside the Territory. XenoPort shall keep Astellas reasonably informed as to the
progress of its and/or [... * ...] its other licensees’ launch, manufacturing and commercialization activities relating to Product outside the Territory, by way of updates to the JSC at its meetings and as otherwise reasonably
requested by Astellas but no more often than once annually other than at the JSC meeting. It is understood and agreed that all manufacturing and commercialization efforts for the Product outside the Territory shall be at the sole discretion and
expense of XenoPort, its Affiliates or its other licensees. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 5.2 Marketing Materials. Any marketing and promotional materials created or used by
Astellas, its Affiliates and Subdistributors for the Product shall be appropriate to the Marketing Approval for the Product in the respective country and consistent with XenoPort’s worldwide profile for the Product, provided that XenoPort shall
respect local marketing needs in the Territory regarding such materials (e.g., the size of letters in such materials). In addition, it is understood that any claim, message or other material part of promotional materials, samples, advertising and
materials for training sales representatives with respect to Product shall be consistent with Marketing Approval and comply with applicable laws. 
 5.3 Reporting Adverse Drug Reactions/Experiences. Promptly following the Effective Date, the Parties will prepare a standard operating procedure governing the collection, investigation, reporting
and exchange of information concerning adverse drug reactions, Product quality and Product complaints, sufficient to permit each Party to comply with its legal obligations. The standard operating procedure will be promptly updated if required by
changes in legal requirements. Each Party shall keep the other Party informed about any adverse drug reactions of which such Party becomes aware or is informed regarding the use of a Product in or outside the Territory. As between the Parties,
Astellas shall be responsible for reporting all adverse drug reactions/experiences to the appropriate regulatory authorities in countries in the Territory, and XenoPort shall be responsible for reporting all adverse drug reactions/experiences to the
appropriate regulatory authorities in countries outside the Territory, in accordance with the appropriate laws and regulations of the relevant countries and authorities. Astellas shall ensure that its Affiliates and Subdistributors comply with such
reporting obligations in the Territory, and XenoPort shall ensure that its Affiliates and licensees (other than Astellas, its Affiliates and Subdistributors) comply with such reporting obligations outside the Territory. These reporting obligations
shall apply to non-serious adverse events as well, which shall mean adverse events occurring from Product overdose or from Product withdrawal, as well as any toxicity, sensitivity, failure of expected pharmacological action or laboratory abnormality
that is, or is thought by the reporter to be, serious or associated with relevant clinical signs or symptoms. Each Party will designate a regulatory affairs liaison to be responsible for communicating with the other Party regarding the reporting of
adverse drug reactions/experiences. The details of such exchange shall be separately discussed and agreed upon in writing by and between such regulatory affairs liaisons within a reasonable period after execution of this Agreement. 
 6. INITIAL PAYMENT AND MILESTONES 
 6.1 Initial Payment. In partial consideration of the costs incurred by XenoPort in connection with the research and development of the Product and in exchange for the exclusive rights granted
herein, Astellas shall pay XenoPort Twenty Five Million Dollars (US $25,000,000) within [... * ...] after execution of this Agreement. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 6.2 Milestones. In further consideration of the costs incurred by XenoPort in
connection with the research and development of the Product and in exchange for the exclusive rights granted herein: 
 6.2.1
Initiation of U.S. Phase III Trial. Upon the first dosing of a human patient in a Phase III Trial of the Compound and/or Product in the United States by or under authority of XenoPort, the date of which XenoPort shall inform Astellas in
writing, Astellas shall pay XenoPort Ten Million Dollars (US $10,000,000). 
 6.2.2 Completion of U.S. Phase III Trial.
Upon the first completion of a Phase III trial of the Compound and/or Product in the United States by or under authority of XenoPort, Astellas shall pay XenoPort Five Million Dollars (US $5,000,000). As used herein, “completion” of a Phase
III trial shall be deemed to occur upon the earliest of (a) receipt by XenoPort of the final report for such Phase III trial, (b) filing of an MAA for the Product or (c) first issuance of a press release by XenoPort or its licensee
announcing completion of a Phase III trial of the Compound and/or Product in the United States, the date of which XenoPort shall inform Astellas in writing. 
 6.2.3 MAA Filing in the United States. Upon first acceptance of a filing of an MAA for the Compound and/or Product in the United States by or under authority of XenoPort, the date of which XenoPort
shall inform Astellas in writing, Astellas shall pay XenoPort Three Million Dollars (US $3,000,000). As used herein, an MAA shall be deemed “accepted” upon the earlier of: (a) the expiration of the period specified in applicable
regulations for any notice by the FDA that such MAA will not be accepted for review, without XenoPort or its designee having received such notice from such agency; or (b) the receipt by XenoPort or its designee from such agency that the MAA
will be accepted for review; provided that in any case, if no such period or acceptance is provided for in the applicable regulations, then the MAA shall be deemed “accepted” on the date such MAA was filed. 
 6.2.4 MAA Filing in Japan. Upon first acceptance of a filing of an MAA for the Compound and/or Product in Japan by or under
authority of Astellas, Astellas shall pay XenoPort [... * ...]. 
 6.2.5 Marketing Approval in the United
States. Upon obtaining the first Marketing Approval of the Compound and/or Product for the first indication in the United States by or under authority of XenoPort, the date of which XenoPort shall inform Astellas in writing, Astellas shall pay
XenoPort [... * ...]. 
 6.2.6 Marketing Approval in Japan. Upon obtaining the first Marketing Approval of
the Compound and/or Product in Japan for the first indication by or under authority of Astellas, Astellas shall pay XenoPort [... * ...]. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 6.2.7 Additional Indications. 
 (a) Second Indication. Upon first acceptance of a filing of an MAA for the Compound and/or Product for a second indication in Japan
by or under authority of Astellas, Astellas shall pay XenoPort [... * ...]. Upon obtaining the first Marketing Approval of the Compound and/or Product for a second indication in Japan by or under authority of Astellas, Astellas shall
pay XenoPort [... * ...]. As used herein, a “second indication” shall mean any indication for which Marketing Approval is obtained, other than the indication triggering payment under Section 6.2.6 above. 
 (b) Third Indication. Upon first acceptance of a filing of an MAA for the Compound and/or Product for a third indication in Japan by
or under authority of Astellas, Astellas shall pay XenoPort [... * ...]. Upon obtaining the first Marketing Approval of the Compound and/or Product for a third indication in Japan by or under authority of Astellas, Astellas shall pay
XenoPort [... * ...]. As used herein, a “third indication” shall mean any indication for which Marketing Approval is obtained, other than the indications triggering payment under Section 6.2.6 and 6.2.7(a) above.

 (c) Subsequent Indications. Astellas shall not be obligated to make any milestone payments with respect to Marketing
Approval for the fourth and subsequent indications of the Compound and/or Product. It is understood that, for purposes of this Section 6.2.7, a single MAA or Marketing Approval may include more than one indication, e.g. both the first and
second indications, or the second and third indications, as the case may be. 
 6.2.8 Timing of Payment. Each payment
provided in Sections 6.2.4, 6.2.6 and 6.2.7 above shall be due within thirty (30) days following the occurrence of each event triggering such payment, and each payment provided in Sections 6.2.1, 6.2.2, 6.2.3 and 6.2.5 shall be due within
thirty (30) days following XenoPort’s notice to Astellas of the event triggering such payment. 
 7. ROYALTY

 7.1 Royalty. In further consideration for the exclusive rights granted herein, during the term of this Agreement,
Astellas shall, subject to the reduction of royalty rate pursuant to Section 7.3 below, pay to XenoPort the royalties as calculated in this Section 7.1 (as determined below, the “Royalty Rate”) on the Net Sales of the
Product in the Territory. Such Royalty Rate shall be determined [... * ...]. The Royalty Rate to be applied to Annual Net Sales shall be calculated as follows: 
 [... * ...] 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 For illustrative purposes only: 
 [... * ...] 
 For the
sake of clarity, subject to Section 7.3: (i) in no event will [... * ...]; and (ii) [... * ...]. 
 As
used herein, “Annual Net Sales” of the Product shall mean the Net Sales of Product(s) sold in the Territory by or under authority of Astellas in each calendar year. 
 In the event that the Product [... * ...], for the purposes of determining royalty payments, shall be [... * ...]. In the event that
 [... * ...], such agreement
not to be unreasonably withheld or delayed. This paragraph shall apply to both this Section 7.1 and Section 7.1.1 below. 
 7.1.1 Non-Japanese Marketing Approval. In the event that the Product receives Marketing Approval in one or more countries in the Territory before receiving Marketing Approval in Japan, Astellas shall, subject to the reduction of
royalty rate pursuant to Section 7.3 below, pay to XenoPort the following running royalties on the Net Sales of the Product in the Territory until the Product receives Marketing Approval in Japan: 
  

			
	Annual Net Sales in the Territory	  	Royalty
	That portion of Annual Net Sales in the Territory up to and including [... *
...]	  	[... * ...] of such Net Sales
	That portion of Annual Net Sales in the Territory above
[... * ...] and up to and including [... * ...]	  	[... * ...] of such Net Sales
	That portion of Annual Net Sales in the Territory above
[... * ...]	  	[... * ...] of such Net Sales

 7.1.2 If the Product subsequently does receive Marketing Approval in Japan, upon
such Marketing Approval in Japan, the Royalty Rate calculation as set forth in Section 7.1 shall apply in lieu of Section 7.1.1. 
 7.2 Intentionally Omitted. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 7.3 Certain Reductions to Royalties. 
 7.3.1 Third Party Royalties. In the event Astellas or its Affiliates is required to pay to a Third Party royalties or any other
amounts under agreements for patent rights, trade secrets or other intellectual property or technology covering the Compound and/or Product (“Third Party Royalties”), then Astellas may deduct [... * ...] of the
Third Party Royalties from those royalties owed to XenoPort pursuant to Section 7.1; provided the royalties paid to XenoPort will not be so reduced to less than [... * ...] of the royalties otherwise due pursuant Section 7.1,
and further provided that neither Sections 7.3.2 nor 7.3.3 applies at the time. For the purposes of Section 7.1 and this Section 7.3, any Third Party royalties or any other amounts under agreements for patent rights, trade secrets or other
intellectual property or technology covering the Compound and/or Product required to be paid by Astellas or its Affiliates [... * ...]. 
 7.3.2 Loss of Exclusivity. On a Product-by-Product and country-by-country basis, after the later of the expiration of (or if there are no) (a) XenoPort Patent Rights or patent rights
Controlled by Astellas containing Valid Claims, which absent a license thereunder, would be infringed by a Third Party selling such Product in such country and/or (b) regulatory exclusivity with respect to such Product, in such country, then
the royalties payable pursuant to Section 7.1 with respect to such Product sold in such country shall thereafter be reduced by [... * ...], provided that Section 7.3.3 below does not apply at the time. For avoidance of doubt,
clause (a) above shall be deemed satisfied when all the patents described in subparagraph (i) below are expired even if any of the patents described in subparagraph (ii) below are unexpired at that time, as applied on a
Product-by-Product and country-by-country basis (i.e., with respect to the Net Sales of such particular Product in such particular country): 
 (i) in the event of expiration of the patents included in XenoPort Patent Rights or patent rights Controlled by Astellas containing Valid Claims, which absent a license thereunder, would be infringed by a
Third Party selling such Product in such country, or if there are no such patent rights in such country, even if 
 (ii) there
are unexpired patents included in XenoPort Patent Rights or patent rights Controlled by Astellas containing Valid Claims, which absent a license thereunder, would NOT be infringed by a Third Party selling such Product in such country. 
 7.3.3 Introduction of Generic Products. On a Product-by-Product and country-by-country basis, in the event that after the occurrence
of both clause (a) and (b) of Section 7.3.2 above, one or more Generic Product(s) are being marketed for an approved indication of such Product in such country; and such Generic Product(s) represent a total number of units of at
least [... * ...] of such Product and such Generic Product(s) for all indications, in the aggregate, in such country in any calendar year, determined by the number of units of such Product and such Generic Product(s) sold to Third
Parties, in the aggregate, during such calendar year (as measured by IMS data or other data agreed upon by the Parties), and Astellas reasonably determines that Astellas is not likely to recover such lost market share; then the royalties payable
pursuant to Section 7.1 with respect to such Product sold in such country shall thereafter be reduced by [... * ...]. “Generic Product” shall mean a [... * ...] being sold in such country in the
Territory, which [... * ...], and is [... * ...]. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 7.3.4 Reductions Not Cumulative. The reductions set forth in this Section 7.3
shall not be cumulative. Notwithstanding anything to the contrary in this Section 7.3, at any time, at most one of Sections 7.3.1, 7.3.2 or 7.3.3 shall apply with respect to any Product in any country. Unless Section 7.3.3 applies, the
royalty payable under this Section 7 shall not be reduced by this Section 7.3 below [... * ...] of the royalties otherwise due pursuant only to Section 7.1 (i.e., without taking into account any of this
Section 7.3). In case Section 7.3.3 applies, the royalties payable under this Section 7 shall not be reduced by this Section 7.3 to below [... * ...] of the royalties otherwise due pursuant to Section 7.1
(i.e., without taking into account any of this Section 7.3). In case Sections 7.3.1 and 7.3.2 apply simultaneously, only Section 7.3.2 shall apply, and in case all three of Sections 7.3.1, 7.3.2 and 7.3.3 apply simultaneously, only
Section 7.3.3 shall apply. 
 7.4 Discounting. Astellas, its Affiliates and Subdistributors shall set prices
and discounts for the Product in the Territory solely in the interest of the commercial success of the Product in the Territory and not for the interest of its other products and services. However, the foregoing shall not be construed to dictate to
Astellas, its Affiliates or Subdistributors any resale prices for the Products in the Territory. 
 7.5 Quarterly
Reports. Commencing with the first occurrence of Net Sales of Product in the Territory, within sixty (60) days after each March 31, June 30, September 30 and December 31 thereafter, Astellas shall deliver to
XenoPort a true and accurate report, giving such particulars of the business conducted by Astellas, its Affiliates and its Subdistributors during the preceding three (3) calendar months as are pertinent to account for payments under this
Section 7. Simultaneously with the delivery of each such report, Astellas shall pay to XenoPort the total amounts, if any, due to XenoPort pursuant to this Section 7 for the period of such report. 
 8. COMPOUND/PRODUCT SUPPLY 
 8.1 Manufacturing and Supply Responsibilities. Contemporaneously with the execution of the Restated License Agreement, the Amended and Restated Non-Commercial Supply Agreement, dated as of
May 15, 2009, by and between the Parties, shall terminate and no longer be in effect. Upon the Restatement Effective Date, subject to the terms and conditions of this Agreement, Astellas shall have the exclusive right and responsibility to
manufacture or have manufactured (including packaging) the Compound, the Material and the Products for both clinical use and commercial distribution in the Territory; except that [... * ...] the Compound, the Material and the Products
[... * ...] the Territory [... * ...]. For the avoidance of doubt, it is understood and agreed that: (i) Astellas shall [... * ...]; (ii) XenoPort shall have no obligation to: (A) [... *
...]; (B) [... * ...]; or (C) [... * ...]; (iii) Astellas shall [... * ...]; and (iv) [... * ...] with respect to the manufacture of the Compound and Products for
distribution [... * ...]. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 8.2 Recalls. To the extent (a) any governmental or regulatory authority issues a
request, directive or order that the Product be recalled or withdrawn in the Territory, (b) a court of competent jurisdiction orders a recall or withdrawal of the Product in the Territory or (c) either Party determines, after consultation
with the other Party, that the Product should be recalled or withdrawn in the Territory, the Parties shall recall or withdraw the Product as set forth in this Section 8.2. As between the Parties, Astellas shall control and coordinate, including
making all contacts with regulatory authorities, all activities it deems necessary in connection with such recall or withdrawal in the Territory. All out-of-pocket expenses related to the execution of any recall or withdrawal of the Product
(“Recall Costs”) shall be shared equally between the Parties, provided that in the case of (c) above, if the Parties do not mutually agree on having the Product recalled or withdrawn, then the Party requesting the recall or
withdrawal shall bear initially the entire expense of such recall or withdrawal; but in each case subject to the final allocation between the Parties as follows. In the event that it is finally determined, or agreed between the Parties, that such
recall or withdrawal is caused by: (a) breach of the representations and warranties of XenoPort set forth in Section 13.2 below, or the gross negligence or willful misconduct of XenoPort, or the failure by XenoPort to comply with
applicable laws and regulations (collectively, the “Fault of XenoPort”) XenoPort shall be responsible for Recall Costs to extent of such Fault of XenoPort, (b) the failure of Astellas to properly perform the manufacturing,
formulation or packaging of the Compound and/or Products, or the gross negligence or willful misconduct of Astellas, or the failure by Astellas to comply with applicable laws and regulations, including its failure to properly file for Marketing
Approval of the Products in the Territory (collectively, the “Fault of Astellas”), Astellas shall be responsible for Recall Costs to the extent of such Fault of Astellas and (c) in all other cases, the Recall Costs shall be
shared by the Parties as follows: [... * ...] shall be borne by Astellas and [... * ...] shall be borne by XenoPort. 
 9. PAYMENTS; BOOKS AND RECORDS 
 9.1 Payment Method. All
payments under this Agreement shall be made by bank wire transfer in immediately available funds to an account designated by the Party to which such payments are due. All dollar amounts specified in this Agreement are in U.S. dollars. Any payments
due under this Agreement that are not paid by the date such payments are due under this Agreement shall bear interest to the extent permitted by applicable law at the prime rate publicly announced by Citibank on the date such payment is due, plus
[... * ...], computed on the basis of a three hundred sixty (360) day year, actual days elapsed. The applicable interest rate shall be adjusted each time there shall be a change in the prime rate announced by Citibank. This
Section 9.1 shall in no way limit any other remedies available to the Parties. All amounts owed by Astellas to XenoPort hereunder shall be paid by a Japanese entity from either a bank account in Japan or the United States. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 9.2 Taxes. If laws or regulations require withholding by Astellas of any taxes
imposed upon XenoPort on account of any royalties, initial or milestone payments paid under this Agreement, such taxes shall be deducted by Astellas as required by law from such payment and shall be paid by Astellas to the proper taxing authorities.
Official receipts of payment of any withholding tax shall be secured and sent to XenoPort as evidence of such payment. The Parties will exercise their reasonable efforts to ensure that any withholding taxes imposed are reduced as far as possible
under the provisions of any applicable tax treaty, and shall cooperate in filing any forms required for such reduction. Both Parties agree that under the applicable tax treaty as of the Effective Date, no withholding taxes are due on any amounts due
hereunder provided that the appropriate forms have been filed with the tax authorities in Japan. 
 9.3 U. S.
Dollars. All sums due under this Agreement shall be payable in U.S. dollars. Monetary conversion from the currency of a foreign country, in which Product is sold, into United States currency shall be calculated at the actual average of the
buying and selling rates of exchange for a calendar quarter in which such sales were made as such rates are reported, as of the last business day of such calendar quarter, by Bank of Tokyo-Mitsubishi. 
 9.4 Records; Inspection.
 9.4.1 Astellas. Astellas shall keep, and require its Affiliates and Subdistributors to keep, complete, true and accurate books of accounts and records for the purpose of determining the amounts
payable to XenoPort pursuant to this Agreement. Such books and records shall be kept for at least three (3) years following the end of the calendar quarter to which they pertain. Such records will be open for inspection during such three
(3) year period by an independent auditor chosen by XenoPort and reasonably acceptable to Astellas for the purpose of verifying the amounts payable by Astellas hereunder. Such inspections may be made no more than once each calendar year, at
reasonable times and on reasonable prior written notice. Such records for any particular calendar quarter shall be subject to no more than one inspection. The independent auditor shall be obligated to execute a reasonable confidentiality agreement
prior to commencing any such inspection. Inspections conducted under this Section 9.4.1 shall be at the expense of XenoPort, unless a variation or error producing an underpayment in amounts payable exceeding [... * ...] of the
amount paid for any period covered by the inspection is established in the course of any such inspection, whereupon all costs relating to the inspection for such period and any unpaid amounts that are discovered shall be paid by Astellas, together
with interest on such unpaid amounts at the rate set forth in Section 9.1 above. The Parties will endeavor in such inspection to minimize disruption of Astellas’ normal business activities to the extent reasonably practicable. 

9.4.2 XenoPort. XenoPort shall keep complete, true and accurate books of accounts and records for the purpose of determining
payments due from Astellas pursuant to this Agreement. Such books and records shall be kept for at least three (3) years following the end of the calendar quarter to which they pertain. Such records will be open for inspection during such three
(3) year period by an independent auditor chosen by Astellas and reasonably acceptable to XenoPort for the purpose of verifying the amounts

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
payable by Astellas hereunder. Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable prior written notice. Such records for any particular
calendar quarter shall be subject to no more than one inspection. Astellas’ independent auditor shall be obligated to execute a reasonable confidentiality agreement prior to commencing any such inspection. Inspections conducted under this
Section 9.4.2 shall be at the expense of Astellas, unless a variation or error producing an overpayment in amounts payable exceeding [... * ...] of the amount paid for any period covered by the inspection is established in the
course of any such inspection, whereupon all costs relating to the inspection for such period and any overpaid amounts that are discovered shall be paid by XenoPort, together with interest on such overpaid amounts at the rate set forth in
Section 9.1 above. The Parties will endeavor in such inspection to minimize disruption of XenoPort’s normal business activities to the extent reasonably practicable. 
 10. INTELLECTUAL PROPERTY 
 10.1 Ownership of Inventions. Title to all inventions and other intellectual property made solely by Astellas personnel in connection with this Agreement shall be owned by Astellas. Title to
all inventions and other intellectual property made solely by XenoPort personnel in connection with this Agreement shall be owned by XenoPort. Title to all inventions and other intellectual property made jointly by personnel of XenoPort and Astellas
in connection with this Agreement shall be jointly owned by Astellas and XenoPort. Prosecution of any patent applications and patents with respect to such jointly owned inventions and intellectual property shall be solely as mutually agreed. Except
as expressly provided in this Agreement, it is understood that neither Party shall have any obligation to obtain any approval of nor pay a share of the proceeds to the other Party to exploit or enforce such jointly owned inventions or intellectual
property, and that neither Party shall, without obtaining the approval of the other Party, license or assign the same to a Third Party other than its licensees of (or an assignee of all or substantially all of its assets or business in any country
pertaining to) the Compound and/or the Product or Subdistributors. For clarity, each Party shall have the right, without having to obtain the approval of, nor to pay a share of the proceeds to, the other Party, to license and/or assign such jointly
owned intellectual property to any licensee of the Compound and/or Product or Subdistributor or to an assignee of all or substantially all of its assets or business pertaining to the Compound and/or Product in any country. Astellas hereby grants to
XenoPort a non-exclusive, worldwide, irrevocable, fully paid-up license, with the right to sublicense, under any Improvements to make, have made, use, sell, offer for sale, import, practice and otherwise exploit the same for the Compound and/or the
Product, subject to the exclusive rights granted to Astellas under this Agreement with respect to the Product in the Territory. As used herein, “Improvements” means any patent rights or other intellectual property made by or under
authority of Astellas in connection with manufacturing, developing and/or commercializing the Product that is applicable to the Compound, Product or transported prodrugs thereof or the manufacture, use or formulation thereof. Notwithstanding
anything to the contrary contained herein, subject to Section 2.7 of the GSK Agreement, XenoPort shall not have the right to sublicense or disclose to GSK any Astellas Manufacturing Know-How and/or Improvements relating to manufacturing the
Compound, the Material and/or the Product inside or outside the Territory until the expiration or earlier termination of this Agreement in all countries of the Territory pursuant to Section 15.2 or 15.3 below or Section 2.4 above.

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 10.2 Prosecution and Maintenance of Patents. 
 10.2.1 Filings. As between Astellas and XenoPort, XenoPort shall have responsibility for the filing, prosecution and maintenance of
all XenoPort Patent Rights in the Territory at XenoPort’ expense. Astellas shall have the right to review pending patent applications and make recommendations to XenoPort concerning the foregoing. XenoPort will consider in good faith all
reasonable suggestions of Astellas with respect thereto. XenoPort agrees to keep Astellas generally informed of the course of patent prosecution or other proceedings with respect to the XenoPort Patent Rights within the Territory, including those
patents and patent applications relating to the Compound and/or the Product in the Territory which shall not be listed in Exhibit B as of the Effective Date. 
 10.2.2 Extensions. XenoPort shall, [... * ...], file for extensions of the terms of any and all of the XenoPort Patent Rights if legally possible in any country of the Territory with
respect to the Product and shall be responsible for prosecuting any required actions for such extensions at its own expense. 
 10.3 Third Party Infringement Claims. If the production, sale or use of any Compound or Product in the Territory pursuant to this Agreement results in a claim, suit or proceeding alleging patent infringement against XenoPort or
Astellas (or their respective Affiliates or Subdistributors) (collectively, “Infringement Actions”), such Party shall promptly notify the other Party hereto in writing. The Party subject to such Infringement Action shall have the
right to direct and control the defense thereof (including the conclusion of a potential settlement, but limited to the rights granted pursuant to this Agreement) using counsel reasonably acceptable to the other Party, and the Infringement Action
shall be at the expense of the Party subject to such Infringement Action; provided, however, that the other Party may participate in the defense and/or settlement thereof at its own expense with counsel of its choice. In any event, the Party that is
subject to the Infringement Action agrees to keep the other Party hereto reasonably informed of all material developments in connection with any such Infringement Action. Astellas agrees not to settle any Infringement Action, or make any admissions
or assert any position in such Infringement Action, in a manner that would adversely affect the Product or the manufacture, use or sale thereof in or outside the Territory, without the prior written consent of XenoPort. XenoPort agrees not to settle
any Infringement Action in a manner that would adversely affect the Product or the manufacture, use or sale thereof in the Territory, without the prior written consent of Astellas. Astellas may treat its Damages from such Infringement Action as
Third Party Royalties under Section 7.3.1 above, and XenoPort may treat its Damages from such Infringement Action as payments for Third Party IP under Section 2.5 above. As used herein, “Damages” shall mean out-of-pocket
costs incurred by a Party, including reasonable attorney’s fees, damages and other liabilities that are part of any final judgment awarded against such Party, and any amounts paid by such Party in a settlement of the action that is approved by
the other Party, such approval not to be unreasonably withheld or delayed. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 10.4 Enforcement. Subject to the provisions of this Section 10.4, in the
event that Astellas reasonably believes that any XenoPort Patent Rights in the Territory is infringed or misappropriated by a third party or is subject to a declaratory judgment action in the Territory arising from such infringement, in each case
with respect to the manufacture, sale or use within the Field in the Territory of a product comprising a prodrug of gabapentin (an “Infringing Product”), Astellas shall promptly notify XenoPort. XenoPort shall have the initial right
(but not the obligation), at its own expense, to enforce the XenoPort Patent Rights with respect to such infringement or defend any declaratory judgment action with respect thereto in the Territory (for purposes of this Section 10.4, an
“Enforcement Action”). Astellas shall, at its expense, have the right to join in as a party plaintiff and to give reasonable assistance to such Enforcement Action. XenoPort shall keep Astellas reasonably informed of the progress of
any such Enforcement Action. XenoPort agrees not to settle any Enforcement Action, or make any admissions or assert any position in such Enforcement Action, in a manner that would materially adversely affect Astellas’ rights or interests in the
Territory, without the prior written consent of Astellas, which shall not be unreasonably withheld or delayed. 
 10.4.1
Initiating Enforcement Actions. In the event that XenoPort fails to initiate an Enforcement Action to enforce the XenoPort Patent Rights against a commercially significant infringement by a third party in a country in the Territory, which
infringement consists of the manufacture, sale or use of an Infringing Product in the Field in such country, within [... * ...] of a request by Astellas to initiate such Enforcement Action, Astellas may initiate an Enforcement Action
against such infringement at its own expense. Upon [... * ...], provided that [... * ...]. Astellas shall keep XenoPort reasonably informed of the progress of any such Enforcement Action. XenoPort shall, at its expense,
have the right to join in as a party plaintiff and to give reasonable assistance to such Enforcement Action. Astellas agrees not to settle any Enforcement Action, or make any admissions or assert any position in such Enforcement Action, in a manner
that would materially adversely affect the validity, enforceability or scope of the XenoPort Patent Rights in or outside the Territory, without the prior written consent of XenoPort, which shall not be unreasonably withheld or delayed. 

10.4.2 Recoveries. Any damages or other monetary awards recovered from an Enforcement Action shall be allocated first to
reimburse the costs and expenses of Party who initiates the Enforcement Action and, if the other Party joins as a party plaintiff, then the costs and expenses of the other Party. Any amounts remaining shall be shared [... * ...] to
Astellas and
 [... * ...] to XenoPort. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 10.5 Third Party Rights. The obligations of XenoPort and the rights of Astellas
under Sections 10.2 and 10.4 above shall be subject to, and limited by, any agreements pursuant to which XenoPort acquired or licensed any particular XenoPort Patent Rights, Data or other subject matter. With respect to the prosecution or
enforcement of XenoPort Patent Rights licensed by XenoPort from a Third Party, to the extent XenoPort has the right to do so, XenoPort shall cooperate with Astellas to prosecute and enforce such XenoPort Patent Rights in the same manner as set forth
in Sections 10.2 and 10.4 above. As between XenoPort and Astellas, any recoveries from enforcement of such XenoPort Patent Rights licensed from a Third Party (including any amounts that XenoPort receives from the Third Party licensor as a result of
such enforcement) shall be shared in accordance with Sections 10.4.2, after deducting from such recoveries any amounts owed to the Third Party licensor for such enforcement; provided that any Enforcement Actions initiated by the Third Party licensor
shall be deemed initiated by XenoPort for purposes of Section 10.4.2 above, and the costs and expenses incurred by XenoPort in such Enforcement Action shall include the costs and expenses reimbursed or required to be reimbursed by XenoPort to
the Third Party licensor in such Enforcement Action. 
 10.6 Patent Marking. Astellas agrees to mark and have its
Affiliates and Subdistributors mark all patented Products they sell or distribute pursuant to this Agreement in accordance with the applicable patent statutes or regulations in the country or countries of manufacture and sale thereof. 
 11. TRADEMARKS 
 11.1 Display. All packaging materials, labels and promotional materials for the Product in the Territory shall display the Product Trademark to the extent such packaging materials, labels and
promotional materials have enough space for such display. Astellas shall include in its packaging materials, labels and promotional materials a statement, of reasonable size and prominence approved by XenoPort, acknowledging that the Product is sold
under license from XenoPort to the extent such packaging materials, labels and promotional materials have enough space for such statement. The Astellas trade dress and style of packaging with respect to each Product may be determined by Astellas so
as to be consistent with Astellas’ standard trade dress and style, but shall, so far as is reasonable, be consistent with XenoPort’s worldwide branding strategy for the Product, provided that XenoPort shall respect local marketing needs in
the Territory regarding trade dress and style. 
 11.2 License. XenoPort hereby grants to Astellas an exclusive
(even as to XenoPort), royalty-free license to use the Product Trademark solely in connection with formulation, packaging, marketing, promoting, distributing and selling the Product in the Territory in accordance with this Agreement. The ownership
and all goodwill from the use of the Product Trademark shall vest in and inure to the benefit of XenoPort. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 11.3 Registration. XenoPort agrees to file, register and be responsible to
maintain a registration for the Product Trademark in Japan (and in countries of the Territory outside Japan, upon notice from Astellas that an MAA for the Product is being filed in such country), for the term of this Agreement, for use with the
Product. The costs of filing and maintaining such registrations in the Territory shall be borne by XenoPort. 
 11.4
Ownership. Astellas hereby acknowledges XenoPort’s exclusive ownership rights in the Product Trademark, and accordingly agrees that at no time during the term of this Agreement or for [... * ...] thereafter to challenge or
assist others to challenge the Product Trademark or the registration thereof, nor during the term of this Agreement to attempt to register any trademarks, marks or trade names confusingly similar to such Product Trademark. 
 11.5 Recordation. In those countries where a trademark license must be recorded, XenoPort will provide and record a separate
trademark license for the Product Trademark, at XenoPort’s sole expense. Astellas shall cooperate in the preparation and execution of such documents. 
 11.6 Approval of Promotional Materials. Astellas shall submit representative samples of promotional materials, packaging and Product using the Product Trademark to XenoPort for XenoPort’s
reasonable approval, which approval shall not be unreasonably withheld or delayed, prior to their first use and prior to any subsequent change or addition to such promotional materials, provided that if XenoPort has not responded within four
(4) weeks after receiving such submissions, XenoPort’s approval will be deemed to have been received. 
 11.7
Termination. Astellas’ right to use the Product Trademark shall terminate in each country of the Territory in which Astellas’ rights to distribute the Product are terminated in accordance with this Agreement. Astellas shall
cooperate in the cancellation of any trademark licenses recorded or entered into in such countries. 
 12.
CONFIDENTIALITY 
 12.1 Confidential Information. Except as expressly provided in this Agreement, the
Parties agree that the receiving Party shall not publish or otherwise disclose and shall not use for any purpose any information furnished to it by the other Party hereto pursuant to this Agreement (collectively, “Confidential
Information”). Notwithstanding the foregoing, Confidential Information shall not include information that, in each case as demonstrated by written documentation: 
 12.1.1 was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure or, as shown
by written documentation, was developed by the receiving Party independent of disclosure by the disclosing Party; 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 12.1.2 was generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving Party; 
 12.1.3 became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 12.1.4 was subsequently lawfully disclosed to the receiving Party by a person other than the disclosing Party, and who did not directly or indirectly receive such information from disclosing Party; or 
 12.1.5 is developed by the receiving Party without use of or reference to any information or materials disclosed by the disclosing Party.

 12.2 Permitted Disclosures. Notwithstanding the provisions of Section 12.1 above, each Party hereto may
disclose the other Party’s Confidential Information to its Affiliates, licensees, Subdistributors and any other Third Parties to the extent such disclosure is reasonably necessary to exercise the rights granted to it, or reserved by it, under
this Agreement (including the right to grant sublicenses, as applicable), prosecuting or defending litigation, complying with applicable governmental laws or regulations, submitting information to tax or other governmental authorities or conducting
clinical trials hereunder with respect to the Product. If a Party is required by law or regulations to make any such disclosure of the other Party’s Confidential Information, to the extent it may legally do so, it will give reasonable advance
notice to the latter Party of such disclosure and, save to the extent inappropriate in the case of patent applications or otherwise, will use its good faith efforts to secure confidential treatment of such Confidential Information prior to its
disclosure (whether through protective orders or otherwise). For any other disclosures of the other Party’s Confidential Information, including to Affiliates, licensees, Subdistributors and other Third Parties, a Party shall ensure that the
recipient thereof is bound by a written confidentiality agreement as materially protective of such Confidential Information as this Section 12. If the Party whose Confidential Information is to be disclosed has not filed a patent application
with respect to such Confidential Information, it may require the other Party to delay the proposed disclosure (to the extent the disclosing Party may legally do so), for up to ninety (90) days, to allow for the filing of such an application.

 12.3 Terms of this Agreement. Each Party agrees [... * ...], except [... * ...] pursuant to
clause (a) above, the [... * ...] 
 12.4 Publicity. Subject to Section 12.3 above, neither
Party shall originate any written publicity, news release or other announcement or statement relating to this Agreement (collectively, a “Written Disclosure”), without the prompt prior review and written approval of the other Party,
which approval shall not be unreasonably withheld or delayed. Notwithstanding the foregoing,

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
either Party may make any public Written Disclosure it believes in good faith based upon the advice of counsel is required by applicable law, rule or regulation or any listing or trading
agreement concerning its or its Affiliates’ publicly traded securities. In addition, the Parties shall agree upon a press release to announce the execution of this Agreement, together with a corresponding Question & Answer outline for
use in responding to inquiries about the Agreement; thereafter, Astellas and XenoPort may each disclose to third parties the information contained in such press release and Question & Answer outline without the need for further approval by
the other. 
 12.5 Prior Non-Disclosure Agreements. Upon execution of this Agreement, the terms of this
Section 12 shall supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties. Any information disclosed under such prior agreements shall be deemed disclosed under this Agreement. 
 12.6 Publication of Product Information. Prior to publishing, publicly presenting and/or submitting for written or oral
publication a manuscript, abstract or the like that includes Data or other information relating to Product that has not previously published pursuant to this Section 12.6, a Party shall provide the other Party a copy thereof in English for its
review for at least thirty (30) days (unless such Party is required by law to publish such information sooner). Such Party shall consider in good faith any comments provided by the other Party during such thirty (30) day period. In
addition, such Party shall, at the request of the other Party, remove any Confidential Information of the other Party therefrom, except each Party shall have the right to publicly disclose any information, including Confidential Information,
pertaining to safety or efficacy of the Compound and/or Product that such Party believes in good faith it is obligated or appropriate to disclose. The contribution of each Party shall be noted in all publications or presentations by acknowledgment
or coauthorship, whichever is appropriate. 
 13. REPRESENTATIONS AND WARRANTIES 
 13.1 Mutual Warranty. Each Party represents and warrants to the other that this Agreement is a legal and valid obligation binding upon
such Party and enforceable in accordance with its terms. The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which
it is bound, nor, to such Party’s knowledge, violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 
 13.2 XenoPort Warranties. XenoPort represents and warrants to Astellas that, as of the Effective Date: 
 13.2.1 it has the full right and authority to enter into this Agreement and grant the rights and licenses as provided herein; 

 

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 13.2.2 it has not previously granted any right, license or interest in or to the XenoPort
Patent Rights, or any portion thereof, that is in conflict with the rights or licenses granted to Astellas under this Agreement; 
 13.2.3 XenoPort has not knowingly withheld from Astellas any material information in the possession of XenoPort related to the safety or efficacy of the Compound and/or the Product (a) that has been requested by Astellas, or
(b) that XenoPort considered to be reasonably material to Astellas’ evaluation of the safety and/or efficacy of the Compound and/or Product; 
 13.2.4 XenoPort has not knowingly withheld from Astellas any material CMC Information in the possession of XenoPort regarding the Existing Product (a) that has been requested by Astellas, or
(b) that XenoPort considered to be reasonably material to Astellas’ evaluation of the quality of the Compound and/or Product. As used herein, “CMC Information” means information of the type required to appear in
Section 7.0 of IND Nos. 68,341 and 71,352; 
 13.2.5 to its best knowledge, there are no actual, pending, alleged or
threatened action, suits, claims, interference or governmental investigations involving the Compound and/or the Product, the XenoPort Patent Rights, the XenoPort Know-How or the Product Trademark by or against XenoPort, or any of its Affiliates or
other licensees in or before any court, governmental or regulatory authority. In particular, to its best knowledge, there is no pending or threatened product liability action nor intellectual property right litigation in relation to the Compound
and/or the Product; 
 13.2.6 all necessary consents, approvals and authorizations of all governmental authorities and other
persons or entities required to be obtained by XenoPort in order to enter into this Agreement have been obtained; 
 13.2.7 to
its best knowledge, there are no actual, pending, alleged or threatened infringement by a Third Party of any of the XenoPort Patent Rights or the XenoPort Know-How; 
 13.2.8 to its best knowledge, none of the issued XenoPort Patent Rights are invalid or unenforceable. 
 13.2.9 there are no XenoPort Patent Right that are licensed by XenoPort from any Third Party, which would, but for the license granted hereunder, be infringed by use, development, formulation, packaging,
import, sale, distribution, promotion or marketing of the Compound and/or the Product by Astellas, any of its Affiliates or Subdistributors in accordance with this Agreement. There are no Data licensed by XenoPort from any Third Party relating to
the Compound and/or the Product. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 13.2.10 XenoPort has not granted a lien or other encumbrances on any of the subject matter
of this Agreement or on any of XenoPort’s rights, benefits or obligations hereunder or on any of the XenoPort Patent Rights, which would conflict with the rights or licenses of Astellas hereunder. 
 13.2.11 Notwithstanding the foregoing, it is understood that substantial information has been published in XenoPort’s SEC filings and
in its scientific publications regarding the Compound and/or the Product, and is available to the public. Accordingly, for purposes of this Section 13.2, Astellas shall be deemed to be on notice of and to have received disclosures of such
information, and the representations and warranties set forth in this Section 13.2 shall be subject to such disclosures. 
 13.3 XenoPort Covenants. XenoPort covenants to Astellas that, during the term of this Agreement (a) it shall not grant any right, license or interest in or to the XenoPort Patent Rights, or any portion thereof, that is in
conflict with the rights or licenses granted under this Agreement, and (b) it shall not grant a lien or other encumbrances on any of the subject matter of this Agreement or on any of XenoPort’s rights, benefits or obligations hereunder or
on any of the XenoPort Patent Rights, which would conflict with the rights or licenses of Astellas hereunder. 
 13.4
Astellas Warranties. Astellas represents and warrants to XenoPort that, as of the Effective Date: (a) it has the full right and authority to enter into this Agreement and grant the rights granted herein; (b) Astellas and its
Affiliates have not initiated any human clinical trials with respect to, and are not commercializing, any products containing the Compound or any Competitive Compound, and are not engaged in contract negotiations with respect to in-licensing or
acquiring any specific product or technology relating to the Compound or any Competitive Compound(s); (c) all necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to be obtained
by Astellas in order to enter into this Agreement have been obtained; and (d) Astellas does not have any knowledge that any of XenoPort’s representations and warranties set forth in Section 13.2 above are inaccurate. 
 13.5 DISCLAIMER. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY
WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OR VALIDITY OF ANY PATENTS ISSUED OR PENDING. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 13.6 LIMITATION OF LIABILITY. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR
OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR ANY INCIDENTAL, INDIRECT, SPECIAL,
EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF BUSINESS) EXCEPT IN THE CASE OF (A) BREACH OF SECTION 2.4.3 BY ASTELLAS OR ITS AFFILIATES,
(B) BREACH OF SECTION 12, (C) SUCH DAMAGES OWED TO THIRD PARTIES PURSUANT TO SECTION 14 OR (D) BREACH OF ASTELLAS’ OBLIGATION TO USE DILIGENT EFFORTS TO DEVELOP AND/OR COMMERCIALIZE THE PRODUCT PURSUANT TO SECTIONS 4.1.1 AND
5.1.1, PROVIDED IT IS UNDERSTOOD THAT IN THE CASE OF (D) DAMAGES SHALL BE CALCULATED BASED ON LOSS OF ROYALTIES AND OTHER AMOUNTS OWED TO XENOPORT HEREUNDER AS A RESULT OF SUCH BREACH, AND NOT BASED ON THE LOSS OF NET SALES RECEIVED BY
ASTELLAS. 
 14. INDEMNIFICATION 
 14.1 Indemnification of XenoPort. Astellas shall indemnify and hold harmless each of XenoPort, its Affiliates and the directors, officers and employees of such entities and the successors and
assigns of any of the foregoing (the “XenoPort Indemnitees”), from and against any and all liabilities, damages, penalties, fines, costs, expenses (including, without limitation, reasonable attorneys’ fees and other expenses of
litigation) (“Liabilities”) from any claims, actions, suits or proceedings brought by a Third Party (a “Third Party Claim”) incurred by any XenoPort Indemnitee, arising from, or occurring as a result of:
(a) the use, marketing, distribution or sale of any Product by Astellas, its Affiliates or Subdistributors in the Territory (and manufacturing, formulation and packaging activities by or under authority of Astellas inside or outside the
Territory pursuant to Section 2.2 or development activities by Astellas or requested by Astellas outside the Territory pursuant to 4.7), including, without limitation, any Products Liability Claim (subject to and shared in accordance with the
mechanism set forth in Section 14.4 below) and Third Party infringement claims (subject to Section 10.3 above), or (b) any material breach of any representations, warranties or covenants by Astellas in Section 13 above; except to
the extent such Third Party Claims fall within the scope of XenoPort’s indemnification obligations set forth in Section 14.2 below. 
 14.2 Indemnification of Astellas. XenoPort shall indemnify and hold harmless each of Astellas, its Affiliates and Subdistributors and the directors, officers and employees of Astellas, its
Affiliates and Subdistributors and the successors and assigns of any of the foregoing (the “Astellas Indemnitees”), from and against any and all Liabilities from any Third Party Claims incurred by any Astellas Indemnitee, arising
from, or occurring as a result of: (a) the use, marketing, distribution or sale of any Product by XenoPort or its licensee outside the Territory (other than manufacturing, formulation and packaging activities by or under authority of Astellas
outside the Territory pursuant to Section 2.2 and development activities by Astellas or requested by Astellas outside the Territory pursuant to 4.7), (b) any material breach of any representations, warranties or covenants by XenoPort in
Section 13 above, or (c) subject to and shared in accordance with the mechanism set forth in Section 14.4 below, any Product Liability Claim asserted against the Astellas Indemnitees. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 14.3 Procedure. Except with respect to Third Party infringement claims subject
to Section 10.3 above, and Product Liability Claims subject to Section 14.4 below, a Party that intends to claim indemnification under this Section 14 (the “Indemnitee”) shall promptly notify the other Party (the
“Indemnitor”) in writing of any Third Party Claim, in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense and/or settlement thereof. The indemnity
arrangement in this Section 14 shall not apply to amounts paid in settlement of any action with respect to a Third Party Claim, if such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld or delayed
unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim, if prejudicial to its ability to defend such action, shall relieve such
Indemnitor of any liability to the Indemnitee under this Section 14, but the omission to so deliver written notice to the Indemnitor shall not relieve the Indemnitor of any liability that it may have to any Indemnitee otherwise than under
this Section 14. The Indemnitee under this Section 14 shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Third Party Claim covered by this indemnification.

 14.4 Products Liability Claims. Each Party shall notify the other Party as promptly as practicable if any Third Party
Claim is commenced or threatened against such Party alleging product liability, product defect, design, manufacturing, packaging or labeling defect, failure to warn, or any similar action relating to the formulation, manufacture, use or safety of
those Products sold by or under authority of Astellas in the Territory hereunder (“Product Liability Claim”). Each Party shall cooperate with the other Party in connection with any such Product Liability Claim that is commenced or
threatened against the other Party. If a Product Liability Claim is asserted against both Parties, each Party will have the right to designate counsel to defend itself in the Product Liability Claim. If a Product Liability Claim is brought against
one Party but not the other Party, the named Party shall control the defense and/or settlement thereof at its own expense with counsel of its choice, subject to this Section 14.4. In such case, the other Party may participate in the defense
and/or settlement thereof at its own expense with counsel of its choice. In any event, the Party that is subject to the Product Liability Claim (if not asserted against both Parties) agrees to keep the other Party hereto reasonably informed of all
material developments in connection with any such Product Liability Claim. Astellas agrees not to settle any Product Liability Claim, or make any admissions or assert any position in such Product Liability Claim, in a manner that would adversely
affect the Product or the manufacture, use or sale thereof in or outside the Territory, without the prior written consent of XenoPort. XenoPort agrees not to settle any Product Liability Claim, or make any admissions or assert any position in such
Product Liability Claim, in a manner that would adversely affect the Product or the manufacture, use or sale thereof in the Territory, without the prior written consent of

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
Astellas. To the extent a Product Liability Claim is caused by: (a) the Fault of XenoPort (as defined in Section 8.2 above), XenoPort shall bear all Liabilities from such Product
Liability Claim to the extent of its Fault, (b) the Fault of Astellas (as defined in Section 8.2 above), Astellas shall bear all Liabilities from such Product Liability Claim to the extent of its Fault and (c) neither the Fault of
XenoPort nor the Fault of Astellas, the Parties shall share the Liabilities from such Product Liability Claim as follows: [... * ...] shall be borne by Astellas, and [... * ...] shall be borne by XenoPort. 
 14.5 Insurance. Each Party shall secure and maintain in effect during the term of this Agreement and for a period of [...
* ...] thereafter insurance policy(ies) underwritten by a reputable insurance company in a form and having limits standard and customary for entities in the biopharmaceutical industry for exposures related to the Product. Such policies shall
include coverage for clinical trial liability and products liability. Upon request by the other Party hereto, certificates of insurance evidencing the coverage required above shall be provided to the other Party. 
 15. TERM AND TERMINATION 
 15.1 Term. This Agreement shall become effective as of the Effective Date and, shall continue, on a country-by-country basis, until terminated pursuant to Section 15.2 or 15.3 below or
Section 2.4 above. 
 15.2 Termination By Astellas. Astellas may terminate this Agreement for any reason under
this Section 15.2 without any penalty, consequence, termination compensation, loss of profits, goodwill indemnity or otherwise solely by reason of such termination (i.e., without prejudice to any remedies XenoPort may have for a breach
of this Agreement by Astellas), as a whole or on a country-by-country basis with respect to countries in the Territory upon written notice to XenoPort; provided that such notice is given after the third anniversary of the Effective Date. In the
event Astellas elects to terminate this Agreement under this Section 15.2 with respect to Japan, Astellas shall have elected to terminate this Agreement in whole. Without limiting the other provisions of this Agreement, if, at any time after
the First Commercial Sale of a Product in a country, [... * ...] with respect to such country (if a country in the Territory other than Japan), or as a whole (if such country is Japan); and this Agreement shall so terminate upon such
notice by XenoPort without any penalty, consequence, termination compensation, loss of profits, goodwill indemnity or otherwise solely by reason of such deemed termination. 
 15.3 Termination for Cause. In the event a Party fails to pay any amount due under this Agreement or otherwise materially breaches
any obligation, covenant or warranty under this Agreement, the other Party shall have the right to terminate this Agreement upon written notice, provided that such breach is not cured within [... * ...] (if a failure to pay), or within
[... * ...] (if any other material breach), after notice thereof specifying such breach. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 16. EFFECT OF TERMINATION 
 16.1 Accrued Obligations. Termination of this Agreement for any reason shall not release any Party hereto from any liability that, at
the time of such termination, has already accrued to the other Party or that is attributable to a period prior to such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with
respect to any breach of this Agreement. 
 16.2 Rights on Termination. This Section 16.2 shall apply upon any
termination of Astellas’ rights under this Agreement in whole or with respect to a particular country, excluding only termination of this Agreement pursuant to Section 15.3 for XenoPort’s breach. As used herein, the “Affected
Area” shall mean the Territory in case of termination of this Agreement as a whole, or the terminated country(ries) in case of termination of this Agreement with respect to such country(ries). 
 16.2.1 Wind-down Period. 
 (a) Development. In the event there are any on-going clinical trials of the Product in an Affected Area, at XenoPort’s request, Astellas agrees to either promptly transition such clinical
trials to XenoPort, or continue to conduct such clinical trials (i) in the case of termination by XenoPort pursuant to Section 15.3 or 2.4, or termination by Astellas pursuant to Section 15.2, at Astellas’ own expense and
(ii) in the case of any other termination, at XenoPort’s expense for a period requested by XenoPort up to a maximum of [... * ...] after such termination. 
 (b) Commercialization. In case of termination by XenoPort pursuant to Section 15.3 or 2.4, or termination by Astellas pursuant
to Section 15.2, Astellas and its Subdistributors shall continue to distribute Products in each country of the Affected Area for which Marketing Approval therefor has been obtained, in accordance with the terms and conditions of this Agreement,
for a period requested by XenoPort not to exceed [... * ...] from such termination (for purposes of this Section 16.2, the “Wind-down Period”); provided that XenoPort may terminate the Wind-down Period upon
[... * ...] written notice to Astellas. Notwithstanding any other provision of this Agreement, during the Wind-down Period, Astellas’ and its Subdistributors’ rights with respect to the Compound and the Product in the Affected
Area shall be non-exclusive, and XenoPort shall have the right to engage one or more other distributor(s) and/or sublicensee(s) of the Product in all or part of the Affected Area. Any Products sold or disposed by Astellas in the Affected Area during
the Wind-down Period shall be subject to royalties under Section 7 above. Within [... * ...] of expiration or termination of the Wind-down Period, Astellas shall notify XenoPort of any quantity of the Products remaining in
Astellas’ inventory and Astellas shall transfer all right, title and interest in and to any such quantities of the Products to XenoPort for no consideration. 
 16.2.2 Assignment of MAA and Marketing Approvals. Astellas shall assign or cause to be assigned to XenoPort (or if not so assignable, Astellas shall take all reasonable actions to make available to
XenoPort the benefits of) all regulatory filings and

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
registrations (including INDs, MAAs and Marketing Approvals) for the Product in the Affected Area, including any such regulatory filings and registrations made or owned by its Affiliates and/or
Subdistributors. In each case, unless otherwise required by any applicable law or regulation, the foregoing assignment (or availability) shall be made within [... * ...] after termination of the Affected Area. In addition, Astellas
shall promptly provide to XenoPort a copy of all Data, Astellas Know-How and Astellas Manufacturing Know-How pertaining to the Product to the extent not previously provided to XenoPort. 
 16.2.3 Supply. Astellas shall use Diligent Efforts to transition to XenoPort upon XenoPort’s request any arrangements with any
contractor from which Astellas had arranged to obtain a supply of the Compound or Products. In the event that such materials are manufactured by Astellas, then, upon request by XenoPort, Astellas shall continue to provide XenoPort with such
materials [... * ...]; provided that XenoPort shall use commercially reasonable efforts to obtain such alternative source as soon as practicable. In addition, Astellas shall promptly provide to XenoPort a copy of all Data, the Astellas
Know-How and the Astellas Manufacturing Know-How pertaining to the manufacture of the Compound and the Products to the extent not previously provided to XenoPort during the term of this Agreement or pursuant to Section 16.2.2, and XenoPort
shall have the right, subject to Section 10.1, to use (and authorize the use of) and to disclose all such Data, Astellas Know-How and Astellas Manufacturing Know-How pertaining to the manufacture of the Compound and the Products following
termination of this Agreement. 
 16.2.4 Transition. Astellas shall use Diligent Efforts to cooperate with XenoPort
and/or its designee to effect a smooth and orderly transition in the development and sale of the Product in the Affected Area during the Wind-down Period. Without limiting the foregoing, Astellas shall, upon written request from XenoPort, provide
XenoPort copies of customer lists, customer data and other customer information relating to the Product in the Affected Area (except as prevented by the applicable laws and regulations relating to the protection of personal information), which
XenoPort shall have the right to use and disclose for any purpose after termination of this Agreement. In addition, Astellas shall refer all inquiries after the Wind-down Period (or after the termination of this Agreement, in case there is no
Wind-down Period) regarding the Product in the Affected Area to XenoPort or any newly appointed distributors. 
 16.2.5
Return of Materials. Except for any Product in Astellas’ inventory that is transferred to XenoPort as set forth in Section 16.2.1(b), within fifteen (15) days after the end of the Wind-down Period (or after the termination of
this Agreement, in the event there is no Wind-down Period), Astellas shall destroy all tangible items comprising, bearing or containing trademarks, marks, tradenames, patents, copyrights, designs, drawings, formulas or other Data, photographs,
samples, literature, sales and promotional aids (“Product Materials”) and Confidential Information of XenoPort, that is in Astellas’ possession, and provide written certification of such destruction, or prepare such
tangible items of Product Materials and Confidential Information for shipment to XenoPort, as

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 
XenoPort may direct, at XenoPort’s expense; provided that Astellas may retain copies of Product Materials and Confidential Information relating to countries in the Territory outside the
Affected Area as reasonably necessary for its continued promotion, marketing, sale and distribution of the Product in such countries under this Agreement. Effective upon the end of the Wind-down Period (or upon termination of this Agreement, in the
event there is no Wind-down Period), Astellas shall cease to use all trademarks and trade names of XenoPort in the Affected Area, and all rights granted to Astellas hereunder with respect to the Product in the Affected Area shall terminate.

 16.2.6 Subdistributors. Any contracts with Subdistributors of the Product in the Affected Area engaged by Astellas
other than Astellas’ Affiliates shall, at the request of XenoPort in its discretion, be assigned to XenoPort to the furthest extent possible, provided that such assignment is accepted by the Subdistributor(s) for such Affected Area. In the
event such assignment is not requested by XenoPort or is not accepted by such Subdistributor(s), then the rights of such Subdistributors with respect to the Product in the Affected Area shall terminate upon termination of Astellas’ rights with
respect to such Affected Area. Astellas shall ensure that its Affiliates and such Subdistributors (if not assigned to XenoPort pursuant to this Section 16.2.6) shall transition the Product back to XenoPort in the manner set forth in this
Section 16.2 as if such Affiliate or Subdistributor were named herein. 
 16.3 No Renewal, Extension or Waiver.
Acceptance of any order from, or sale or license of, any Product to Astellas after the effective date of termination of this Agreement shall not be construed as a renewal or extension hereof, or as a waiver of termination of this Agreement.

 16.4 Survival. Upon termination of this Agreement in whole, all rights and obligations of the parties under this
Agreement shall terminate except: (a) Sections [... * ...], and (b) those provisions of this Agreement [... * ...]. For clarity, in the event this Agreement is terminated with respect to one or more countries, but
not the entire Territory, then the Affected Area shall thereafter cease to be within the Territory for all purposes of this Agreement, but Sections [... * ...] shall survive such termination with respect to the Affected Area.

 17. DISPUTE RESOLUTION 
 17.1 Disputes. In the event of any dispute between the Parties arising out of or in connection with this Agreement, either Party may, by written notice to the other, have such dispute referred to
the CEO of XenoPort and the CEO of Astellas for attempted resolution by good faith negotiations within thirty (30) days after such notice is received, and, in such event, each Party shall cause its representative to meet and be available to
attempt to resolve such issue. Notwithstanding the foregoing, neither Party shall be obligated to negotiate for more than thirty (30) days. If the Parties should resolve such dispute or claim, a memorandum setting forth their agreement will be
prepared and signed by both Parties if requested by either Party. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 17.2 Arbitration. Any dispute, controversy or claim with respect to the breach,
interpretation or enforcement of this Agreement, including disputes relating to termination of this Agreement that cannot be resolved pursuant to Section 17.1 (or which this Agreement directs shall be resolved pursuant to this
Section 17.2) shall be settled by binding arbitration in the manner described in this Section 17. The arbitration shall be conducted by the Judicial Arbitration and Mediation Services, Inc. (“JAMS”) under its rules of
arbitration then in effect. Notwithstanding those rules, the following provisions shall apply to the arbitration hereunder: 
 17.2.1 Arbitrators. The arbitration shall be conducted by a single JAMS arbitrator; provided that at the request of either Party, the arbitration shall be conducted by a panel of three (3) arbitrators, with one (1) JAMS
arbitrator chosen by each of Astellas and XenoPort and the third appointed by the other two (2) arbitrators. If the Parties are unable to agree upon a single arbitrator, or the other two arbitrators are unable to agree upon the third arbitrator
in case of a panel of three (3), such single or third arbitrator (as the case may be) shall be appointed in accordance with the rules of JAMS. In any event, the arbitrator or arbitrators selected in accordance with this Section 17.2.1 are
referred to herein as the “Panel” and shall be comprised of arbitrators who are familiar with worldwide research and business development in the pharmaceutical industry, unless otherwise agreed. 
 17.2.2 Proceedings. Except as otherwise provided herein, the Parties and the arbitrators shall use their best efforts to complete
the arbitration within one (1) year after the appointment of the Panel under Section 17.2.1 above, unless a Party can demonstrate to the Panel that the complexity of the issues or other reasons warrant the extension of one or more of the
time tables. In such case, the Panel may extend such time table as reasonably required. The Panel shall, in rendering its decision, apply the substantive law of the State of New York, without regard to its conflicts of laws provisions, except that
the interpretation and enforcement of this Section 17 shall be governed by the U.S. Federal Arbitration Act. The proceeding shall take place in San Francisco, California, United States of America. The arbitral proceedings and all pleadings,
responses and evidence shall be in the English language. If so requested by the arbitrator(s), any evidence originally in a language other than English shall be submitted with an English translation accompanied by an original or true copy thereof.
The decision and/or award rendered by the arbitrator(s) shall be written, final and non-appealable, and judgment on such decision and/or award may be entered in any court of competent jurisdiction. If the Panel determines that it is reasonable to do
so, the fees of the Panel shall be paid by the losing Party, which Party shall be designated by the Panel. Otherwise, the fees of the Panel shall be split equally between the Parties. Each Party shall bear the costs of its own attorneys’ and
experts’ fees; provided that the Panel may in its discretion award the prevailing Party all or part of the costs and expenses incurred by the prevailing Party in connection with the arbitration proceeding. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 17.2.3 Interim Relief. Notwithstanding anything in this Section 17.2 to the
contrary, Astellas and XenoPort shall each have the right to apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other similar interim or conservatory relief, as necessary, pending resolution
under the above described arbitration procedures. Nothing in the preceding sentence shall be interpreted as limiting the powers of the arbitrators with respect to any dispute subject to arbitration under this Agreement. The Panel may award
injunctive relief. 
 18. MISCELLANEOUS 
 18.1 Governing Law, Venue. This Agreement and any dispute arising from the performance or breach hereof shall be governed by, and
construed and enforced in accordance with, the laws of the State of New York, U.S.A., without reference to conflicts of laws principles. The U.N. Convention on the Sale of Goods shall not apply to this Agreement. 
 18.2 Force Majeure. Nonperformance of any Party, except for failure to pay amounts due hereunder, shall be excused to the extent
that performance is prevented by strike, fire, earthquake, flood, acts of terrorism, governmental acts or orders or restrictions, failure of suppliers or any other reason where failure to perform is beyond the reasonable control of the nonperforming
Party (“Force Majeure”). In such event, Astellas or XenoPort, as the case may be, shall promptly notify the other Party of such inability and of the period for which such inability is anticipated to continue. Without limiting the
foregoing, the Party subject to such inability shall use reasonable efforts to minimize the duration of any Force Majeure event. 
 18.3 No Implied Waivers; Rights Cumulative. No failure on the part of XenoPort or Astellas to exercise and no delay in exercising any right under this Agreement, or provided by statute or at law or in equity or otherwise, shall
impair, prejudice or constitute a waiver of any such right, nor shall any partial exercise of any such right preclude any other or further exercise thereof or the exercise of any other right. 
 18.4 Independent Contractors. Nothing contained in this Agreement is intended implicitly, or is to be construed, to constitute
XenoPort or Astellas as partners in the legal sense. No Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of any other Party or to bind any other Party to any
contract, agreement or undertaking with any third party. This Agreement does not create a partnership for United States federal income tax purposes (as defined in Section 761 of the United States Internal Revenue Code), for any state or local
jurisdiction in the United States or in any country other than the United States. Therefore, except for filing regarding withholding tax which, if not filed, shall be imposed upon royalties and milestone payments paid under this Agreement, there is
no requirement to file Form 1065, United States Partnership Return of Income, any similar state or local income tax return or any similar document with tax authorities in any country other than the United States. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 18.5 Notices. All notices, requests and other communications hereunder shall be
in writing and shall be personally delivered or sent by registered or certified airmail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in writing to the
other Parties hereto: 
  

			
	Astellas:	  	Astellas Pharma Inc.
		  	3-11, Nihonbashi-Honcho 2-chome
		  	Chuou-ku, Tokyo, 103-8411, Japan
		  	Attn: Vice President, Licensing, Corporate Strategy
		  	Fax: +81-3-5203-7164
		
	With a copy to:	  	Astellas Pharma Inc.
		  	3-11, Nihonbashi-Honcho 2-chome
		  	Chuou-ku, Tokyo, 103-8411, Japan
		  	Attn: Vice President, Legal, Corporate Administration
		  	Fax: +81-3-3244-5811
		
	XenoPort:	  	XenoPort, Inc.
		  	3410 Central Expressway
		  	Santa Clara, California 95051,
		  	United States of America
		  	Attn: CEO
		  	Fax: +1 (408) 616-7211
		
	with a copy to:	  	Wilson Sonsini Goodrich & Rosati
		  	650 Page Mill Road
		  	Palo Alto, California 94304-1050
		  	United States of America
		  	Attn: Kenneth A. Clark, Esq.
		  	Fax: +1 (650) 493-6811

 18.6 Assignment. This Agreement shall not be assignable by either Party
to any Third Party hereto without the written consent of the other Party hereto; except either Party may assign this Agreement without the other Party’s consent to an entity that acquires substantially all of the business or assets of the
assigning Party, whether by merger, acquisition or otherwise, provided that the acquiring Party assumes this Agreement in writing or by operation of law. In addition, either Party shall have the right to assign this Agreement to a Subsidiary upon
written notice to the non-assigning Party; provided that the assigning Party guarantees the performance of this Agreement by such Subsidiary, and further provided that if the non-assigning Party reasonably believes such assignment could result in
material adverse tax consequences to the non-assigning Party, such assignment shall not be made without the non-assigning Party’s consent. Subject to the foregoing, this Agreement shall inure to the benefit of each Party, its successors and
permitted assigns. Any assignment of this Agreement in contravention of this Section 18.6 shall be null and void. 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 18.7 Modification. No amendment or modification of any provision of this
Agreement shall be effective unless in writing signed by all Parties hereto. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an
agreement in writing and signed by all Parties. 
 18.8 Severability. If any provision hereof should be held
invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall
remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the
validity, legality or enforceability of such provision in any other jurisdiction. In the event a Party seeks to avoid a provision of this Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, the other Party
shall have the right to terminate this Agreement upon sixty (60) days’ prior written notice to the asserting Party, unless such assertion is eliminated and the effect of such assertion is cured within such sixty (60) day period.
Any termination in accordance with the foregoing sentence shall be deemed an election by Astellas to terminate pursuant to Section 15.2 if XenoPort exercises its right to terminate under this Section 18.8, and a termination for the
breach of XenoPort pursuant to Section 15.3 if Astellas exercises its right to terminate under this Section 18.8. 
 18.9 Counterparts. This Agreement may be executed in two counterparts, each of which shall be deemed an original, and all of which, together, shall constitute one and the same instrument. 
 18.10 Headings. Headings used herein are for convenience only and shall not in any way affect the construction of, or be taken
into consideration in interpreting, this Agreement. 
 18.11 Export Laws. Notwithstanding anything to the contrary
contained herein, all obligations of XenoPort and Astellas are subject to prior compliance with United States and foreign export regulations and such other United States and foreign laws and regulations as may be applicable, and to obtaining all
necessary approvals required by the applicable agencies of the governments of the United States and foreign jurisdictions. XenoPort and Astellas shall cooperate with each other and shall provide assistance to the other as reasonably necessary to
obtain any required approvals. 
 [continued on next page] 
  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 18.12 Entire Agreement. This Restated License Agreement, together with
all the Exhibits thereto, constitute the entire agreement, both written or oral, with respect to the subject matter hereof, and supersede all prior or contemporaneous understandings or agreements, whether written or oral, between XenoPort and
Astellas with respect to such subject matter on and after the Restatement Effective Date. The Original Agreement shall govern the rights and obligations between the Parties prior to the Restatement Effective Date, and this Restated License Agreement
shall govern the rights and obligations between the Parties on and after the Restatement Effective Date. 
 IN WITNESS WHEREOF,
the Parties hereto have caused this Restated License Agreement to be duly executed and delivered in duplicate originals as of the Restatement Effective Date. 
  

									
	XENOPORT, INC.	 		 	ASTELLAS PHARMA, INC.
					
	By:	  	 /s/ Ronald W. Barrett
	 		 	By:	 	 /s/ Chihiro Yokota

	Name:	  	 Ronald W. Barrett
	 		 	 Name:
	 	 Chihiro Yokota

	Title:	  	 Chief Executive Officer
	 		 	Title:	 	 Vice President, Licensing and Alliances

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 EXHIBIT A 
 COMPOUND 
 [... * ...] 

 

  
 * CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 EXHIBIT B 
 XENOPORT PATENT RIGHTS 
 [... * ...]

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 

 EXHIBIT C 
 INITIAL DEVELOPMENT PLAN 
 [... * ...]

  

  

	*	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.Share Purchase Agreement

 Exhibit 10.1 
 Project Tiller 
 Share Purchase Agreement for the Purchase of the Entire Issued

 Share Capital of each of the Companies listed in Part 1 and Part 2 of 
 Schedule 1 
 October 2009 
 Veris plc 
 and

 Aramark Ireland Holdings Limited 
 and 
 Aramark Investments Limited 
 and 
 Aramark Corporation 

 Table of Contents 
  

					
	 1
	  	Definitions and Interpretation	  	2
	 2
	  	Conditions	  	27
	 3
	  	Sale and Purchase of the Shares	  	28
	 4
	  	Consideration	  	28
	 5
	  	Adjustment of Consideration	  	30
	 6
	  	Management of the Company Pending Completion	  	30
	 7
	  	Completion	  	33
	 8
	  	Warranties	  	33
	 9
	  	Warranties by the Buyer	  	34
	 10
	  	Protection of Goodwill	  	46
	 11
	  	Retention Amount	  	47
	 12
	  	Release of Claims Against the Group Companies	  	49
	 13
	  	Announcements	  	51
	 14
	  	Confidentiality	  	52
	 15
	  	Entire Agreement	  	52
	 16
	  	Assignment and Transfer	  	53
	 17
	  	Exclusivity	  	54
	 18
	  	Costs and Expenses	  	54
	 19
	  	Interest on Late Payments	  	55
	 20
	  	Payments under this Agreement	  	56
	 21
	  	Effect of Completion	  	56
	 22
	  	Waiver and Remedies	  	56
	 23
	  	Variation	  	57
	 24
	  	No Benefit to Others	  	57
	 25
	  	Severance	  	57
	 26
	  	Further Assurance	  	58
	 27
	  	Notices	  	58
	 28
	  	Guarantee and indemnity	  	60
	 29
	  	Maintenance and availability of records	  	61
	 30
	  	Joint and several	  	61
	 31
	  	The Covenantors	  	61
	 32
	  	Counterparts	  	61
	 33
	  	Language	  	62
	 34
	  	Governing Law and Jurisdiction	  	62
	 35
	  	Acceptance of Service	  	62
	Schedule 1 Part 1: Particulars of the Irish Companies	  	63
	Schedule 1 Part 2: Particulars of VUKL	  	68
	Schedule 1 Part 3: Particulars of The Subsidiaries	  	69
	Schedule 1 Part 4: The Covenantors	  	75
	Schedule 2 Conditions	  	76
	 1
	  	Shareholder Approval	  	76
	 2
	  	Competition Authority Approval	  	76
	 3
	  	Compliance with Schedule 3 Undertakings	  	76
	 4
	  	No Litigation	  	76
	 5
	  	No Legislation	  	76
	 6
	  	No Material Adverse Changes	  	77
	 7
	  	Representations and Warranties	  	77
	Schedule 3 Conduct of Business between Exchange and Completion	  	79
	Schedule 4 Part 1: Documents which have been delivered prior to execution of this Agreement	  	82
	Schedule 4 Part 2: Documents which are to be delivered at Completion	  	83
	Schedule 5 Part 1: Title Warranties	  	86
	 1
	  	Share Capital	  	86
	 2
	  	Capacity and Authority of Seller	  	86

  

 2 

					
	 3
	  	Commissions	  	87
	Schedule 5 Part 2: General Warranties	  	88
	 1
	  	Information	  	89
	 2
	  	Constitution of the Company	  	89
	 3
	  	Companies Acts and International Law	  	89
	 4
	  	Accounts	  	90
	 5
	  	Transaction since the Accounts Date	  	91
	 6
	  	Solvency	  	93
	 7
	  	Information Technology and E-Commerce	  	93
	 8
	  	Intellectual Property, Confidential Information and Know-How	  	94
	 9
	  	Agreements and Arrangements	  	95
	 10
	  	Assets	  	97
	 11
	  	Directors and Employees	  	97
	 12
	  	Pensions	  	100
	 13
	  	Environment	  	103
	 14
	  	Properties	  	104
	 15
	  	Miscellaneous	  	105
	 16
	  	Litigation and Disputes	  	106
	 17
	  	Insurance	  	107
	Schedule 5 Part 3: Tax Warranties	  	109
	Schedule 6 [Intentionally left blank]	  	111
	Schedule 7 Agreed Treatments	  	112
	Schedule 8	  	114
	Working Capital – Worked example of calculations based of the combined management accounts of the Group Companies as at the Management Accounts Date	  	114
	Schedule 9 Properties	  	115
	Schedule 10 Anglo Other Charges	  	116
	Schedule 11 Guarantees	  	118

  

 3 

 This Agreement is dated      October 2009. 
 Between: 
  

	(1)	Veris plc a company incorporated under the laws of Ireland (company number 395138) whose registered office is at Heather House, Heather Road, Sandyford Industrial Estate,
Dublin 18, Ireland (the “Seller”); 

  

	(2)	Aramark Ireland Holdings Limited a company incorporated under the laws of Ireland (company number 324452) whose registered office is at 70 Sir John Rogerson’s Quay,
Dublin 2 (the “Irish Buyer”); 

  

	(3)	 Aramark Investments Limited a company incorporated under the laws of England and Wales (company number 2808311) whose registered office is at Millbank
Tower (28th Floor), 21 – 24 Millbank, London, SW1P 4QP, England (the
“UK Buyer”); 

  

	(4)	Aramark Corporation a company incorporated under the laws of Delaware (whose principal place of business is at Aramark Tower, 1101 Market Street, Philadelphia PA19107 USA
(the “Guarantor”); and 

  

	(5)	The Persons listed in Part 4 of Schedule 1 of this Agreement and their successors and permitted assigns (the “Covenantors”) 

 Introduction: 
  

	(A)	Each of the Irish Companies (as defined below) are private companies limited by shares and incorporated in Ireland, further details of which are set out in Part 1 of Schedule 1.

  

	(B)	Veris UK Limited (“VUKL”) is a private company limited by shares and incorporated in England and Wales, further details of which are set out in Part 2 of
Schedule 1. 

  

	(C)	The Irish Companies and VUKL have a number of subsidiaries, further details of which are set out in Part 3 of Schedule 1. 

  

	(D)	The Seller is the legal and beneficial owner of the entire issued share capital of the shares in the Irish Companies and VUKL, free in each case from all Encumbrances (as defined
below) other than the Anglo Charges (as defined below). In the case of each of the Subsidiaries (as defined below) either an Irish Company or VUKL or a Subsidiary of VUKL is the legal and beneficial owner of the entire issued share capital of that
Subsidiary, free in each case from all Encumbrances other than the Anglo Charges. 

  

	(E)	The Seller has agreed to sell to the Irish Buyer and the Irish Buyer has agreed to purchase the Irish Facility Management Shares (as defined below) and the Irish Property
Management Shares (as defined below) and the Seller has agreed to sell to the UK Buyer and the UK Buyer has agreed to purchase the UK Shares (as defined below), each upon the terms and subject to the conditions set out in this Agreement (the
“Transaction”), and in each case free from all Encumbrances. 

  

 1 

	(F)	The Seller has agreed to give warranties to the Irish Buyer and the UK Buyer in the terms of the Warranties (defined below) set out herein, with the intention that the Irish
Buyer and the UK Buyer should rely upon such Warranties in entering into this Agreement. 

  

	(G)	The Seller and the Covenantors have agreed to protect the benefit and value of the goodwill attaching to the Shares (as defined below) and to release the Group Companies from all
claims on the terms set out in this Agreement. 

  

	(H)	Immediately prior to execution of this Agreement, the Seller has delivered (or the Seller’s Solicitors have delivered) to the Buyers (or to the Buyers’ Solicitors) the
documents referred to in Part 1 of Schedule 4, and the Buyers have acknowledged receipt of such documents. 

  

	(I)	The Guarantor is a holding company of the Buyers and has become a party to this Agreement for the purpose of entering into the guarantee and indemnity set out in Clause 28 and
the undertakings set out in Clauses 13 and 14 and the giving of the warranties set out in Clause 9.2. 

  

	(J)	The Covenantors are party to this Agreement solely for the purpose of providing for their agreement to comply with the provisions of Clauses 10, 12 and
17 of this Agreement. 

 It is agreed as follows: 
  

	1	Definitions and Interpretation 

  

	1.1	In this Agreement the following words and expressions shall, unless the context otherwise requires, have the following meanings: 

  

			
	“1990 ACT”	  	MEANS THE COMPANIES ACT 1990;
		
	“ACCOUNTS”	  	MEANS THE AUDITED BALANCE SHEET OF EACH OF THE GROUP COMPANIES AS AT THE ACCOUNTS DATE, AND THE AUDITED PROFIT AND LOSS ACCOUNT OF EACH OF THE GROUP COMPANIES FOR THE PERIOD ENDED ON
THE ACCOUNTS DATE, TOGETHER WITH THE NOTES THERETO AND THE DIRECTORS’ REPORT AND AUDITOR’S REPORT THEREON AND TOGETHER WITH ALL DOCUMENTS WHICH ARE REQUIRED BY LAW TO BE ATTACHED THERETO, A COPY OF WHICH IS SET OUT IN THE DISCLOSURE
LETTER;
		
	“ACCOUNTS DATE”	  	MEANS 31 DECEMBER 2008;
		
	“AGREED TREATMENTS”	  	MEANS THE SPECIFIC ACCOUNTING TREATMENTS AND POLICIES SET OUT IN SCHEDULE 7;

  

 2 

			
	“ALLOCATION SCHEDULE”	  	MEANS THE SCHEDULE TO BE PREPARED BY THE BUYERS AND EXCHANGED AND AGREED BETWEEN THE BUYERS AND THE SELLER IN ACCORDANCE WITH CLAUSE 4.2;
		
	“ANGLO CHARGES”	  	MEANS THE ANGLO SHARE CHARGES AND THE ANGLO OTHER CHARGES;
		
	“ANGLO DEBT”	  	MEANS THE VERIS DEBT AND THE VUKL DEBT;
		
	“ANGLO OTHER CHARGES”	  	MEANS THE DEBENTURE, COMPOSITE DEBENTURES, GUARANTEES AND INDEMNITIES, AND OTHER AGREEMENTS SET OUT IN SCHEDULE 10;
		
	“ANGLO SHARE CHARGES”	  	 MEANS THE FOLLOWING SHARE CHARGES GRANTED BY THE SELLER OR A GROUP COMPANY IN FAVOUR OF THE BANK:
  
 (A) SHARE CHARGE DATED 22ND DECEMBER 2004 BETWEEN THE SELLER AND THE BANK IN RESPECT OF
THE VWFM SHARES;
  
 (B) SHARE CHARGE DATED 22ND DECEMBER 2004 BETWEEN THE
SELLER AND THE BANK IN RESPECT OF THE IEM SHARES;
  
 (C) SHARE CHARGE DATED
30 NOVEMBER 2006 BETWEEN THE SELLER AND THE BANK IN RESPECT OF THE PMC SHARES;
  
 (D) SHARE CHARGE DATED 30 NOVEMBER 2006 BETWEEN THE SELLER AND THE BANK IN RESPECT OF THE GPS SHARES; AND
  
 (E) SHARE CHARGE DATED 22 DECEMBER 2004 BETWEEN THE SELLER AND THE BANK IN RESPECT OF THE SHARES OF IRISH ESTATES (FACILITIES MANAGEMENT)
LIMITED;
  
 (F) SHARE CHARGE DATED 29 NOVEMBER 2007 MADE BETWEEN VUKL AND
THE BANK IN RESPECT OF SHARES IN ORANGE ENVIRONMENTAL BUILDING SERVICES LIMITED AND ORANGE SUPPORT SERVICES LIMITED;
  
 (G) SHARE CHARGE DATED 21 DECEMBER 2007 MADE BETWEEN ORANGE ENVIRONMENTAL BUILDING SERVICES

  

 3 

			
		  	 LIMITED AND THE BANK IN RESPECT OF SHARES IN ORANGE FABRIC SERVICES LIMITED (NOW KNOWN AS VERIS PROPERTY MANAGEMENT LIMITED);
AND
  
 (H) SHARE CHARGE DATED 29 NOVEMBER 2007 BETWEEN THE SELLER AND THE
BANK REGARDING THE SHARES IN VUKL;

		
	“APPLICABLE RATE”	  	MEANS THE APPLICABLE EURO EXCHANGE RATE QUOTED BY THE GOVERNOR AND COMPANY OF THE BANK OF IRELAND AT 5.00 PM ON THE BUSINESS DAY PRIOR TO THE BALANCE SHEET DATE;
		
	“APPROVED”	  	MEANS EXEMPT APPROVED BY THE REVENUE COMMISSIONERS FOR THE PURPOSES OF SECTION 774 OF THE TAXES CONSOLIDATION ACT AND REFERENCE TO “APPROVAL” SHALL BE CONSTRUED
ACCORDINGLY;
		
	“BALANCE SHEET DATE”	  	MEANS THE COMPLETION DATE;
		
	“BANK”	  	MEANS ANGLO IRISH BANK;
		
	“BANK’S SOLICITORS”	  	MEANS ARTHUR COX, OF EARLSFORT CENTRE, EARLSFORT TERRACE, DUBLIN 2
		
	“BUSINESS”	  	MEANS THE BUSINESS OF FACILITY MANAGEMENT, PROPERTY MANAGEMENT AND ALL OTHER BUSINESS AS CARRIED ON BY THE GROUP AT THE DATE HEREOF;
		
	“BUSINESS DAY”	  	MEANS A DAY (OTHER THAN A SATURDAY OR SUNDAY) ON WHICH BANKS ARE OPEN FOR THE CONDUCT OF THEIR NORMAL BUSINESS IN DUBLIN;
		
	“BUYERS”	  	MEANS THE IRISH BUYER AND THE UK BUYER;
		
	“BUYERS’ GROUP”	  	MEANS THE PARENT COMPANY OF THE BUYERS AND ANY SUBSIDIARY OF THE PARENT COMPANY OF THE BUYERS, SUBSIDIARY AND PARENT COMPANY FOR THIS PURPOSE TO BE AS DEFINED IN SECTION 155 OF THE
COMPANIES ACT 1963;

  

 4 

			
	“BUYER NON-DISCLOSABLE INFORMATION”	  	 MEANS ALL INFORMATION (INCLUDING BUT NOT LIMITED TO CONFIDENTIAL INFORMATION) WHICH RELATES TO:
  
 (A) THE GROUP;
  
 (B) ANY ASPECT OF THE BUSINESS;
  
 (C) THE PROVISIONS OF THIS AGREEMENT;
  
 (D) THE NEGOTIATIONS RELATING TO THIS AGREEMENT;
  
 (E) THE SUBJECT MATTER OF THIS AGREEMENT; OR
  
 (F) THE BUYERS OR ANY MEMBER OF THE BUYERS’ GROUP FROM TIME TO
TIME;

		
	“BUYERS’ SOLICITORS”	  	MEANS MATHESON ORMSBY PRENTICE OF 70 SIR JOHN ROGERSON’S QUAY, DUBLIN 2, IRELAND AND MORGAN, LEWIS & BOCKIUS OF CONDOR HOUSE, 5-10 ST. PAUL’S CHURCHYARD, LONDON, EC4M
8AL;
		
	“CASH AMOUNT”	  	 MEANS, AS AT 5.00PM ON THE BALANCE SHEET DATE, THE AGGREGATE, IN EUROS (INCLUDING FOR THE AVOIDANCE OF DOUBT ANY OTHER CURRENCY ON AN AS
CONVERTED BASIS INTO EUROS AT THE APPLICABLE RATE), OF ALL:
  
 (A) POSITIVE
(CREDIT) BALANCES IN THE BANK ACCOUNTS OF EACH OF THE GROUP COMPANIES;
  
 (B)
CASH AT HAND OF EACH OF THE GROUP COMPANIES AND ANY CASH EQUIVALENTS;
  
 (C)
UNPRESENTED OR UNCLEARED CHEQUES BEARING A DATE NOT MORE THAN 14 DAYS PRIOR TO THE COMPLETION DATE IN THE POSSESSION OF EACH OF THE GROUP COMPANIES AND MADE OUT TO SUCH GROUP COMPANY;
  
 LESS THE AGGREGATE OF ALL:
  
 (D) CHEQUES WHICH HAVE BEEN SIGNED AND DATED BY EACH OF THE GROUP COMPANIES BUT NOT YET
PRESENTED OR CLEARED; AND
  
 (E) ANY COSTS, EXPENSES AND FEES
FOR

  

 5 

			
		  	 LEGAL, ACCOUNTING, FINANCIAL ADVISORY, CONSULTING OR INVESTMENT BANKING INCURRED BY ANY GROUP COMPANY IN CONNECTION WITH THE NEGOTIATION,
DOCUMENTATION AND PERFORMANCE OF THIS AGREEMENT AND THE CONSUMMATION OF THE TRANSACTION, WHICH REMAIN OUTSTANDING AS AT COMPLETION;
  
 FOR THE AVOIDANCE OF DOUBT THE VAT RECLAIM IS NOT TO BE CONSIDERED AS A COMPONENT OF THE CASH AMOUNT.

		
	“CLAIM”	  	MEANS ANY CLAIM BY THE BUYERS IN RELATION TO A BREACH OF WARRANTY, OR THE TAX COVENANT OR THE MM INDEMNITY OR OTHER BREACH BY THE SELLER OF THIS AGREEMENT OR ANY ANCILLARY
DOCUMENTS;
		
	“COMPANIES ACTS”	  	MEANS THE COMPANIES ACTS 1963 TO 2009 OF IRELAND AND THE COMPANIES ACTS 1985 AND 2006 OF THE UNITED KINGDOM AND ANY LEGISLATION IN WHATEVER FORM TO BE CONSTRUED AS ONE WITH THOSE
ACTS;
		
	“COMPETITION ACT”	  	MEANS THE COMPETITION ACT, 2002;
		
	“COMPLETION”	  	MEANS COMPLETION OF THE SALE AND PURCHASE OF THE SHARES IN ACCORDANCE WITH THIS AGREEMENT;
		
	“COMPLETION ADJUSTMENT”	  	MEANS AN AMOUNT, IF ANY, PAYABLE BY THE BUYERS OR THE SELLER PURSUANT TO CLAUSE 5;
		
	“COMPLETION DATE”	  	HAS THE MEANING GIVEN TO IT IN CLAUSE 7.2;
		
	“COMPUTER SYSTEMS”	  	MEANS THE HARDWARE AND THE SOFTWARE;
		
	“CONDITIONS”	  	MEANS THE CONDITIONS SET OUT IN SCHEDULE 2;
		
	“CONFIDENTIAL INFORMATION”	  	MEANS ALL TECHNICAL, FINANCIAL, COMMERCIAL AND OTHER INFORMATION OF A CONFIDENTIAL NATURE RELATING TO THE BUSINESS, INCLUDING TRADE SECRETS, KNOW-HOW, INVENTIONS, PRODUCT INFORMATION
AND UNPUBLISHED INFORMATION RELATING TO INTELLECTUAL PROPERTY, OBJECT CODE

  

 6 

			
		  	AND SOURCE CODE, MARKETING AND BUSINESS PLANS, PROJECTIONS, INFORMATION ON CURRENT OR PROJECTED PLANS OR INTERNAL AFFAIRS OF THE GROUP, SECRET INFORMATION, INFORMATION ON CURRENT AND/OR
PROSPECTIVE SUPPLIERS AND CUSTOMERS (INCLUDING ANY CUSTOMER OR SUPPLIER LISTS) AND INFORMATION ON ANY OTHER PERSON WHO HAS HAD MATERIAL DEALINGS WITH THEM;
		
	“CONNECTED PERSON”	  	MEANS IN RELATION TO A PERSON, ANY PERSON WHO IS CONNECTED WITH THAT PERSON BY VIRTUE OF SECTION 10 OF THE TCA;
		
	“CONSIDERATION”	  	MEANS THE TOTAL CONSIDERATION TO BE PAID FOR THE SHARES AS SET OUT IN CLAUSE 4.1 OF THIS AGREEMENT, AS ADJUSTED IN ACCORDANCE WITH CLAUSE 5;
		
	“CONSIDERATION STATEMENT”	  	MEANS THE STATEMENT AS AT THE BALANCE SHEET DATE AGREED OR DETERMINED IN ACCORDANCE WITH CLAUSE 5;
		
	“CONTINUING DIRECTORS”	  	MEANS THE DIRECTORS AS NOTIFIED BY THE BUYERS TO THE SELLER AT LEAST 3 BUSINESS DAYS PRIOR TO COMPLETION;
		
	“CORPORATE INTELLECTUAL PROPERTY”	  	MEANS ANY AND ALL INTELLECTUAL PROPERTY RIGHTS WHICH ARE OWNED BY OR ARISE DIRECTLY FROM THE ACTIVITIES OF THE GROUP COMPANIES, OR WHICH ARE USED IN THE CONNECTION WITH THE
BUSINESS;
		
	“CURRENT ASSETS AMOUNT”	  	 MEANS THE AGGREGATE AMOUNT, IN EUROS (INCLUDING FOR THE AVOIDANCE OF DOUBT ANY OTHER CURRENCY ON AN AS CONVERTED BASIS INTO EUROS AT THE
APPLICABLE RATE), OF THE VALUE OF THE GROUP’S:
  
 (A) BOOK DEBTS (NET OF
PROVISIONS);
  
 (B) ACCRUED INCOME;
  
 (C) PREPAYMENTS, BEING PAYMENTS MADE PRIOR TO THEIR RESPECTIVE DUE DATE;
AND

  

 7 

			
		  	 (D) STOCK-IN-TRADE,
  
 (OTHER THAN TO THE EXTENT COMPRISED IN THE CASH AMOUNT) AND EITHER: (I) AS AT 5.00PM IRISH TIME ON THE BALANCE SHEET DATE FOR THE PURPOSES OF CALCULATING THE
WORKING CAPITAL AMOUNT OR (II) ON THE DAY FALLING ON THE LAST DAY OF THE RELEVANT CALENDAR MONTH FOR THE PURPOSES OF CALCULATING THE MANAGEMENT ACCOUNTS WORKING CAPITAL AMOUNT; IN BOTH CASES EXCLUDING ANY AMOUNTS OWED OR OWING BY A GROUP COMPANY TO
(A) ANOTHER GROUP COMPANY OR (B) THE SELLER;

		
	“CURRENT LIABILITIES AMOUNT”	  	 MEANS THE AGGREGATE AMOUNT, IN EUROS (INCLUDING FOR THE AVOIDANCE OF DOUBT ANY OTHER CURRENCY ON AN AS CONVERTED BASIS INTO EUROS AT THE
APPLICABLE RATE), OF THE GROUP’S:
  
 (A) ACCOUNTS PAYABLE;

 
 (B) VAT PAYABLE BUT UNPAID, EXCLUDING ANY VAT IN CONNECTION WITH THE PRE-COMPLETION
SUPPLIES;
  
 (C) PAYE PAYABLE BUT UNPAID;
  
 (D) ACCRUALS AND PROVISIONS (INCLUDING LITIGATION PROVISIONS); AND
  
 (E) SOCIAL SECURITY CONTRIBUTION PROVISIONS,
  
 OTHER THAN TO THE EXTENT COMPRISED IN THE DEBT AMOUNT AND EITHER: (I) AS AT 5.00PM IRISH TIME
ON THE BALANCE SHEET DATE FOR THE PURPOSES OF CALCULATING THE WORKING CAPITAL AMOUNT OR (II) ON THE DAY FALLING ON THE LAST DAY OF THE RELEVANT CALENDAR MONTH FOR THE PURPOSES OF CALCULATING THE MANAGEMENT ACCOUNTS WORKING CAPITAL AMOUNT; IN BOTH
CASES EXCLUDING ANY AMOUNTS OWED OR OWING BY A GROUP COMPANY TO (A) ANOTHER GROUP COMPANY OR (B) THE SELLER;

		
	“DATA PROTECTION ACTS”	  	MEANS THE DATA PROTECTION ACTS 1988 AND 2003 OF IRELAND AND THE DATA

  

 8 

			
		  	PROTECTION ACTS 1994 AND 1998 OF THE UNITED KINGDOM;
		
	“DEBT AMOUNT”	  	 MEANS, AS AT 5.00PM IRISH TIME ON THE BALANCE SHEET DATE,
  
 (I) THE PENSION DEFICIT AMOUNT;
  
 (II) THE AGGREGATE IN EUROS (INCLUDING FOR THE AVOIDANCE OF DOUBT ANY OTHER CURRENCY ON AN AS
CONVERTED BASIS INTO EUROS AT THE APPLICABLE RATE) OF ALL BORROWINGS; AND
  
 (III) OTHER INDEBTEDNESS IN THE NATURE OF THE BORROWINGS OF EACH OF THE GROUP COMPANIES, INCLUDING ALL:
  
 (A) FACILITIES;
  
 (B) BREAK FEES,
PREPAYMENT FEES OR OTHER COSTS, EXPENSES OR PENALTIES RELATED TO OR ARISING AS A RESULT OF THE TERMINATION OR PREPAYMENT OF ANY FACILITIES PURSUANT TO THIS TRANSACTION;
  
 (C) AMOUNTS OWED BY THE GROUP COMPANIES TO THE SELLER OR ANY SHAREHOLDER OF THE SELLER (OTHER
THAN IN HIS OR HER CAPACITY AS AN EMPLOYEE);
  
 (D) RECOURSE FACTORING OR
RECOURSE DISCOUNTING OF RECEIVABLES;
  
 (E) ANY AMOUNTS DRAWN DOWN ON ALL
LETTERS OF CREDIT ISSUED FOR THE ACCOUNT OF THE GROUP;
  
 (F) THE AMOUNT OF ANY
OBLIGATION GUARANTEEING INDEBTEDNESS OR OTHER OBLIGATIONS OF ANY PERSON OTHER THAN A GROUP COMPANY TO THE EXTENT NOT RELEASED AT OR PRIOR TO THE COMPLETION DATE;
  
 (G) OBLIGATIONS OF THE GROUP TO PAY THE DEFERRED PURCHASE PRICE OR ACQUISITION PRICE FOR ANY SHARES OF THE GROUP COMPANIES OR FOR ANY PROPERTY OR SERVICES, OTHER
THAN TRADE OR ACCOUNTS PAYABLE ARISING, AND ACCRUED EXPENSES INCURRED, IN THE ORDINARY COURSE OF BUSINESS

  

 9 

			
		  	 CONSISTENT WITH PAST PRACTICE;
  
 (H) NEGATIVE (DEBIT) BALANCES IN THE BANK ACCOUNTS OF EACH OF THE GROUP COMPANIES;
  
 (I) ALL INTEREST, FEES AND OTHER EXPENSES ACCRUED ON ANY OR ALL OF THE BORROWINGS DETAILED IN
(A) TO (H) ABOVE;
  
 (J) ALL CORPORATION AND CAPITAL GAINS TAX LIABILITIES OF
THE GROUP COMPANIES ARISING ON OR BEFORE 5.00PM ON THE BALANCE SHEET DATE (TO THE EXTENT NOT PAID BY THE SELLER OR A GROUP COMPANY PRIOR TO SUCH TIME) AND INCLUDING ANY ACCRUED CORPORATION TAX (COMPUTED AS AT 5.00 PM ON THE BALANCE SHEET DATE AS IF
SUCH TIME WAS THE END OF AN ACCOUNTING PERIOD FOR THE GROUP COMPANIES); AND
  
 BUT EXCLUDING ANY AMOUNTS OWED BY A GROUP COMPANY TO ANOTHER GROUP COMPANY AND ANY AMOUNTS OWING BY ANY GROUP COMPANY IN RESPECT OF OPERATING LEASES OR ANY AMOUNT ATTRIBUTABLE TO THE VERIS FACILITY OR THE VUKL FACILITY, PROVIDED THAT THE
VERIS FACILITY AND THE VUKL FACILITY ARE REPAID IN ACCORDANCE WITH CLAUSE 4.2;

		
	“DEFINED BENEFIT SCHEME”	  	MEANS A PENSION SCHEME UNDER WHICH THE AMOUNT OF SOME OR ALL OF THE BENEFITS PAYABLE TO OR IN RESPECT OF A MEMBER OF THE SCHEME IS CALCULATED IN ACCORDANCE WITH A FORMULA WHICH TAKES
ACCOUNT OF THE SERVICE OF THE MEMBER TO RETIREMENT, DEATH OR WITHDRAWAL AND THE REMUNERATION OF THE MEMBER AVERAGED OVER HIS SERVICE AT OR CLOSE TO HIS RETIREMENT, DEATH OR WITHDRAWAL;
		
	“DEFINED CONTRIBUTION SCHEME”	  	MEANS A SCHEME UNDER WHICH THE AMOUNT OF THE BENEFITS OTHER THAN SOME OR ALL OF THE BENEFITS PAYABLE ON DEATH BEFORE BECOMING A PENSIONER, PAYABLE TO OR IN RESPECT OF A MEMBER OF THE
SCHEME IS CALCULATED BY REFERENCE TO THE

  

 10 

			
		  	CONTRIBUTIONS MADE TO THE SCHEME BY AND IN RESPECT OF THE MEMBER;
		
	“DIRECTORS”	  	MEANS THE PERSONS SPECIFIED AS DIRECTORS OF ANY OF THE GROUP COMPANIES IN PARTS 1, 2 OR 3 OF SCHEDULE 1 (THE EXPRESSION “DIRECTOR” MEANING ANY OF THEM), BEING ALL THE
DIRECTORS OF THE GROUP COMPANIES AS AT THE DATE OF THIS AGREEMENT;
		
	“DISCLOSED”	  	MEANS FAIRLY DISCLOSED IN THE DISCLOSURE LETTER, IN THE MANNER AND IN SUCH REASONABLE DETAIL AS TO ENABLE THE BUYERS TO MAKE A REASONABLE ASSESSMENT OF THE NATURE AND SCOPE OF THE
MATTER DISCLOSED AND WITH SPECIFIC REFERENCE OR CROSS REFERENCE TO THE WARRANTY AGAINST WHICH SUCH DISCLOSURE IS MADE AND FOR THE AVOIDANCE OF DOUBT, ANY DISCLOSURE MADE BY THE SELLER AFTER THE DATE OF THIS AGREEMENT BUT PRIOR TO COMPLETION SHALL
NOT BE TAKEN TO BE DISCLOSED;
		
	“DISCLOSURE LETTER”	  	MEANS THE LETTER OF TODAY’S DATE FROM THE SELLER TO THE BUYERS (TOGETHER WITH ALL DOCUMENTS SCHEDULED OR APPENDED THERETO) DISCLOSING CERTAIN EXCEPTIONS TO THE
WARRANTIES;
		
	“DRAFT CONSIDERATION STATEMENT”	  	SHALL HAVE THE MEANING ASCRIBED TO SUCH TERM IN CLAUSE 5.1;
		
	“ENCUMBRANCE”	  	MEANS ANY RIGHT, ADVERSE CLAIM, INTEREST OR EQUITY OF ANY PERSON (INCLUDING WITHOUT LIMITATION ANY PRE-EMPTION RIGHT, RIGHT OF FIRST REFUSAL, OPTION, RIGHT TO ACQUIRE OR RIGHT TO
RESTRICT) OR ANY MORTGAGE, CHARGE, PLEDGE, LIEN, ASSIGNMENT, RESTRICTION, HYPOTHECATION, SECURITY OR PRIORITY INTEREST, TITLE RETENTION, HIRE PURCHASE, LEASE OR INSTALMENT PURCHASE AGREEMENT OR OTHER SECURITY OR PRIORITY AGREEMENT OR
ARRANGEMENT;
		
	“ENVIRONMENT”	  	INCLUDES (A) ANY AND ALL BUILDINGS, STRUCTURES, FIXTURES, FITTINGS, APPURTENANCES, PIPES, CONDUITS,

  

 11 

			
		  	VALVES, TANKS, VESSELS AND CONTAINERS WHETHER ABOVE OR BELOW GROUND LEVEL, AND (B) AMBIENT AIR, LAND SURFACE, SUB-SURFACE STRATA, SOIL, SURFACE WATER, GROUND WATER, RIVER SEDIMENT,
MARSHES, WET LANDS, FLORA AND FAUNA;
		
	“ENVIRONMENTAL LAWS”	  	MEANS (A) THE COMMON LAW AND (B) ALL LAWS, BY-LAWS, STATUTES, REGULATIONS, RULES, ORDERS, INSTRUMENTS, DECREES, DIRECTIVES, DECISIONS, INJUNCTIONS, RULINGS AND JUDGMENTS OF ANY
GOVERNMENT, LOCAL GOVERNMENT, INTERNATIONAL, SUPRANATIONAL, EXECUTIVE, ADMINISTRATIVE, JUDICIAL OR REGULATORY AUTHORITY OR AGENCY WHETHER OF IRELAND, THE UNITED KINGDOM, THE EUROPEAN UNION OR ELSEWHERE AND ALL APPROVED CODES OF PRACTICE (WHETHER
VOLUNTARY OR COMPULSORY) RELATING TO THE PROTECTION OF THE ENVIRONMENT OR OF HUMAN HEALTH OR SAFETY OR WELFARE OR TO THE MANUFACTURE, FORMULATION, PROCESSING, TREATMENT, STORAGE, CONTAINMENT, LABELLING, HANDLING, TRANSPORTATION, DISTRIBUTION,
RECYCLING, REUSE, RELEASE, DISPOSAL, REMOVAL, REMEDIATION, ABATEMENT OR CLEAN-UP OF ANY HAZARDOUS MATERIAL INCLUDING THE PROVISIONS OF THE PUBLIC HEALTH (IRELAND) ACT 1878, THE FISHERIES ACTS 1959-2000, THE LOCAL GOVERNMENT (WATER POLLUTION) ACTS
1977 AND 1990, THE EUROPEAN COMMUNITIES (WASTE) REGULATIONS 1979, THE AIR POLLUTION ACT 1987, THE EUROPEAN COMMUNITIES (ENVIRONMENTAL IMPACT ASSESSMENT) REGULATIONS 1989, THE PLANNING ACTS THE PLANNING AND DEVELOPMENT REGULATIONS 2001, THE BUILDING
CONTROL ACT 1990, THE ENVIRONMENTAL PROTECTION AGENCY ACT 1992, AND THE WASTE MANAGEMENT ACT 1996, THE HEALTH AND SAFETY AT WORK ACT 1974, THE CONTROL OF ASBESTOS REGULATIONS 2006 AND THE CONSTRUCTION (DESIGN AND MANAGEMENT) REGULATIONS 2007 AND ANY
AMENDMENT THERETO AND ANY AND ALL REGULATIONS, ORDERS AND NOTICES MADE OR SERVED THEREUNDER OR

  

 12 

			
		  	PURSUANT THERETO;
		
	“ENVIRONMENTAL LICENCE”	  	MEANS ANY PERMIT, LICENCE, APPROVAL, PERMISSION, CONSENT OR AUTHORISATION REQUIRED BY OR PURSUANT TO ANY APPLICABLE ENVIRONMENTAL LAWS;
		
	“ESTIMATED NET CASH AMOUNT”	  	MEANS, €3,800,000, OR SUCH OTHER AMOUNT (IN EUROS) AGREED BETWEEN THE
SELLER AND THE BUYER PRIOR TO THE COMPLETION DATE;
		
	“EVENT”	  	INCLUDES (WITHOUT LIMITATION) COMPLETION OF THE SALE OF THE SHARES TO THE BUYERS, THE DEATH OR THE WINDING UP OR DISSOLUTION OF ANY PERSON, OR ANY ACT, FAILURE TO ACT, TRANSACTION OR
OMISSION WHATSOEVER WHETHER OR NOT THE GROUP COMPANY IS A PARTY TO THE ACT OR FAILURE TO ACT OR TRANSACTION OR INVOLVED IN THE OMISSION, AND ANY REFERENCE TO AN EVENT OCCURRING ON OR BEFORE A PARTICULAR DATE SHALL INCLUDE AN EVENT WHICH FOR TAX
PURPOSES IS DEEMED TO HAVE, OR IS TREATED OR REGARDED AS HAVING, OCCURRED ON OR BEFORE THAT DATE AND REFERENCES TO AN EVENT OCCURRING ON OR BEFORE COMPLETION SHALL BE DEEMED TO INCLUDE A SERIES OR COMBINATION OF EVENTS, THE FIRST OF WHICH OCCURRED
ON OR BEFORE COMPLETION OUTSIDE THE ORDINARY COURSE OF BUSINESS AND THE SECOND OF WHICH OCCURRED AFTER COMPLETION WITHIN THE ORDINARY COURSE OF BUSINESS AND THE ORDINARY COURSE OF BUSINESS FOR THESE PURPOSES SHALL BE THE ORDINARY COURSE OF BUSINESS
AS CARRIED ON IMMEDIATELY BEFORE COMPLETION;
		
	“EXCLUSIVE ASSETS”	  	MEANS ANY OF THE SHARES, ANY SHARES IN THE SELLER, ANY ASSETS OF A GROUP COMPANY OR ANY PART THEREOF;
		
	“EXPIRY DATE”	  	MEANS THE DATE FALLING 6 MONTHS AFTER THE COMPLETION DATE;
		
	“FACILITIES”	  	MEANS THE VERIS FACILITY AND ALL DEBENTURES, ACCEPTANCE CREDITS, OVERDRAFTS, LOANS, LOAN STOCKS OR OTHER FINANCIAL FACILITIES OUTSTANDING OR AVAILABLE TO THE GROUP COMPANIES INCLUDING
THE VUKL

  

 13 

			
		  	FACILITY;
		
	“GENERAL WARRANTIES”	  	MEANS THE WARRANTIES AND UNDERTAKINGS SET OUT IN PART 2 OF SCHEDULE 5;
		
	“GOVERNMENTAL AUTHORITY”	  	MEANS ANY GOVERNMENT AND ANY GOVERNMENTAL ENTITY, DEPARTMENT, COMMISSION, BOARD, AGENCY, COURT, TRIBUNAL, ARBITRATOR, INSTRUMENTALITY, OR GOVERNMENTAL OR REGULATORY OFFICIAL, WHETHER
FEDERAL, STATE, LOCAL OR FOREIGN;
		
	“GPS”	  	MEANS GLENRYE PROPERTIES SERVICES LIMITED;
		
	“GPS SHARES”	  	MEANS 1,052 ISSUED ORDINARY SHARES OF €1.269738 EACH IN THE CAPITAL OF GPS
BEING THE ENTIRE ISSUED SHARE CAPITAL OF GPS;
		
	“GROUP”	  	MEANS THE IRISH COMPANIES, VUKL AND EACH OF THE SUBSIDIARIES, EACH A “GROUP COMPANY”;
		
	“GROUP DIRECTORS”	  	MEANS THE DIRECTORS OF THE SELLER AND THE DIRECTORS;
		
	“HARDWARE”	  	MEANS ANY COMPUTER EQUIPMENT USED BY OR FOR THE BENEFIT OF THE GROUP AT ANY TIME INCLUDING, WITHOUT LIMITATION, COMMUNICATION SYSTEMS, INFRASTRUCTURE AND NETWORKS AND COMPONENTS OR
ELEMENTS OF THE FOREGOING SUCH AS FIRMWARE, SCREENS, TERMINALS, KEYBOARDS, DISKS AND CABLING AND OTHER PERIPHERAL AND ASSOCIATED ELECTRONIC EQUIPMENT BUT EXCLUDING ALL SOFTWARE;
		
	“HAZARDOUS MATERIALS”	  	MEANS (I) ANY CHEMICAL, MATERIAL OR SUBSTANCE AT ANY TIME DEFINED AS OR INCLUDED IN THE DEFINITION OF “HAZARDOUS SUBSTANCES”, “HAZARDOUS WASTES”, “HAZARDOUS
MATERIALS”, “EXTREMELY HAZARDOUS WASTE”, ACUTELY HAZARDOUS WASTE”, “RADIOACTIVE WASTE”, “BIOHAZARDOUS WASTE”, “POLLUTANT”, “TOXIC POLLUTANT”, “CONTAMINANT”, “RESTRICTED
HAZARDOUS WASTE”, “INFECTIOUS WASTE”, “TOXIC

  

 14 

			
		  	SUBSTANCES”, OR ANY OTHER TERM OR EXPRESSION INTENDED TO DEFINE, LIST OR CLASSIFY SUBSTANCES BY REASON OF PROPERTIES HARMFUL TO HEALTH, SAFETY OR THE INDOOR OR OUTDOOR ENVIRONMENT
(INCLUDING HARMFUL PROPERTIES SUCH AS IGNITABILITY, CORROSIVITY, REACTIVITY, CARCINOGENICITY, TOXICITY, REPRODUCTIVE TOXICITY, “TCLP TOXICITY” OR “EP TOXICITY” OR WORDS OF SIMILAR IMPORT UNDER ANY APPLICABLE ENVIRONMENTAL LAWS);
(II) ANY OIL, PETROLEUM, PETROLEUM FRACTION OR PETROLEUM DERIVED SUBSTANCE; (III) ANY DRILLING FLUIDS, PRODUCED WATERS AND OTHER WASTES ASSOCIATED WITH THE EXPLORATION, DEVELOPMENT OR PRODUCTION OF CRUDE OIL, NATURAL GAS OR GEOTHERMAL RESOURCES;
(IV) ANY FLAMMABLE SUBSTANCES OR EXPLOSIVES; (V) ANY RADIOACTIVE MATERIALS; (VI) ANY ASBESTOS-CONTAINING MATERIALS; (VII) UREA FORMALDEHYDE FOAM INSULATION; (VIII) ELECTRICAL EQUIPMENT WHICH CONTAINS ANY OIL OR DIELECTRIC FLUID CONTAINING
POLYCHLORINATED BIPHENYLS OR RADON; (IX) PESTICIDES; AND (X) ANY OTHER CHEMICAL, MATERIAL OR SUBSTANCE, EXPOSURE TO WHICH IS PROHIBITED, LIMITED OR REGULATED BY ANY GOVERNMENTAL AUTHORITY OR WHICH MAY OR COULD POSE A HAZARD TO THE HEALTH AND SAFETY
OF THE OWNERS, OCCUPANTS OR ANY PERSONS IN THE VICINITY OF ANY LOCATION OF A GROUP COMPANY’S OPERATIONS OR TO THE INDOOR OR OUTDOOR ENVIRONMENT;
		
	“HAZARDOUS MATERIALS ACTIVITY”	  	MEANS ANY PAST, CURRENT, PROPOSED OR THREATENED ACTIVITY, EVENT OR OCCURRENCE INVOLVING ANY HAZARDOUS MATERIALS, INCLUDING THE USE, MANUFACTURE, POSSESSION, STORAGE, HOLDING, PRESENCE,
EXISTENCE, LOCATION, RELEASE, THREATENED RELEASE, DISCHARGE, PLACEMENT, GENERATION, TRANSPORTATION, PROCESSING, CONSTRUCTION, TREATMENT, ABATEMENT, REMOVAL, REMEDIATION, DISPOSAL, DISPOSITION OR HANDLING OF ANY HAZARDOUS MATERIALS, AND ANY
CORRECTIVE ACTION OR RESPONSE ACTION WITH RESPECT TO

  

 15 

			
		  	ANY OF THE FOREGOING;
		
	“IEFM”	  	MEANS IRISH ESTATES (FACILITIES MANAGEMENT) LIMITED, A SUBSIDIARY OF IEM;
		
	“IEM”	  	MEANS IRISH ESTATES (MANAGEMENT) LIMITED;
		
	“IEM SHARES”	  	MEANS 260,100 ISSUED ORDINARY SHARES OF €1.25 EACH IN THE CAPITAL OF IEM
BEING THE ENTIRE ISSUED SHARE CAPITAL OF IEM;
		
	“INDEPENDENT ACCOUNTANT”	  	MEANS AN ACCOUNTING EXPERT APPOINTED BY AGREEMENT BETWEEN THE SELLER AND THE BUYERS OR, IN DEFAULT OF APPOINTMENT BY AGREEMENT BETWEEN THEM OVER A PERIOD OF 5 BUSINESS DAYS, ON
APPLICATION OF EITHER PARTY BY THE PRESIDENT FROM TIME TO TIME OF THE INSTITUTE OF CHARTERED ACCOUNTANTS IN IRELAND (OR ANY SUCCESSOR BODY) PROVIDED HOWEVER THAT SUCH ACCOUNTING EXPERT MUST BE A QUALIFIED MEMBER OF THE INSTITUTE OF CHARTERED
ACCOUNTANTS IN IRELAND WITH AN APPROPRIATE LEVEL OF EXPERIENCE AND MUST PRACTICE IN ONE OF THE “BIG FOUR” ACCOUNTING PRACTICES (PRICE WATERHOUSECOOPERS, KPMG, ERNST & YOUNG AND DELOITTE) PROVIDED FURTHER THAT SUCH INDIVIDUAL SHALL NOT
HAVE PREVIOUSLY PERFORMED ADVISORY SERVICES FOR ANY MEMBER OF THE BUYERS’ GROUP;
		
	“INDEPENDENT COUNSEL”	  	MEANS A SENIOR COUNSEL APPOINTED BY AGREEMENT BETWEEN THE SELLER AND THE BUYERS OR, IN DEFAULT OF APPOINTMENT BY AGREEMENT BETWEEN THEM OVER A PERIOD OF 5 BUSINESS DAYS, ON APPLICATION
OF EITHER PARTY BY THE PRESIDENT FROM TIME TO TIME OF THE LAW SOCIETY OF IRELAND (OR ANY SUCCESSOR BODY) PROVIDED HOWEVER THAT SUCH COUNSEL MUST BE A QUALIFIED MEMBER OF THE BAR COUNCIL OF IRELAND WITH AN APPROPRIATE LEVEL OF EXPERIENCE PROVIDED
FURTHER THAT SUCH INDIVIDUAL SHALL NOT HAVE PREVIOUSLY PERFORMED ADVISORY SERVICES FOR ANY MEMBER OF THE BUYERS’ GROUP OR THE SELLER, OR ANY

  

 16 

			
		  	OF THE COVENANTORS OR ANY OF THE SELLER’S AFFILIATES;
		
	“INITIAL CONSIDERATION”	  	MEANS THE CONSIDERATION TO BE PAID BY THE BUYERS TO THE SELLER AT COMPLETION, COMPRISING THE AMOUNTS SET OUT AT CLAUSE 4.3 AND TO BE PAID AS PROVIDED PURSUANT TO CLAUSE
4.3;
		
	“INTELLECTUAL PROPERTY RIGHTS”	  	MEANS ANY AND ALL TRADE MARKS, SERVICE MARKS, RIGHTS IN GET UP, TRADE NAMES, BUSINESS NAMES AND DOMAIN NAMES, RIGHTS IN GOODWILL (INCLUDING RIGHTS TO SUE FOR PAST, PRESENT AND FUTURE
INFRINGEMENTS), RIGHTS IN DESIGNS (WHETHER REGISTERED OR UNREGISTERED), COPYRIGHT AND RELATED RIGHTS (INCLUDING RIGHTS IN COMPUTER PROGRAMS), DATABASE RIGHTS, SEMI-CONDUCTOR TOPOGRAPHY RIGHTS, PATENTS, UTILITY MODELS, KNOW-HOW, RIGHTS IN INVENTIONS,
DISCOVERIES AND IMPROVEMENTS, CONFIDENTIAL INFORMATION AND ALL APPLICATIONS TO REGISTER AND RIGHTS TO APPLY FOR REGISTRATION OF ANY OF THE FOREGOING RIGHTS TOGETHER WITH ALL OTHER RIGHTS OF A SIMILAR OR CORRESPONDING CHARACTER WHICH NOW, OR IN THE
FUTURE, MAY SUBSIST IN ANY PART OF THE WORLD;
		
	“IRELAND”	  	MEANS IRELAND (EXCLUDING NORTHERN IRELAND) AND “IRISH” WILL BE CONSTRUED ACCORDINGLY;
		
	“IRISH COMPANIES”	  	MEANS EACH OF THE COMPANIES NAMED IN PART 1 OF SCHEDULE 1, SHORT PARTICULARS OF WHICH ARE SET OUT THEREIN;
		
	“IRISH FACILITIES MANAGEMENT SHARES”	  	MEANS THE VWFM SHARES;
		
	“IRISH PROPERTY MANAGEMENT SHARES”	  	MEANS THE IEM SHARES, THE GPS SHARES AND THE PMC SHARES;
		
	“IRISH SHARES”	  	MEANS THE IRISH FACILITIES MANAGEMENT SHARES AND THE IRISH PROPERTY MANAGEMENT SHARES;
		
	“KNOW-HOW”	  	MEANS ALL INFORMATION, METHODS AND TECHNIQUES USED BY THE GROUP THAT IS NECESSARY FOR UNDERSTANDING AND OPERATING THE PROCESSES EMPLOYED,

  

 17 

			
		  	PRODUCTS MADE AND SERVICES PROVIDED BY THE GROUP AND INCLUDES, WITHOUT LIMITATION, ALL INSTRUCTION MANUALS, FORMULAE, SPECIFICATIONS, TEST RESULTS, PROCESS AND PRODUCT DESCRIPTIONS,
MARKET FORECASTS, AND CUSTOMER AND SUPPLIER PARTICULARS;
		
	“MANAGEMENT ACCOUNTS”	  	MEANS THE COMBINED BALANCE SHEET OF THE GROUP AS AT THE MANAGEMENT ACCOUNTS DATE AND THE COMBINED PROFIT AND LOSS ACCOUNT AND STATEMENT OF CASH FLOWS OF THE GROUP FOR THE PERIOD ENDED
ON THE MANAGEMENT ACCOUNTS DATE, A COPY OF WHICH IS SET OUT IN THE DISCLOSURE LETTER;
		
	“MANAGEMENT ACCOUNTS DATE”	  	MEANS 31 AUGUST 2009;
		
	“MANAGEMENT ACCOUNTS WORKING CAPITAL AMOUNT”	  	MEANS, IN RESPECT OF ANY GROUP COMPANY AND IN RESPECT OF ANY CALENDAR MONTH, THE AMOUNT IN EUROS OF THE CURRENT ASSETS AMOUNT LESS THE CURRENT LIABILITIES AMOUNT, A WORKED EXAMPLE OF
WHICH IS SET OUT AT SCHEDULE 8;
		
	“MATERIAL ADVERSE CHANGE”	  	MEANS AN ADVERSE AND LONG TERM CHANGE IN THE FINANCIAL CONDITION, ASSETS OR LIABILITIES OF THE GROUP COMPANIES (TAKEN AS A WHOLE) THAT SUBSTANTIALLY DIMINISHES THE REVENUE GENERATING
ABILITY OF THE GROUP COMPANIES (TAKEN AS A WHOLE) OVER THE LONG TERM;
		
	“MM INDEMNITY”	  	MEANS THE INDEMNITY GIVEN BY THE SELLER TO THE BUYER AND SET OUT IN CLAUSE 8.27;
		
	“NET CASH AMOUNT”	  	MEANS, IN EUROS, THE CASH AMOUNT LESS THE DEBT AMOUNT AS SET OUT IN THE CONSIDERATION STATEMENT;
		
	“NET CASH EXCESS AMOUNT”	  	MEANS, IN EUROS, THE AMOUNT (IF ANY) BY WHICH THE NET CASH AMOUNT IS GREATER THAN THE ESTIMATED NET CASH AMOUNT;
		
	“NET CASH AMOUNT SHORTFALL”	  	MEANS, IN EUROS, THE AMOUNT (IF ANY) BY WHICH THE NET CASH AMOUNT IS LESS THAN THE ESTIMATED NET CASH AMOUNT;

  

 18 

			
	“PENSION DEFICIT AMOUNT”	  	MEANS €1,200,000;
		
	“PENSION SCHEMES”	  	MEANS ALL EXISTING PENSION SCHEMES OF OR OPERATED BY OR IN RELATION TO THE GROUP, FULL PARTICULARS OF WHICH ARE SET OUT IN THE DISCLOSURE LETTER;
		
	“PENSIONS ACT”	  	MEANS THE PENSIONS ACT 1990 TO 2009 AND ALL REGULATIONS MADE THEREUNDER;
		
	“PERSONAL DATA”	  	HAS THE SAME MEANING AS IN THE DATA PROTECTION ACTS;
		
	“PHI SCHEMES”	  	MEANS ALL PERMANENT HEALTH INSURANCE SCHEMES, FULL DETAILS OF WHICH ARE SET OUT IN THE DISCLOSURE LETTER;
		
	“PLANNING ACTS”	  	MEANS THE LOCAL GOVERNMENT (PLANNING AND DEVELOPMENT) ACTS 1963 TO 1999 AND THE PLANNING AND DEVELOPMENT ACT 2000;
		
	“PMC”	  	MEANS PREMIER MANAGEMENT COMPANY (DUBLIN) LIMITED;
		
	“PMC SHARES”	  	MEANS 3,000 ISSUED ORDINARY SHARES OF €1.269738 EACH IN THE CAPITAL OF PMC
BEING THE ENTIRE ISSUED SHARE CAPITAL OF PMC;
		
	“PRE-COMPLETION SUPPLIES”	  	MEANS SUPPLIES OF INTRA-GROUP MANAGEMENT SERVICES RECEIVED BY A GROUP COMPANY FROM THE SELLER AFTER THE ACCOUNTS DATE BUT ON OR PRIOR TO COMPLETION AND WHICH THE REVENUE COMMISSIONERS
ACCEPT AS VALIDLY CHARGEABLE TO VAT;
		
	“PROPERTIES”	  	MEANS THE PROPERTIES OF THE GROUP, PARTICULARS OF WHICH ARE SET OUT IN SCHEDULE 9;
		
	“RETENTION ACCOUNT”	  	SHALL HAVE THE MEANING GIVEN TO THE TERM “ACCOUNT” IN THE RETENTION CHARGE;
		
	“RETENTION AMOUNT”	  	MEANS THE INITIAL AMOUNT OF €5,000,000 TO BE PAID BY THE BUYERS TO THE
RETENTION ACCOUNT AT COMPLETION AND HELD BY THE SELLER IN ACCORDANCE WITH CLAUSE 11 AND AFTER THE THREE

  

 19 

			
		  	MONTH DATE MEANS €5,000,000 LESS ANY AMOUNT RELEASED PURSUANT TO CLAUSE
11.2;
		
	“RETENTION CHARGE”	  	MEANS A MORTGAGE IN RESPECT OF THE RETENTION AMOUNT AND THE RETENTION ACCOUNT IN FAVOUR OF THE BUYERS, IN THE AGREED FORM;
		
	“SELLER’S AFFILIATES”	  	 MEANS:
  
 (A) ANY SUBSIDIARY OF THE SELLER AS AT THE DATE OF THIS AGREEMENT OR ANY SUBSIDIARY OF THE SELLER IN THE TWO YEARS PRIOR TO THE DATE OF THIS AGREEMENT, SUBSIDIARY FOR THE PURPOSE OF THIS DEFINITION TO BE DEFINED
AS IN SECTION 155 OF THE COMPANIES ACT 1963;
  
 (B) ANY GROUP
DIRECTOR;
  
 (C) ANY CONNECTED PERSON OF THE SELLER,
  
 AND SELLER’S AFFILIATE MEANS ANY ONE OF THEM;

		
	“SELLER’S COMPLETION DOCUMENTS”	  	MEANS THIS AGREEMENT, THE DISCLOSURE LETTER AND ANY OTHER DOCUMENTS WHICH ARE TO BE EXECUTED ON THE DATE OF THIS AGREEMENT BY THE SELLER SET OUT IN SCHEDULE 4, PART
1;
		
	“SELLER’S DIRECTORS”	  	MEANS THE DIRECTORS OF THE SELLER FROM TIME TO TIME;
		
	“SELLER NON-DISCLOSABLE INFORMATION”	  	 MEANS ALL INFORMATION WHICH RELATES TO:
  
 (A) THE PROVISIONS OF THIS AGREEMENT;
  
 (B) THE NEGOTIATIONS RELATING TO THIS AGREEMENT;
  
 (C) THE SUBJECT MATTER OF THIS AGREEMENT; OR
  
 (D) THE SELLER OR ANY OF ITS AFFILIATES (OTHER THAN THE GROUP);

		
	“SELLER’S SOLICITORS”	  	MEANS MAPLES AND CALDER, 75 ST. STEPHENS GREEN, DUBLIN 2, IRELAND;

  

 20 

			
	“SHARES”	  	MEANS THE IRISH SHARES AND THE UK SHARES;
		
	“SOFTWARE”	  	MEANS ANY SET OF INSTRUCTIONS FOR EXECUTION BY A COMPUTER PROCESSOR (INCLUDING BOTH SOURCE AND OBJECT CODE) USED BY THE GROUP AT ANY TIME IRRESPECTIVE OF APPLICATION, LANGUAGE OR MEDIUM
AND INCLUDING FOR THE AVOIDANCE OF DOUBT, ANY CODES OR SETS OF INSTRUCTIONS THAT ARE EMBODIED OR INCORPORATED IN ANY FIRMWARE;
		
	“SUBSIDIARIES”	  	MEANS THOSE COMPANIES OR OTHER PERSONS (WHETHER OR NOT REGISTERED IN THE IRELAND) SHORT PARTICULARS OF WHICH APPEAR IN PART 3 OF SCHEDULE 1 AND THE EXPRESSION “SUBSIDIARY”
SHALL MEAN ANY ONE OF THE SUBSIDIARIES;
		
	“STAMP DUTY AMOUNT”	  	MEANS €500,000;
		
	“TAX” OR “TAXATION”	  	 MEANS ALL FORMS OF TAXATION EITHER IN IRELAND, UK OR ELSEWHERE WHEREVER AND WHENEVER CREATED OR IMPOSED, INCLUDING, WITHOUT LIMITATION:

  
 (A) CORPORATION TAX (INCLUDING ANY SURCHARGE), ADVANCE CORPORATION TAX, INCOME
TAX (INCLUDING TAX OR AMOUNTS ON ACCOUNT OF TAX REQUIRED TO BE DEDUCTED OR WITHHELD FROM OR ACCOUNTED FOR IN RESPECT OF ANY PAYMENT), CAPITAL GAINS TAX, INHERITANCE TAX, GIFT TAX, CAPITAL ACQUISITION TAX, VALUE ADDED TAX, DIVIDEND (DISTRIBUTION)
WITHHOLDING TAX, NATIONAL INSURANCE CONTRIBUTION, PAYE DEDUCTIONS, PAY RELATED SOCIAL INSURANCE AND LEVIES, STAMP DUTY RESERVE TAX, STAMP DUTY LAND TAX, DEPOSIT INTEREST, RETENTION TAX, PROFESSIONAL SERVICES WITHHOLDING TAX, RELEVANT CONTRACTS TAX,
SURTAX, DUTIES OF CUSTOMS AND EXCISE AND IMPORT, PETROLEUM REVENUE TAX, ENVIRONMENTAL LEVIES (INCLUDING ENVIRONMENTAL LEVY ON PLASTIC BAGS), RATES AND ALL TAXES, DUTIES OR SIMILAR CHARGES REPLACED BY OR REPLACING ANY OF THE
FOREGOING;

  

 21 

			
		  	 (B) ALL OTHER TAXES ON GROSS OR NET INCOME, PROFITS OR GAINS, DISTRIBUTIONS, RECEIPTS, SALES, USE, OCCUPATION, FRANCHISE, VALUE ADDED AND
PERSONAL PROPERTY;
  
 (C) ALL TAXES, LEVIES, IMPOSTS, DUTIES, CHARGES OR
WITHHOLDINGS OF ANY NATURE WHATSOEVER CHARGEABLE AND/OR COLLECTABLE BY ANY TAX AUTHORITIES IN ANY JURISDICTION; AND
  
 (D) ANY PAYMENT WHATSOEVER WHICH A GROUP COMPANY MAY BE OR BECOME BOUND TO MAKE TO ANY PERSON AS A RESULT OF THE DISCHARGE BY THAT PERSON OF ANY TAX WHICH A GROUP COMPANY HAS FAILED TO DISCHARGE.

 
 TOGETHER WITH ALL PENALTIES, FINES, SURCHARGES, CHARGES AND INTEREST RELATING TO ANY OF THE
FOREGOING OR TO ANY LATE OR INCORRECT RETURN IN RESPECT OF ANY OF THEM, AND REGARDLESS OF WHETHER ANY SUCH TAXES, LEVIES, DUTIES, IMPOSTS, CHARGES, WITHHOLDINGS, PENALTIES AND INTEREST ARE CHARGEABLE DIRECTLY OR PRIMARILY AGAINST, OR ATTRIBUTABLE
DIRECTLY OR PRIMARILY, TO A GROUP COMPANY OR ANY OTHER PERSON AND REGARDLESS OF WHETHER ANY AMOUNT IN RESPECT OF ANY OF THEM IS RECOVERABLE FROM ANY OTHER PERSON;

		
	“TAX AUTHORITY”	  	MEANS ANY TAXING OR OTHER AUTHORITY (WHETHER WITHIN OR OUTSIDE IRELAND OR THE UNITED KINGDOM) COMPETENT TO IMPOSE ANY LIABILITY TO TAX, OR RESPONSIBLE FOR THE ADMINISTRATION OR
COLLECTION OF TAX, AND “TAX AUTHORITIES” SHALL BE CONSTRUED ACCORDINGLY;
		
	“TAX COVENANT”	  	MEANS THE TAX COVENANT PROVIDED FOR IN CLAUSE 8.12;
		
	“TAX WARRANTIES”	  	MEANS THE WARRANTIES AND UNDERTAKINGS SET OUT IN PART 3 OF SCHEDULE 5;
		
	“TCA”	  	MEANS THE TAXES CONSOLIDATION ACT 1997;

  

 22 

			
	“THREE MONTHS DATE”	  	MEANS THE DATE FALLING THREE MONTHS AFTER THE COMPLETION DATE;
		
	“TITLE WARRANTIES”	  	MEANS THE REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS SET OUT IN PART 1 OF SCHEDULE 5;
		
	“TRANSACTION DOCUMENTS”	  	MEANS THIS AGREEMENT AND THE DISCLOSURE LETTER;
		
	“TERRITORY”	  	MEANS IRELAND, THE UNITED KINGDOM AND EACH OTHER COUNTRY IN WHICH THE BUSINESS IS CONDUCTED AS AT THE DATE OF THIS AGREEMENT OR AS AT COMPLETION;
		
	“UK SHARES”	  	MEANS THE VUKL SHARES;
		
	“VAT”	  	MEANS VALUE ADDED TAX;
		
	“VAT RECLAIM”	  	MEANS AN AMOUNT OF INPUT VAT INCLUDED IN A GROUP COMPANY’S VAT RETURN (BEING THE NEXT VAT RETURN FOLLOWING COMPLETION) RESULTING SPECIFICALLY FROM PRE-COMPLETION SUPPLIES AND WHICH
EITHER RESULTED IN A REDUCED VAT LIABILITY FOR THE GROUP COMPANY OR A REFUND FROM THE REVENUE COMMISSIONERS TO THE COMPANY ON ACCOUNT OF VAT INCURRED;
		
	“VERIS DEBT”	  	MEANS ANY INDEBTEDNESS OWING TO THE BANK PURSUANT TO THE VERIS FACILITY, INCLUDING ANY BREAK FEES, PREPAYMENT FEES OR OTHER COSTS, EXPENSES OR PENALTIES RELATED TO OR ARISING AS A
RESULT OF THE TERMINATION OR PREPAYMENT OF THE VERIS FACILITY;
		
	“VERIS FACILITY”	  	MEANS THE TERM LOAN, REVOLVING CREDIT AND GUARANTEE FACILITY BETWEEN THE SELLER AND THE BANK, ENTERED INTO PURSUANT TO A FACILITY DEED DATED 30 NOVEMBER 2006 AS AMENDED AND
RESTATED BY A FIRST SUPPLEMENTAL FACILITIES AGREEMENT DATED 11 JANUARY 2007, A SECOND SUPPLEMENTAL FACILITIES AGREEMENT DATED 30 MARCH 2007 AND A THIRD SUPPLEMENTAL FACILITIES AGREEMENT DATED 27 NOVEMBER 2007, AS AMENDED AND RESTATED
BY A SUPPLEMENTAL AGREEMENT DATED 15 DECEMBER 2008,

  

 23 

			
		  	PURSUANT TO WHICH €28,665,333 HAS BEEN FULLY ADVANCED BY THE BANK TO THE
SELLER AS AT THE DATE OF THIS AGREEMENT;
		
	“VUKL”	  	MEANS VERIS UK LIMITED;
		
	“VUKL DEBT”	  	MEANS ANY INDEBTEDNESS OWING TO THE BANK PURSUANT TO THE VUKL FACILITY, INCLUDING ANY BREAK FEES, PREPAYMENT FEES OR OTHER COSTS, EXPENSES OR PENALTIES RELATED TO OR ARISING AS A RESULT
OF THE TERMINATION OR PREPAYMENT OF THE VUKL FACILITY;
		
	“VUKL FACILITY”	  	MEANS THE TERM LOAN, REVOLVING CREDIT AND GUARANTEE FACILITY BETWEEN VUKL, THE SELLER, ORANGE ENVIRONMENTAL BUILDING SERVICES LIMITED, ORANGE SUPPORT SERVICES LIMITED, ORANGE FABRIC
SERVICES LIMITED AND THE BANK, ENTERED INTO PURSUANT TO A FACILITY DEED DATED 27 NOVEMBER 2007, AS AMENDED BY THE FIRST SUPPLEMENTAL FACILITIES AGREEMENT DATED 21 DECEMBER 2007 AND AS AMENDED BY THE SECOND SUPPLEMENTAL FACILITIES AGREEMENT
DATED 15 DECEMBER 2008, PURSUANT TO WHICH £10,0236,546 HAS BEEN FULLY ADVANCED BY THE BANK TO VUKL AS AT THE DATE OF THIS AGREEMENT;
		
	“VUKL SHARES”	  	MEANS 1 ISSUED ORDINARY SHARE OF £1 IN THE CAPITAL OF VUKL BEING THE ENTIRE ISSUED SHARE CAPITAL OF VUKL;
		
	“VWFM”	  	MEANS VECTOR WORKPLACE AND FACILITY MANAGEMENT LIMITED;
		
	“VWFM SHARES”	  	MEANS 675,175 ISSUED ORDINARY SHARES OF €0.01 EACH IN THE CAPITAL OF VWFM
BEING THE ENTIRE ISSUED SHARE CAPITAL OF VWFM;
		
	“WARRANTIES”	  	MEANS THE TITLE WARRANTIES, THE TAX WARRANTIES AND THE GENERAL WARRANTIES GIVEN IN CLAUSE 8 AND SCHEDULE 5 AND EACH WARRANTY STATEMENT SHALL BE A
“WARRANTY”;
		
	“WORKING CAPITAL AMOUNT”	  	MEANS THE AMOUNT, IN EUROS, OF THE CURRENT ASSETS AMOUNT LESS THE CURRENT LIABILITIES AMOUNT AS SET OUT

  

 24 

			
		  	IN THE CONSIDERATION STATEMENT, A WORKED EXAMPLE OF WHICH, IS SET OUT IN SCHEDULE 8;
		
	“WORKING CAPITAL BASE”	  	MEANS THE AVERAGE OF THE COMBINED MANAGEMENT ACCOUNTS WORKING CAPITAL AMOUNT OF THE GROUP FOR EACH OF THE SIX (6) CALENDAR MONTHS UP TO AND INCLUDING THE MONTH ENDING ON THE COMPLETION
DATE, AS SET OUT IN THE CONSIDERATION STATEMENT;
		
	“WORKING CAPITAL EXCESS”	  	MEANS THE AMOUNT (IF ANY) BY WHICH THE WORKING CAPITAL AMOUNT EXCEEDS THE WORKING CAPITAL BASE; AND
		
	“WORKING CAPITAL SHORTFALL”	  	MEANS THE AMOUNT (IF ANY) BY WHICH THE WORKING CAPITAL AMOUNT IS LESS THAN THE WORKING CAPITAL BASE.

  

	1.2	Interpretation 

 In this Agreement, unless the
context requires otherwise: 
  

	 	(a)	words and phrases the definitions of which are contained or referred to in the Companies Acts shall be construed as having the meanings thereby attributed to them;

  

	 	(b)	any reference to a Recital, Clause or Schedule is to the relevant Recital, Clause or Schedule of or to this Agreement and any reference to a Sub-Clause or paragraph is to the
relevant Sub-Clause or paragraph of the Clause or Schedule in which it appears; 

  

	 	(c)	the table of contents and clause headings are included for convenience only and shall not affect the interpretation of this Agreement; 

  

	 	(d)	the singular includes the plural and vice versa; 

  

	 	(e)	any gender includes the other genders; 

  

	 	(f)	any reference to a “person” or “persons” includes natural persons, firms, partnerships, companies, corporations, limited liability companies, associations,
organisations, governments, states, foundations and trusts (in each case whether or not having separate legal personality); 

  

	 	(g)	 any reference to a statute, statutory provision or subordinate legislation (“Legislation”) shall (except where the context otherwise requires) be
construed as referring to such legislation as amended and in force from time to time and to any legislation which re-enacts or consolidates, with or without modification) any such legislation provided that, as between the parties, no such amendment
or modification shall apply for the purposes of this Agreement to the extent that it would impose any new or extended

  

 25 

	 	 
obligation, liability or restriction on, or otherwise adversely affect the rights of, any party; 

  

	 	(h)	any reference to this Agreement or any other document or to any other specified provision of this Agreement or any other document are to this Agreement, that document or that
provision as in force for the time being and as amended from time to time in accordance with the terms of this Agreement or that document or, as the case may be, with the agreement of the relevant parties; 

  

	 	(i)	any reference to a person includes his successors, personal representatives and permitted assigns; 

  

	 	(j)	any reference to a document being “in the agreed form” means a document in a form agreed by the parties and initialled by, or on behalf of, each of them for the purpose
of identification as such; 

  

	 	(k)	any phrase introduced by the terms “including”, “include”, “in particular” or any similar expression shall be construed as illustrative and shall
not limit the sense of the words preceding those terms and general words introduced by the word “other” shall not be given a restrictive meaning by reason of the fact that they are preceded by words indicating a particular class of acts,
matters or things; 

  

	 	(l)	words such as “hereunder”, “hereto”, “hereof”, and “herein” and other words commencing with “here” shall, unless the context
clearly indicates to the contrary, refer to the whole of this Agreement and not to any particular Clause or Sub-Clause; 

  

	 	(m)	the provisions of the Schedules to this Agreement shall form an integral part of this Agreement and shall have as full effect as if they were incorporated in the body of this
Agreement and the expressions “this Agreement” and “ the Agreement” shall be deemed to include the Schedules to this Agreement; 

  

	 	(n)	any reference to a breach of any of the Warranties (as the case may be) shall be construed as including reference to any matter not being in all respects as stated by the
Warranties (as the case may be) and to any of the Warranties (as the case may be) being inaccurate or untrue in any respect; 

  

	 	(o)	where any Warranty is qualified by the expression “so far as the Seller is aware” or “to the best of the knowledge, information and belief of the Seller” or
words having similar effect, the awareness or knowledge of the Seller shall be the awareness or knowledge of Martin McMahon, John O’Donoghue, Anne-Ita Ryan, Bobby Lloyd, Derry Robertson, Michael Ferguson, Colm Phelan, Kevin McCambridge and such
individuals shall be deemed for such purpose to have all such knowledge that they would have had if they had made reasonable enquiry concerning the relevant Warranty. 

  

	 	(p)	references to books, records or other information include paper, electronically or magnetically stored data, film, microfilm, and information in any other form or media and
references to ‘writing’ or ‘written’ include faxes and any other method of reproducing words in a legible and non transitory form (excluding email); 

  

 26 

	 	(q)	if any action or duty to be taken or performed under any of the provisions of this Agreement would fall to be taken or performed on a day which is not a Business Day such action
or duty shall be taken or performed on the Business Day next following such day; and 

  

	 	(r)	References to “€”, “EUR”, “euro”,
“c” and “cents” are references to the lawful currency of Ireland. 

  

	1.3	Contra Proferentem 

 The parties have
participated jointly in the negotiating and drafting of this Agreement. In the event that an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or
burden of proof shall arise favouring or disfavouring any party by virtue of the authorship of any of the provisions of this Agreement. 
  

	1.4	Warranties 

 Unless the context otherwise
requires or unless otherwise specified, for the purpose of construction of the Warranties, insofar as any Group Company carries on any part of its business outside Ireland, the references to any statutory provision enacted or accounting principles
applying in Ireland shall be deemed to include references to any corresponding or equivalent provision in the local legislation in force or generally accepted accounting principles applying where the Group Company so carries on business and the
references to any governmental or administrative authority or agency shall include references to the equivalent local government or administrative authority or agency. 
  

	2	Conditions 

  

	2.1	Completion of this Agreement is subject to the Conditions being satisfied or waived by the date and time provided in Clause 2.4. 

  

	2.2	If any of the Conditions are not satisfied or waived by the date and time referred to in Clause 2.4, this Agreement shall cease to have effect immediately after that date and
time except for: 

  

	 	(a)	the provisions set out in Clause 2.3; and 

  

	 	(b)	any rights or liabilities that have accrued under this Agreement save that the Seller shall not be liable in respect of any claim under the Warranties or the Tax Covenant for
breach of the Warranties or the Tax Covenant. 

  

	2.3	The provisions of Clauses 1, 2.1, 2.2, 2.3 and Clauses 13.3 to 35 (inclusive) shall continue to have effect, notwithstanding failure to waive or satisfy the Conditions.

  

	2.4	The Seller and the Buyers shall use all reasonable endeavours to procure that the Conditions are satisfied as soon as practicable and in any event no later than:

  

	 	(a)	6.00 pm on 31 December 2009; or 

  

 27 

	 	(b)	such later time and date as may be agreed in writing by the Seller and the Buyers. 

  

	2.5	In particular, the Seller shall take all steps necessary to convene an extraordinary general meeting of its shareholders as soon as reasonably practicable after the date of this
Agreement for the purpose of seeking the approval of the Seller’s shareholders to the Transaction and the satisfaction of the Condition set out at paragraph 1 of Schedule 2. 

  

	2.6	The Buyers and the Seller shall cooperate fully in all actions necessary to procure the satisfaction of the Conditions including, but not limited to, the provision by all parties
of all information reasonably necessary to make any notification or filing required to be made with or as requested by any relevant authority, keeping all parties informed of the progress of any notification or filing and providing such assistance
as may reasonably be required in connection with such notification or filing. 

  

	2.7	The Buyers may at their option in writing and on such terms and subject to such conditions as they deem appropriate waive compliance in whole or in part with any of the
Conditions other than Conditions set out at paragraphs 1 and 2 in Schedule 2 and without prejudice to any rights or remedies they may each have in respect of non-compliance with or non-fulfilment of any such Conditions. 

  

	3	Sale and Purchase of the Shares 

  

	3.1	Subject to Clause 3.2, the Seller shall sell on and with effect from Completion: 

  

	 	(a)	the Irish Shares to the Irish Buyer and the Irish Buyer shall purchase the Irish Shares; and 

  

	 	(b)	the UK Shares to the UK Buyer and the UK Buyer shall purchase the UK Shares, 

 together with all rights attaching to them at Completion free from all Encumbrances and, including, in particular, the right to receive dividends and distributions declared, made or paid on or after the Completion
Date. 
  

	3.2	Neither the Irish Buyer, the UK Buyer nor the Seller shall be obliged to complete the purchase of any of the Shares unless the purchase of all the Shares is completed
simultaneously in accordance with this Agreement. 

  

	4	Consideration 

  

	4.1	In consideration of the sale of the Shares in accordance with the terms of this Agreement, the total consideration payable by the Buyers to the Seller, including the Retention
Amount which shall be held by the Seller after Completion in accordance with Clause 11.2 of this Agreement, shall be €52,500,000 plus the
Estimated Net Cash Amount and either: 

  

	 	(a)	plus the Completion Adjustment (if any), if it is an amount payable by the Buyers pursuant to Clause 5; or 

  

	 	(b)	less the Completion Adjustment (if any), if it is an amount payable by the Seller pursuant to Clause 5. 

  

 28 

	4.2	Within fifteen (15) days of the date of this Agreement, the Buyers and the Seller shall negotiate and agree the allocation of the Consideration between:

  

	 	(a)	the amount payable by the Irish Buyer in respect of the Irish Facility Management Shares; 

  

	 	(b)	the amount payable by the Irish Buyer in respect of the Irish Property Management Shares; and 

  

	 	(c)	the amount payable by the UK Buyer in respect of the UK Shares, 

 and prior to twenty (20) days after the date of this Agreement the Buyers shall prepare and provide to the Seller for approval an Allocation Schedule setting out this allocation of the Consideration. The
Allocation Schedule shall be reasonable and signed, for the purposes of evidencing agreement, by both the Buyers and the Seller prior to Completion. 
  

	4.3	Subject to clause 4.4, at Completion, in satisfaction of the Initial Consideration, the Irish Buyer shall pay the Consideration attributable to the Irish Facility Management
Shares and the Irish Property Management Shares and the UK Buyer shall pay the Consideration attributable to the UK Shares, all as set out in the Allocation Schedule, by way of wire transfer as follows; 

  

	 	(a)	first, by making a payment on behalf of the Seller by way of wire transfer to the Bank’s Solicitors of an amount required to satisfy in full the Veris Debt;

  

	 	(b)	secondly, by making a payment in Euros on behalf of VUKL by way of wire transfer to the Bank’s Solicitors of an amount required to satisfy in full the VUKL Debt;

  

	 	(c)	thirdly by making a payment of the Stamp Duty Amount to the Buyers’ Solicitors to be paid by the Buyers’ Solicitors to the Irish and the UK Revenue promptly in full or
part satisfaction of stamp duty relating to this Agreement; 

  

	 	(d)	fourthly, by transferring the Retention Amount by way of wire transfer into the Retention Account to be held on the terms and conditions set out in Clause 11 of this Agreement;
and 

  

	 	(e)	thereafter, by wire transfer of the remainder to the Seller’s Solicitors. 

  

	4.4	The amounts payable pursuant to Clause 4.3 shall be reduced for any applicable withholding tax if certificates or other documentation of the type referred to at paragraph 1.11 of
Part 2 of Schedule 4 have not been furnished to the Buyers. 

  

	4.5	Any payment made by the Seller to either of the Buyers under or in respect of any breach of this Agreement (including, without limitation, in respect of any claim for breach of
the Warranties) or pursuant to the Tax Covenant shall be and shall be deemed to be a reduction in the price paid under this Agreement for the relevant Shares in respect of which such payment arises, to the extent legally possible.

  

 29 

	5	Adjustment of Consideration 

  

	5.1	As soon as practicable after Completion, but not later than 20 Business Days thereafter, the Buyers shall prepare and deliver to the Seller a draft of the Consideration Statement
(the “Draft Consideration Statement”) which statement shall set out the Buyers’ calculation of the Net Cash Amount, the Working Capital Base and the Working Capital Amount and any Net Cash Excess Amount or Net Cash Amount
Shortfall and Working Capital Shortfall or Working Capital Excess. 

  

	5.2	If the Draft Consideration Statement provides for a Net Cash Excess Amount, Net Cash Amount Shortfall, Working Capital Shortfall or Working Capital Excess which will give rise to
a payment from or to the Buyers or from or to the Sellers pursuant to this Clause 5, the Draft Consideration Statement shall also, where reasonably practicable, include a breakdown of the amount payable as allocated between the Irish Facilities
Management Shares, the Irish Property Management Shares and the UK Shares. 

  

	5.3	The following shall apply to the preparation of the Draft Consideration Statement and for delivery of such statement to the Seller in accordance with Clause 5.1:

  

	 	(a)	The Draft Consideration Statement shall be prepared on the same accounting policies, accounting principles and practices which were used in the preparation of the Accounts (the
“Group’s Accounting Principles”) subject to: 

  

	 	(A)	the Agreed Treatments; and 

  

	 	(B)	any adjustments required to conform the Company’s Accounting Principles to generally accepted accounting principles and practices in Ireland current at the date of
preparation of the Draft Consideration Accounts. 

  

	 	(b)	If there is any inconsistency between the Company’s Accounting Principles, the adjustments referred to in paragraph (A) above and the adjustments referred to in
paragraph (B) above then paragraph (A) above shall prevail over paragraph (B) above which shall in turn prevail over the Group’s Accounting Principles; 

  

	 	(c)	The Seller shall within 15 Business Days after receipt of the Draft Consideration Statement submit a report to the Buyers stating: 

  

	 	(i)	whether or not it agrees with the Draft Consideration Statement; or 

  

	 	(ii)	in the case of disagreement, the items which are disputed, the specific basis for the dispute and the effect the Seller believes that the items in dispute would have on the
calculation of the Net Cash Amount and the Working Capital Amount in the Draft Consideration Statement. 

  

	5.4	 If the Seller notifies its agreement with the Draft Consideration Statement within the 15 Business Day period referred to above or fails to give any notification
within that period, the Draft Consideration Statement shall then become the Consideration Statement and the Net

  

 30 

	 	 
Cash Amount and the Working Capital Amount as set out therein shall constitute the final statement of the Net Cash Amount and the Working Capital Amount. 

  

	5.5	If the Seller notifies its disagreement with the Draft Consideration Statement within the 15 Business Day period referred to above (the “Notification”) the
Buyers and the Seller shall endeavour to agree the dispute and: 

  

	 	(a)	where the dispute is resolved by agreement between them the Draft Consideration Statement (subject to any amendment agreed between them) shall then become the Consideration
Statement and the Net Cash Amount and the Working Capital Amount as set out therein shall constitute the final statement of the Net Cash Amount and the Working Capital Amount; or 

  

	 	(b)	if within 15 Business Days of the date of receipt by the Seller of the Notification, the Buyers and the Seller are unable to resolve the dispute, the dispute shall be referred to
the Independent Accountant for determination. 

  

	5.6	The Independent Accountant shall act in resolving any dispute on the following basis: 

  

	 	(a)	the Independent Accountant shall act as an expert and not as an arbitrator and the provisions of the Arbitration Acts 1954 to 1998 shall not apply to it or its determination;

  

	 	(b)	the Independent Accountant shall be requested to make a decision on the dispute and notify the Buyers and the Seller of his decision within 30 Business Days of the reference (or
by such later date as may be agreed by such Independent Accountant with each of the Buyers and the Seller); 

  

	 	(c)	the Independent Accountant shall apply the provisions of this Agreement in making its determination; 

  

	 	(d)	the Seller and the Buyers shall respectively provide all the information relating to the Group Companies which the Independent Accountant reasonably requires; and

  

	 	(e)	the fees and disbursements of the Independent Accountant shall be allocated between the Seller and the Buyers so that the Seller bears the proportion of total fees and
disbursements equal to the proportion of disputed items that are unsuccessfully disputed and the Buyers bear the balance. Other than such fees and disbursements of the Independent Accountant, the Seller and the Buyers shall each be responsible for
their own costs and expenses incurred in connection with any actions taken pursuant to this Clause 5. 

  

	5.7	If the Draft Consideration Statement is referred to the Independent Accountant, the Draft Consideration Statement as may be adjusted and amended in accordance with the
determination of the Independent Accountant shall constitute the Consideration Statement, and the Net Cash Amount and the Working Capital Amount as set out therein shall constitute the final statement of Net Cash Amount and the Working Capital
Amount. 

  

	5.8	If the Independent Accountant does not or refuses to make a determination in respect of a dispute as aforesaid within the period set out in Clause 5.6(b), a further Independent
Accountant may be appointed to determine the dispute. 

  

 31 

	5.9	The Seller shall pay an amount equal to the Net Cash Shortfall (if any) as a reduction in the consideration paid for the Shares to: 

  

	 	(a)	the Irish Buyer to the extent the amount payable is agreed in the Consideration Statement to be in respect of the Irish Facility Management Shares and the Irish Property
Management Shares; and 

  

	 	(b)	the UK Buyer to the extent the amount payable is agreed in the Consideration Statement to be in respect of the UK Shares. 

  

	5.10	The Buyers shall pay to the Seller’s Solicitors an amount equal to the Net Cash Excess Amount (if any) as an increase in the consideration paid for the Shares, with:

  

	 	(a)	the Irish Buyer paying such amount to the extent the amount payable is agreed in the Consideration Statement to be in respect of the Irish Facility Management Shares and the
Irish Property Management Shares; and 

  

	 	(b)	the UK Buyer paying such amount to the extent the amount payable is agreed in the Consideration Statement to be in respect of the UK Shares. 

  

	5.11	The Seller shall pay an amount equal to the Working Capital Shortfall (if any) as a reduction in the consideration paid for the Shares to: 

  

	 	(a)	the Irish Buyer, to the extent the amount payable is agreed in the Consideration Statement to be in respect of the Irish Facility Management Shares and the Irish Property
Management Shares; and 

  

	 	(b)	the UK Buyer, to the extent the amount payable is agreed in the Consideration Statement to be in respect of the UK Shares. 

  

	5.12	The Buyers shall pay to the Seller’s Solicitors an amount equal to the Working Capital Excess (if any) as an increase in the consideration paid for the Shares, with:

  

	 	(a)	the Irish Buyer paying such amount, to the extent the amount payable is agreed in the Consideration Statement to be in respect of the Irish Facility Management Shares and the
Irish Property Management Shares; and 

  

	 	(b)	the UK Buyer paying such amount, to the extent the amount payable is agreed in the Consideration Statement to be in respect of the UK Shares. 

  

	5.13	Any payment to be made pursuant to this Clause 5 shall be made within 5 Business Days of the agreement or determination of the Consideration Statement by telegraphic transfer to
such bank account as may be nominated by the party entitled to receive such payment. 

  

	5.14	Each party shall, with reasonable promptness, supply each other with all information and give each other access to all documentation and personnel as each other reasonably
requires to make a submission under this Clause 5. 

  

 32 

	6	Management of the Company Pending Completion 

  

	6.1	The Seller hereby covenants with and undertakes to the Buyers to comply with the provisions of Schedule 3. 

  

	6.2	The Seller shall keep the Buyers informed of any steps taken between the date of this Agreement and the Completion Date to reduce or eliminate the intercompany balances existing
between the Seller and the Group Companies. 

  

	7	Completion 

  

	7.1	Completion shall take place on the Completion Date at the offices of the Seller’s Solicitors (or any other location outside the UK agreed upon by the Seller and the Buyers).

  

	7.2	The Completion Date shall mean: 

  

	 	(a)	the last day of the calendar month in which the Conditions are all satisfied or waived; or 

  

	 	(b)	any other date agreed in writing by the Seller and the Buyers; or 

  

	 	(c)	if Completion is deferred in accordance with Clause 7.6, the date to which it is deferred. 

  

	7.3	At Completion, the Seller shall: 

  

	 	(a)	do all those things required of it pursuant to Part 2 of Schedule 4; and 

  

	 	(b)	take all steps necessary to enable the Anglo Debt to be paid out of the Initial Consideration or otherwise than from the funds of the Group Companies and to enable the Anglo
Charges and any Encumbrances in respect of the Shares to be released. 

  

	7.4	Immediately following satisfaction of the Seller’s obligations pursuant to Clause 7.3, the Buyers shall procure the delivery of: 

  

	 	(a)	the payments required pursuant to Clause 3; 

  

	 	(b)	a certified copy of each of the respective resolutions of the board of Directors of the Irish Buyer authorising the purchase of the Irish Shares and of the UK Buyer authorising
the purchase of the UK Shares, to the Seller and of the Guarantor authorising the entering into the guarantee and indemnity set out in Clause 28. 

  

	7.5	 The Seller hereby confirms that the Seller’s Solicitors are irrevocably authorised by the Seller to receive payment of the Initial Consideration and any
payment due to the Seller pursuant to Clause 5 on the Seller’s behalf and the payment to the Seller’s Solicitor of the Initial Consideration in accordance with Clause 4.3 or any payment pursuant to Clause 5.13 to the

  

 33 

	 	 
Seller’s Solicitor, subject to Clause 11, shall be a sufficient discharge for the Buyers of their obligations under Clauses 7.4 and 5.13 respectively and the Buyer shall not be concerned to
see to the application thereof or be responsible for the loss or misapplication of such sum. The Buyers hereby confirm that the Buyers’ Solicitors are irrevocably authorised by the Buyers to receive any payment due to the Buyers pursuant to
Clause 5 on the Buyers’ behalf and the payment to the Buyers’ Solicitor of any payment pursuant to Clause 5.13 or Clause 8, subject to Clause 11, shall be a sufficient discharge for the Seller of its obligations under Clauses 5.13 and 8
respectively and the Seller shall not be concerned to see to the application thereof or be responsible for the loss or misapplication of such sum. 

  

	7.6	If in any respect the provisions of Clause 7.3 are not complied with by the Seller or if the provisions of Clause 7.4 are not complied with by the Buyers, the Buyers or the
Seller, as the case may be, may, without prejudice to any other rights or remedies they have, including for the avoidance of doubt without prejudice to the rights the Buyers may have pursuant to Clause 18.2: 

  

	 	(a)	proceed to Completion as far as is practicable; or 

  

	 	(b)	defer Completion to a date falling on the last day of the calendar month after the date on which Completion would otherwise have taken place (and so that the provisions of this
Clause 7.6 shall apply to Completion so deferred); or 

  

	 	(c)	rescind this Agreement by notice in writing to the other parties. 

  

	7.7	Any right of rescission conferred upon a party under this Agreement shall be in addition to and without prejudice to all other rights and remedies available to such party and no
exercise or failure to exercise such right shall constitute a waiver by the party of any such right or remedy. 

  

	7.8	The Seller declares that so long as it remains the registered holder of any of the Shares after Completion, it will: 

  

	 	(a)	hold those Shares and all dividends and other distributions in respect of them, and all other rights arising out of or in connection with them, in trust for the Buyer; and

  

	 	(b)	at all times deal with and dispose of those Shares, and all such dividends, distributions and rights attaching to them, as the Buyer may direct on a timely basis.

  

	8	Warranties 

  

	8.1	Title Warranties 

 In consideration of, and as an
inducement to, the Buyers entering into this Agreement the Seller hereby warrants and undertakes to the Buyers that, save as Disclosed, each of the Title Warranties is at the date hereof true and accurate in all respects and, save as Disclosed shall
be deemed to be repeated and to be true and accurate in all respects on the Completion Date by reference to the circumstances subsisting at such time. 
  

 34 

	8.2	General Warranties and Tax Warranties 

 In
consideration of, and as an inducement to, the Buyers entering into this Agreement the Seller hereby warrants and undertakes to the Buyers that, save as Disclosed, each of the General Warranties and the Tax Warranties are at the date hereof true and
accurate in all respects and, save as Disclosed, each of the General Warranties and the Tax Warranties shall be deemed to be repeated and to be true and accurate in all respects on the Completion Date by reference to the circumstances subsisting at
such time. 
  

	8.3	Basis of Agreement 

 The Parties acknowledge that the
Buyers are entering into this Agreement in reliance on, inter alia, the Warranties and furthermore that the Buyers have entered into this Agreement with the intention that the business of the Group shall or may be continued as a going concern
utilising all the assets and subject only to the liabilities to which the Group would on Completion, in accordance with the terms of this Agreement, be entitled and bound. 
  

	8.4	Separate Warranties 

 Each of the Warranties shall be
construed as separate and independent and save as otherwise expressly provided shall not be limited by reference to any other warranty, clause, sub-clause, paragraph, sub-paragraph or any provision in this Agreement or the Schedules. 
  

	8.5	Buyers’ Knowledge 

 Save as Disclosed, no
information of which the Buyers may have knowledge (whether actual, constructive or imputed and for the avoidance of doubt, no information of which the Buyers are made aware (whether actual, constructive or imputed) after entering into this
Agreement) shall qualify or shall be deemed to qualify any of the Warranties or prejudice any claim by the Buyers under the Warranties or operate to reduce any amount recoverable by the Buyers in respect of any breach of any of the Warranties. The
rights and remedies of the Buyers in respect of the Warranties shall not be affected by any audit or investigation made by or on behalf of the Buyers into the affairs of the Group or the decision of any party to complete the Transaction. 

 

	8.6	Warranties in Full Force and Effect 

 The Warranties
shall continue in full force and effect after Completion and shall not in any respect be extinguished or affected by Completion and Completion shall not in any way constitute a waiver of the rights of the Buyers in respect of any of the Warranties.

  

	8.7	Waiver by Seller 

 Except as otherwise set out in
this Agreement, none of the information supplied by any Group Company or its officers, employees, agents, representatives or advisers to the Seller or their officers, employees, agents, representatives or advisers prior to the date of this Agreement
in connection with the Warranties, the contents of the Disclosure Letter or otherwise in relation to the business or affairs of the Group shall constitute or be deemed a representation, warranty or guarantee of its accuracy by such Group Company to
the Seller and the Seller hereby waive any claims against such Group Company or its officers, employees, agents, representatives or advisers which they might otherwise have in respect of the same. 
  

 35 

	8.8	Acknowledgement 

 The Buyers acknowledge and agree
that the Warranties set out in this Agreement are the only warranties and assurances given by the Seller in relation to the Transaction contemplated by this Agreement and the Buyer acknowledges that it has not relied on any other assurances,
warranties, representations or information (whether verbal or in writing). 
  

	8.9	Seller’s Liability 

 Without prejudice to the
limitations of the Seller’s liability expressly set out in this Agreement, if there shall be any breach of any of the Warranties the Seller shall (at the election of the Buyers) be liable to pay to the Buyers on demand an amount equal to:

  

	 	(a)	any depletion or diminution in value of any of the Group Companies; or 

  

	 	(b)	if the result of any breach of any of the Warranties is either that some asset of any Group Company is worth less than its value would have been had such breach not arisen, or
that such Group Company is under an actual liability or increased or substituted liability which would not have arisen had such breach not arisen, an amount equal to the depletion or diminution in the value of the asset in question or the loss
occasioned to such Group Company by such liability or increased or substituted liability, 

 such payment in each case to be
provided on a full indemnity basis for any costs and expenses reasonably incurred investigating, resisting or negotiating any claim which is successful and has given rise to a liability on the part of the Seller under this Clause. 
  

	8.10	Limitation of Liability 

  

	 	(a)	Without prejudice to Clauses 8.10(b) to 8.10(e) inclusive, the aggregate maximum liability of the Seller in respect of all or any claims under the Title Warranties, the General
Warranties, the Tax Covenant, the MM Indemnity or the Tax Warranties (including any amount payable by the Seller pursuant to the gross up provisions contained in Clause 20) shall in no event exceed an amount equal to the Consideration less the Stamp
Duty Amount. 

  

	 	(b)	Without prejudice to Clause 8.10(e), the aggregate maximum liability of the Seller in respect of all claims under the General Warranties, the Tax Covenant, the MM Indemnity and
the Tax Warranties (including any amount payable by the Seller pursuant to the gross up provisions contained in Clause 20) made by the Buyers in the period from Completion until the Expiry Date shall in no event exceed €5,000,000. 

  

	 	(c)	The aggregate maximum liability of the Seller in respect of all claims under the General Warranties, the Tax Warranties, the MM Indemnity and the Tax Covenant (including any
amount payable by the Seller pursuant to the gross up provisions contained in Clause 20) made by the Buyers in the period from the Three Months Date until the Expiry Date shall in no event exceed the amount of €3,500,000. 

  

	 	(d)	 The Seller shall not be liable in respect of any claim under the Title Warranties unless notice in writing specifying in reasonable detail the nature of such
claim and the

  

 36 

	 	 
amount claimed shall have been served by the Buyers on the Seller on or before 31 December 2009. 

  

	 	(e)	The Seller shall not be liable under any claim under the General Warranties, the Tax Warranties, the Tax Covenant or the MM Indemnity, unless notice in writing specifying in
reasonable detail the nature of the claim and the amount claimed shall have been served by the Buyers on the Seller on or before the end of the Expiry Date. 

  

	8.11	Other Limitations in respect of the Warranties and the Tax Covenant 

 The Seller shall not be liable in respect of any claim under the Warranties or the Tax Covenant: 
  

	 	(a)	unless the loss thereby sustained exceeds €37,500 (“De
Minimis Claim”); 

  

	 	(b)	unless and until the aggregate cumulative loss thereby sustained in respect of any and all claims under the Warranties or the Tax Covenant (ignoring for these purposes the
amounts of all De Minimis Claims) exceeds €500,000 in which event the Seller shall be liable for the whole of such amounts and not merely
the excess. 

 The Seller shall not be liable in respect of any claim under the Warranties or the MM Indemnity: 

 

	 	(c)	as regards any claim if and to the extent that payment or discharge of the claim or provision in respect of it has been taken into account in the formula for adjustment of the
Consideration set out in Clause 5; 

  

	 	(d)	as regards any claim if such claim would not have arisen but for an act or omission carried out after the Completion Date otherwise than in the ordinary course of business by any
of the Buyers or any member of the Buyers’ Group or any member of the Group or any other person connected with any of them or any of their respective directors, employees or agents; otherwise than where such act or omission is pursuant to a
legally binding commitment entered into or is necessary to enable the Business or any member of the Group to comply with any law, regulation, accounting practice or contract in effect at or coming into effect after the date hereof.

  

	 	(e)	as regards any claim to the extent that it arises or that it is increased as a result of any change in, or in the interpretations of, any law or regulation or in the
administrative practice of any government department agency or regulatory body, or any increase in the rates of or any changes in the method of calculating any Tax or the imposition of any new Taxation coming into effect after the date of this
Agreement (whether or not prospectively in force at the Completion Date); or 

  

	 	(f)	as regards any claim to the extent that such claim or liability arises or that the amount thereof is increased as a result of any change after the Completion Date in the
accounting reference date or in any of the accounting or actuarial policies, bases or practices of the Company/any member of the Group or any of the Buyers or Pension Schemes, otherwise than where such change is necessary to enable the Business or
any member of the Group to comply with any law, regulation or generally accepted accounting practice in effect at or coming into effect after the date hereof. 

  

 37 

	8.12	Tax Covenant 

 The Seller shall covenant, without
prejudice to any other rights which the Buyers may have, to pay to the Buyers (so far as possible by way of repayment of the consideration payable for the Shares under this Agreement) an amount equal to: 
  

	 	(a)	any liability to Tax of a Group Company arising in respect of, by reference to or in consequence of: 

  

	 	(i)	any income, profits or gains earned, accrued or received on or before Completion and in such cases the liability to Tax shall be deemed to arise at the time the income, profits
or gains are earned, accrued or received even if the due date for payment of the Tax is after Completion; 

  

	 	(ii)	any Event which occurs or occurred on or before Completion; 

  

	 	(b)	any liability to Tax which the Group Companies are or become required to discharge as a result of being a member of the same group of companies as the person primarily liable or
having control of, being controlled by or otherwise connected with, the person primarily liable or being controlled by the same person as the person primarily liable for any Tax purpose, in each case at any time before Completion.

  

	 	(c)	all reasonable costs and expenses incurred by the Buyers or a Group Company in connection with a claim under this Clause 8.12 or in connection with the subject matter of such
claim. 

  

	 	(d)	The Seller agrees with the Buyers that, in the event of a breach by the Seller of the stamp duty warranty contained in paragraph 10 of Schedule 5, Part 3 (Tax Warranties), the
Buyers will be entitled to payment from the Seller by way of liquidated damages in an amount equal to the unpaid stamp duty together with any interest and penalties payable in relation thereto. 

 The obligations of the Sellers under this Clause 8.12 shall not be affected by the knowledge of the Buyers (or of any of their respective officers,
employees agents or advisers) or by the disclosure, in the Disclosure Letter or otherwise, of the liability to Tax or of the circumstances giving rise to any liability to Tax. 
  

	8.13	Tax covenant exclusions 

 The covenant given in
Clause 8.12 and the warranty given in Clause 8.12(d) shall not cover any liability to Tax to the extent that: 
  

	 	(a)	specific provision or reserve for such liability to Tax was made in the Consideration Statement (excluding the notes to the Consideration Statement or any provision in respect of
deferred Tax); 

  

	 	(b)	such liability to Tax would not have arisen but for a voluntary transaction, act or omission effected by the Group Companies at any time after Completion other than any such
transaction, act or omission: 

  

 38 

	 	(i)	carried out or effected in either the ordinary course of trading or the ordinary course of acquiring and disposing of capital assets; 

  

	 	(ii)	consisting of the Group Companies ceasing (or being deemed to cease) to be a member of any group of companies or associated with any other company for any Tax purposes; or

  

	 	(iii)	carried out or effected under a legally binding commitment created on or before Completion; 

 and for the avoidance of doubt, a disclosure to a Tax Authority shall not constitute a voluntary transaction, act or omission 
  

	 	(c)	such liability to Tax arises or is increased as a consequence only of any change in law (including the published interpretation or published practice of any Tax Authority) which
is announced and comes into force after Completion with retrospective effect; 

  

	 	(d)	such liability to Tax arises or is increased as a consequence only of any increase in any rate of Tax entering into force after Completion with retrospective effect; or

  

	 	(e)	the Buyers have made recovery in respect of that Tax Liability by means of a claim for breach of any of the warranties contained in this Agreement; 

  

	 	(f)	such Tax was discharged (whether by payment or the utilisation of any relief) prior to Completion and such discharge was reflected in the Consideration Statement;

  

	 	(g)	such Tax arises (or is increased) as a result of any failure by the Buyer, any member of the Buyer’s group or any Group Company after Completion to comply with any of the
obligations contained in this Agreement, provided that such failure was not due to any act or omission in the first instance of the Seller; 

  

	 	(h)	any profits to which that Tax is attributable were not reflected in the Consideration Statement but were actually earned or received by or actually accrued and were available to
any Group Company after Completion; 

  

	 	(i)	such Tax arises as a result of any changes after Completion in the accounting method or policies of any Group Company other than where GAAP or other applicable accounting
standards were not complied with prior to Completion; or 

  

	 	(j)	such Tax would not have arisen but for the cessation of or any change in the nature or conduct of, any trade carried on by any Group Company where such cessation and change
occurs on or after Completion. 

  

	8.14	Counter Covenant 

  

	 	(a)	Covenant to Pay 

 The Buyers
covenants to pay to the Seller an amount equal to the following: 
  

 39 

	 	(i)	any liability to Tax of the Seller (or any subsidiary of the Seller) resulting from the residence of a Group Company being transferred outside of Ireland at any time on or after
Completion; or 

  

	 	(ii)	any liability to Tax of the Seller (or any subsidiary of the Seller) resulting from any total or partial withdrawal or amendment effected by any Group Company after Completion of
any surrender of group relief which was correctly submitted to a Tax Authority on or before Completion or any amendment to or withdrawal after Completion of a claim correctly made by a Group Company of any capital allowances available in respect of
any accounting period ended on or before Completion, or 

  

	 	(iii)	any out of pocket legal and accounting costs and expenses reasonably and properly incurred by the Sellers (or any of their subsidiaries) in connection with any such liability or
increased liability to Tax in taking an action under this Clause 8.14. 

  

	 	(b)	Payments under this clause 

  

	 	(i)	any payments to be made by the Buyers to the Seller under this Clause 8.14 shall be made free and clear of all deductions or withholdings unless such deduction or withholding is
required by law, in which event the Buyers shall pay such additional amount as shall be required to ensure that the net amount received by the Seller from the relevant Buyer will equal the full amount which would have been received by it had no such
deduction or withholding been required. 

  

	 	(ii)	if any Tax Authority brings into charge to Tax any sum paid to the Seller under this Clause 8.14 (including in circumstances where any relief is available in respect of such
charge to Tax), then the Buyer shall pay such additional amount as shall be required to ensure that the total amount paid, less the Tax chargeable on such amount (or that would be so chargeable but for such relief), is equal to the amount that would
otherwise be payable under this Clause. 

  

	8.15	Sole Basis of Claim 

 An action for damages shall be
the Buyers’ sole and exclusive remedy against the Seller in respect of a breach of the Warranties which remedy shall be subject to the provisions of this Clause 8. Notwithstanding that the Buyer may become or becomes aware at any time after
Completion that there has been a breach of the Warranties or any other terms of this Agreement or a claim under the Tax Covenant or the MM Indemnity, the Buyer shall not be entitled to rescind this Agreement or treat it as terminated but shall only
be entitled to claim damages in accordance with the terms of this Clause 8 or enforce the covenant to pay in accordance with the Tax Covenant. 
  

	8.16	Limitation of Liability 

 The liability of the Seller
in respect of any claim under the Warranties or a claim under the Tax Covenant or the MM Indemnity shall be limited as provided in this Clause 8. The provisions of this Clause 8 which, among other things, regulate or otherwise affect the liability
of the Seller

  

 40 

 
shall remain in full force and be fully applicable in all circumstances and, in particular, notwithstanding any breach of the Warranties or any claim against any of the Seller in respect of the
Warranties or the Tax Covenant or the MM Indemnity, whatever its nature or consequences. 
  

	8.17	Contingent Claims 

 If any Claim is based upon a
liability which is contingent only, the Seller shall not be liable to make payment unless and until such contingent liability becomes an actual liability and is due and payable, provided that where a contingent liability is notified prior to the end
of the time periods referred to in Clause 8.10(d) and 8.10(e) and it becomes an actual liability after the end of such time periods, it shall not be so excluded and the Claim shall be taken to have been notified in accordance with Clause 8.10(d) and
8.10(e). 
  

	8.18	Proceedings 

 Any claim under the Warranties or under
the MM Indemnity or Tax Covenant in respect of which notice shall have been given in accordance with this Agreement or otherwise if it is not previously satisfied, settled or withdrawn, shall be deemed to have been irrevocably withdrawn and lapsed
unless proceedings in respect of such claim have commenced by being both issued and served on the Seller within 6 months of the date of the notice served in accordance with Clause 8.10(d) and 8.10(e) on the Seller in respect of such claim.

  

	8.19	Third Party Recovery 

  

	 	(a)	Without prejudice to the rights of the Buyers to bring a claim pursuant to the Warranties or the Tax Covenant, where the Buyers or the Group Companies are entitled to recover, or
reasonably believe that they are entitled to recover (taking into account any deductible) under an insurance policy a sum in respect of a matter giving rise to a Claim, then the Buyers shall procure that all reasonable steps are taken to enforce
such recovery as soon as practicable. 

  

	 	(b)	Without prejudice to the rights of the Buyers to bring a claim under the Warranties or the Tax Covenant and subject to Clause 8.19(c), where the Buyers or the Group Companies are
entitled to, or the Buyers or Group Companies reasonably believe they will or are likely to be able to, recover a sum from a third party in respect of a matter giving rise to a Claim, then the Buyers shall procure that all reasonable steps are taken
to enforce such recovery as soon as practicable. 

  

	 	(c)	The Buyers or Group Companies shall not be under any obligation to comply with Clause 8.19(b) if the taking of any action pursuant to that Clause would reasonably be expected to
have a significant adverse effect on the commercial interests of, or on the business of, any member of the Group or the Buyers. 

  

	 	(d)	In the event that the Buyers or any of the Group Companies do not enforce such recovery, or rely on Clause 8.19(c), the Buyers shall and shall procure that the Group /relevant
member of the Group shall: 

  

	 	(i)	promptly notify the Seller of such reliance; 

  

 41 

	 	(ii)	give the Seller and its professional advisers reasonable access during business hours to the premises and personnel of the Buyers and the Group Companies and to copies of any
documents and records which the Seller may reasonably request in order to appraise itself of all facts, matters and information directly relevant to the investigation and enforcement of the recovery from a third party provided that:

  

	 	(A)	the Buyers shall not be obliged to provide any documentation which is legally privileged; 

  

	 	(B)	such documents and records may only be used for the purpose of investigating or enforcing a third party claim for which the Seller has rights pursuant to this Clause; and

  

	 	(C)	appropriate confidentiality agreements shall be entered into by the Seller on terms reasonably acceptable to the Buyers; 

  

	 	(iii)	subject to the Seller providing to the reasonable satisfaction of the Buyers security or indemnities, or both, in respect of any costs incurred in relation thereto, permit the
Seller in the name of the Buyers and/or the relevant member of the Group (as appropriate) to take all steps which the Seller reasonably believes to be necessary or desirable to enforce the recovery from such third party, subject only to consulting
the Buyers and/or the relevant member of the Group (as appropriate) to the extent reasonably practicable, prior to taking any such action. 

  

	 	(e)	Where the Buyers and/or Group Companies recover any amount from a third party and the amount so recovered (less the costs of recovery, interest or liability to Tax on such amount
and any corresponding increase in insurance premia) is less than the amount that the Buyers would have been entitled to recover pursuant to a Claim, (the amount by which it is less being the “Claim Deficiency”), in respect of the
matter which was the subject of such recovery, the Seller shall remain liable to the Buyers for the amount of the Claim Deficiency, without prejudice to the limitations of the Seller’s liability expressly set out in this Agreement.

  

	 	(f)	If the Seller pays an amount to the Buyers pursuant to a Claim and the Buyers and/or a Group Company subsequently recover from some other person (including any insurance company
under the terms of any insurance policy) a sum in respect of the matter giving rise to such Claim, the Buyers shall, once it has received such sum, forthwith repay to the Seller so much of the recovered amount from the third party (less the costs of
recovery, interest or liability to Tax on such amount and, where the amount is recovered under an insurance policy, less any corresponding increase in insurance premia) as does not exceed the sum paid by the Seller to the Buyer in respect of such
Claim. 

  

	8.20	No Double Recovery 

 Where the same facts or
circumstances could give rise to more than one Claim, the Buyers shall not be entitled to recover more than once for the same loss. 
  

 42 

	8.21	No Punitive damages 

 Subject to Clause 8.10, the
Buyers shall not be entitled to claim against the Seller for any punitive damages, indirect or consequential loss in respect of any Claim. For the avoidance of doubt, subject to Clause 8.10, this shall not exclude any claim for punitive, indirect or
consequential damages awarded against the Buyers or a Group Company in respect of which the Buyers are entitled to bring a Claim. 
  

	8.22	Mitigation 

  

	 	(a)	The Buyers shall be obligated to mitigate any loss or damage which they may suffer in consequence of any breach by the Seller of the terms of this Agreement.

  

	 	(b)	The duty to mitigate set out in 8.22(a) above shall not apply to the Tax Covenant. 

  

	8.23	Conduct of disputes 

 Without prejudice to the
Buyers’ right to make a claim under the Warranties or the Tax Covenant, if the Buyers become aware of a matter or circumstance which might give rise to a claim, action or demand against it and which might give rise to a claim under the
Warranties or the Tax Covenant (a “Third Party Claim”): 
  

	 	(a)	the Buyers shall: 

  

	 	(i)	promptly notify the Seller of such matter, giving reasonable details (but excluding any details which are subject to legal privilege prior to receiving appropriate
confidentiality undertakings) of the Third Party Claim; 

  

	 	(ii)	keep the Seller promptly informed of all material developments and communications relating to the Third Party Claim; 

  

	 	(iii)	give the Seller and its professional advisers reasonable access during normal business hours to the premises and personnel of the Buyers and the Group Companies and copies of any
documents and records of the Buyers and the Group Companies which the Seller may reasonably request in order to appraise itself of all facts, matters and information directly relevant to the Third Party Claim provided that:-

  

	 	(A)	the Buyers shall not be obliged to provide any documentation which is legally privileged; 

  

	 	(B)	such documents and records may only be used for the purpose of investigating or resolving a Third Party Claim; and 

  

	 	(C)	appropriate confidentiality agreements shall be entered into by the Seller on terms reasonably acceptable to the Buyers; 

  

 43 

	 	(b)	subject to the Seller providing to the reasonable satisfaction of the Buyers security or indemnities, or both, in respect of any costs incurred, the Buyers shall take all steps
that the Seller may reasonably request to avoid, dispute, resist, compromise or defend the Third Party Claim provided that the Buyers shall not be obliged to take any action which would reasonably be expected to have a significant adverse effect on
the commercial interests of, or on the business of, any member of the Group or the Buyers; and 

  

	 	(c)	subject to the Seller providing to the reasonable satisfaction of the Buyers security or indemnities, or both, in respect of any costs incurred in relation thereto, the Buyers
shall not, and shall procure that the Group Companies shall not, make any admission of liability or agreement or compromise in relation to the Third Party Claim without the prior written consent of the Seller (such consent not to be unreasonably
withheld or delayed and in any event if the Seller does not confirm whether it is giving or withholding its consent in this regard within 10 Business Days of a request from the Buyers for consent, the Seller shall be deemed to have given its written
consent) provided that neither the Buyers nor any member of the Group shall be obliged to take, or refrain from taking, any action which would reasonably be expected to have a significant adverse effect on the commercial interests of, or on the
business of, any member of the Group or the Buyers; and 

  

	 	(d)	In the event that the Buyers or any of the Group Companies do not take such steps as the Seller requests or rely on the proviso set out in Clause 8.23(b), or Clause 8.23 (c), the
Buyers shall and shall procure that the Group Companies as relevant shall: 

  

	 	(i)	promptly notify the Seller; 

  

	 	(ii)	subject to the Seller providing to the reasonable satisfaction of the Buyers security or indemnities, or both, in respect of any costs incurred in relation thereto, permit the
Seller in the name of the Buyers and/or the relevant member of the Group (as appropriate) to take all steps which the Seller reasonably believes to be necessary or desirable to avoid, dispute, resist, compromise or defend the Third Party Claim,
subject only to consulting the Buyers and/or the relevant member of the Group (as appropriate) to the extent reasonably practicable, prior to taking any such action. 

  

	8.24	Tax Returns 

 The Buyers shall: 
  

	 	(a)	furnish to the Seller copies of the Tax returns relating to each Group Company in respect of all accounting periods ended on or prior to Completion and for the accounting period
current at Completion prior to their submission to the relevant Tax Authority and in a timely manner to enable the Sellers to review, and if appropriate, request reasonable amendment to, such Tax returns and documentation; and

  

	 	(b)	procure that the relevant Group Company shall cause the Tax returns mentioned in this Clause 8.24 to be authorised, signed and submitted to the appropriate Tax Authority with
such amendments as the Seller shall reasonably request in writing. 

  

 44 

	 	(c)	The Buyers shall not be obliged to procure that any Group Company accepts any amendments requested by the Seller to the extent that such acceptance would mean that the Tax return
was not full, true and accurate in all material respects. 

  

	8.25	Reliefs 

  

	 	(a)	Payment giving rise to Relief 

 The Seller may
request (at its own expense) that the auditors of a Group Company certify that any liability to Tax which has resulted in a payment having been due under the Tax Covenant would give rise to a relief for Tax purposes which would not otherwise have
arisen and if the auditors so certify then when the liability of a Group Company to make an actual payment of (or in respect of) Tax is reduced by reason of the availability of that relief (having first taken into account other reliefs available)
the amount by which that liability is reduced shall be certified. 
  

	 	(b)	Use of Relief 

 Where an amount has been certified
under paragraphs 8.25(a) above that amount is to be dealt with as follows: 
  

	 	(i)	such amount shall first be set off against any payment then due from the Seller under the Tax Covenant; 

  

	 	(ii)	to the extent that there is a surplus, a refund shall be made to the Seller of any previous payment or payments made by the Seller under the Tax Covenant and not previously
refunded under this Clause 8.25 up to the amount of such surplus; and 

  

	 	(iii)	to the extent that the surplus referred to in paragraph (ii) is not exhausted under that paragraph, the remainder of that surplus shall be carried forward and set off
against any future payment or payments which become due from the Seller under the Tax Covenant. 

  

	8.26	VAT reclaim 

  

	 	(a)	The Buyers agree that they will remit to the Seller, as soon as is reasonably practicable, an amount equal to any VAT Reclaim in respect of any Pre-Completion Supplies;

  

	 	(b)	The Buyers undertake that they will provide the Seller with a draft of the VAT return in which a VAT Reclaim is made prior to submission of the return to the Revenue
Commissioners and in a timely manner and will procure that the relevant Group Company accepts any reasonable comments made by the Seller; 

  

	 	(c)	Nothing in this Clause 8.26 shall oblige a Group Company to accept an amendment requested by the Seller to the extent that such acceptance would mean that the VAT return was not
full, true and accurate in all material respects. 

  

	8.27	MM Indemnity 

  

 45 

 The Seller confirms that it has made payments of €119,000 and €527,280 to Martin McMahon pursuant to the employment
agreement entered into between Martin McMahon and the Seller dated 13th March 2009 as amended by a letter of variation between those parties of 13th March 2009 and agrees to indemnify the Buyers in respect to any liability whatsoever of a
Group Company directly arising from the obligation to make such payments. 
  

	9	Warranties by the Buyer 

  

	9.1	The Buyers warrant to the Seller that: 

  

	 	(a)	the Irish Buyer is duly incorporated and validly existing under the laws of Ireland; 

  

	 	(b)	the UK Buyer is duly incorporated and validly existing under the laws of England; 

  

	 	(c)	the Buyers each have the power to enter into this Agreement and to perform the obligations expressed to be assumed by such Buyer and have taken all necessary corporate action to
authorise the execution, delivery and performance of this Agreement; 

  

	 	(d)	this Agreement has been duly executed by the Buyers; 

  

	 	(e)	the execution, delivery and performance of the terms of this Agreement by the Buyers does not infringe any provisions of: 

  

	 	(i)	any law or regulation or any order or decree of any authority, agency or court binding on the Buyers; 

  

	 	(ii)	the rules of any stock exchange on which the shares of the Buyers are listed; 

  

	 	(iii)	the memorandum and articles of association of the Buyers; or 

  

	 	(iv)	any loan stock, bond, debenture or other deed, mortgage, contract or other undertaking or instrument to which the Buyers are party; and 

  

	 	(f)	in acquiring the Shares, the Buyers are acting as principals and not as agents or brokers for any other person. 

  

	9.2	The Guarantor warrants to the Seller that: 

  

	 	(a)	it is duly incorporated and validly existing under the laws of Delaware; 

  

	 	(b)	it has the power to enter into this Agreement and to perform the obligations expressed to be assumed by the Guarantor and has taken all necessary corporate action to authorise
the execution, delivery and performance of this Agreement; 

  

	 	(c)	this Agreement has been duly executed by the Guarantor; 

  

 46 

	 	(d)	the execution, delivery and performance of the terms of this Agreement by the Guarantor does not infringe any provisions of: 

  

	 	(i)	any law or regulation or any order or decree of any authority, agency or court binding on the Guarantor; 

  

	 	(ii)	the rules of any stock exchange on which the shares of the Guarantor are listed; 

  

	 	(iii)	the constituting documents and bye-laws of the Guarantor; or 

  

	 	(iv)	any loan stock, bond, debenture or other deed, mortgage, contract or other undertaking or instrument to which the Guarantor is party; 

  

	10	Protection of Goodwill 

  

	10.1	As further consideration for the Buyers agreeing to purchase the Shares on the terms set out in this Agreement and with the intent of assuring to the Buyers the full benefit and
value of the goodwill of the Group and as a constituent part of the sale of the Shares, the Seller and the Covenantors hereby covenant and undertake to the Buyers (contracting for themselves and as trustees for each of the Group Companies) that,
except with the prior written consent of the Buyers, they shall not either alone or jointly or in conjunction with or on behalf of or through the agency of any person and whether as principal, agent, partner, shareholder, holding company, director,
manager, adviser, consultant, employee or in any other manner howsoever and whether directly or indirectly: 

  

	 	(a)	in the Restrained Period (as defined below): 

  

	 	(i)	carry on or participate or assist or be engaged or concerned or interested (except as the holder or beneficial owner for investment purposes of not more than five (5) per
cent in nominal value of any class of securities listed or dealt in on a generally recognised stock exchange) in any business in the Territory which competes with any part of the Business; 

  

	 	(ii)	in relation to or in connection with any business which may in any way be the same as or similar to or in competition with any part of the Business, procure or seek to procure
orders from or do business with or procure directly or indirectly any other person to procure orders from or do business with any person who is at Completion or who has been at any time during the period of two (2) years immediately preceding
Completion a customer of any Group Company; 

  

	 	(iii)	interfere or seek to interfere or take such steps as may interfere with the continuance of supplies to such Group Company (or the terms relating to such supplies) from any
suppliers who are at Completion or who have been at any time during the period of two (2) years immediately preceding Completion supplying materials, components, products, goods or services to the Group; 

  

 47 

	 	(iv)	do or say anything which could reasonably be expected to lead any person to cease to do business with any Group Company on substantially equivalent terms to those previously
offered or at all or which may prevent any person in the future, whether or not doing business with such Group Company at Completion, from doing business with such Group Company or do or say anything which is harmful to the reputation of such Group
Company; 

  

	 	(v)	solicit or entice away or offer employment to or endeavour to solicit or entice away or offer employment to any person who is at the date hereof or who between that date and
Completion becomes an employee, officer or manager of any Group Company whether or not such person would commit a breach of contract by reason of leaving the employment, office or service of such Group Company; or 

  

	 	(vi)	enter into partnership with or appoint as a consultant or adviser any person who is at the date hereof or who between that date and Completion becomes an employee, officer,
manager or representative of or consultant (other than a consultant providing professional services) to any Group Company; and 

  

	 	(b)	at any time after Completion save in respect of Mr McMahon in the case of clauses (b) (i) and (b) (ii) below, in furtherance of his duties as an employee of
such Group Company: 

  

	 	(i)	use or adopt or purport to use or adopt the name of any Group Company (save for the word “Veris” as used in the corporate name of the Seller); 

 

	 	(ii)	(save for the word and logo “Veris” as used in the corporate name and logo of the Seller) use or procure the use, in connection with any business, of any name or any
trade name used or owned by any Group Company on Completion or any part or combination or abbreviations thereof likely to be confused therewith or any Intellectual Property Rights owned or exclusively entitled to be used by any Group Company; or

  

	 	(iii)	disclose or cause to be disclosed to any person or use for any purpose any Confidential Information or any information in relation to which any Group Company is bound by an
obligation of confidence to a third party and he shall use his best endeavours to prevent the publication or disclosure of any such in formation. 

  

	10.2	Each of the Seller and the Covenantors hereby acknowledges and agrees with the Buyers that each of the undertakings contained in clause 10.1 constitutes an entirely separate,
severable, independent and separately enforceable restriction on it or him respectively and that the duration, extent and application of the respective restrictions in clause 10.1 are no greater than is reasonable and necessary for the protection of
the legitimate interests of the Buyers and the Group but that if any such restriction shall be adjudged by any court or regulatory authority or agency of competent jurisdiction to be void or unenforceable but would be valid if part of the wording
thereof was deleted and/or the period thereof and/or the application thereof and/or the geographical area dealt with thereby was reduced, the said restriction shall apply within the jurisdiction of that court or regulatory authority or agency with
such modifications as may be necessary to make it valid, effective and enforceable. 

  

 48 

	10.3	Each party acknowledges that each of the restrictions in this Clause 10 is no more extensive than is reasonable and necessary to protect the interests of the Buyers as the buyers
of the Shares. The Covenantors agree that they will each receive substantial consideration as a result of the Transaction, including in respect of each, a distribution from the Seller of the proceeds received as part of its plan to distribute such
proceeds to shareholders and in respect of Mr McMahon the payment of various incentives and option entitlements in respect of shares in the Seller as incentive payments arising upon the Completion. 

  

	10.4	The Restrained Period for the purpose of this Clause 10 means: 

  

	 	(a)	The period from Completion until the second anniversary of Completion in respect of the Seller and Mr McMahon; 

  

	 	(b)	the period from Completion until 6 months after Completion in respect of Mr McFadden. 

  

	11	Retention Amount 

  

	11.1	The Retention Amount shall be held by the Seller in the Retention Account in its name from Completion and such amount shall not be distributed or otherwise paid out of that
account by the Seller to any other person other than in accordance with this Clause 11. 

  

	11.2	On the Three Months Date, the Seller shall be entitled to have released from the Retention Account the sum of €1,500,000 less: 

  

	 	(a)	the amounts of all claims under the Warranties or the Tax Covenant in respect of which payment has been made to the Buyers; and 

  

	 	(b)	the amount of all claims under the Warranties or the Tax Covenant then outstanding and in respect of which notifications have been delivered to the Seller on or prior to the
Three Months Date in accordance with this Agreement. 

  

	11.3	On the Expiry Date, the Seller shall be entitled to have released from the Retention Account the amount standing to the credit of the Retention Account less the amount of all
claims under the Warranties or the Tax Covenant then outstanding and in respect of which notifications have been delivered to the Seller on or prior to the Expiry Date in accordance with this Agreement 

  

	11.4	Without prejudice to Clause 8.17, any sum standing to the balance of the Retention Account in respect of a claim under the Warranties or the Tax Covenant which is based upon a
liability which is contingent only, shall be released to the Seller on the earlier of (i) such claim being determined, settled or withdrawn and (ii) the date falling the second anniversary of the Expiry Date if such contingent liability
has not become an actual liability and has not become due and payable by that date, in which case the Seller shall have no ongoing liability for such claim and such claim shall be deemed irrevocably withdrawn. 

  

	11.5	 After the Expiry Date, the remaining sums standing to the balance of the Retention Account shall be released, less any amounts paid or payable to the Buyers
pursuant to Clause 11.6, to the Seller on the date on which every claim under the Warranties or the Tax Covenant made

  

 49 

	 	 
by the Buyers prior to Expiry Date has been determined, settled or withdrawn and the Buyers agree to procure the release of the Retention Charge to permit such release of the Retention Amount to
the Seller. 

  

	11.6	If a claim or claims under the Warranties or the Tax Covenant has been made by the Buyers prior to the Expiry Date, the Seller may not distribute, release or pay any part of the
amounts standing to the credit of the Retention Account to any person if such distribution, release or payment would result in the amounts standing to the credit of the Retention Account being less than the amounts of the claim or claims under the
Warranties or the Tax Covenant, other than to the Buyers. If an amount payable to the Buyers in respect of a claim under the Warranties or the Tax Covenant is agreed between the Seller and the Buyers or is finally determined by a Court of competent
jurisdiction to be payable to the Buyers, the Retention Amount shall be used to discharge (in whole or, in respect of a claim under the Title Warranties, if such amount is greater than the Retention Amount, in part) the payment of such amount to the
Buyers. 

  

	11.7	If the Seller disputes the merits of a claim made by any of the Buyers under the Warranties or the Tax Covenant, it shall notify the Buyers thereof in writing. If such dispute is
unresolved between the Buyers and the Seller within 15 Business Days of the date of receipt by the Buyers of such notification, the Seller may refer the dispute to the Independent Counsel. The Independent Counsel shall act in resolving any dispute
on the following basis: 

  

	 	(a)	the Independent Counsel shall act as an expert and not as an arbitrator and the provisions of the Arbitration Acts 1954 to 1998 shall not apply to it or its determination;

  

	 	(b)	The Independent Counsel shall be requested to give his opinion on whether ,on the balance of probabilities, a motion to dismiss any proceedings relating to such claim on the
grounds that the claim is either frivolous, vexatious or that no reasonable cause of action is disclosed would succeed and notify the Buyers and the Seller of his decision within 30 Business Days of the reference (or by such later date as may be
agreed by such Independent Counsel with each of the Buyers and the Seller); 

  

	 	(c)	the Seller and Buyers shall be entitled to make one written submission each to the Independent Counsel within ten days of his appointment and shall respectively provide all the
information relating to the Group Companies which the Independent Accountant reasonably requires; and 

  

	 	(d)	the fees and disbursements of the Independent Counsel shall be paid by the Seller if the Independent Counsel determines that , on the balance of probabilities, a motion to
dismiss any proceedings relating to such claim on the grounds that such claim is either frivolous, vexatious or that no reasonable cause of action is disclosed would not succeed and shall be paid by the Buyers if the Independent Counsel determines
that , on the balance of probabilities, a motion to dismiss any proceedings relating to such claim on the grounds that the claim is either frivolous, vexatious or that no reasonable cause of action is disclosed would succeed. Other than such fees
and disbursements of the Independent Counsel, the Seller and the Buyers shall each be responsible for their own costs and expenses incurred in connection with any actions taken pursuant to this Clause 5. 

  

	 	(e)	 If the Independent Counsel determines that, on the balance of probabilities, a motion to dismiss any proceedings relating to a Claim on the grounds that the
Claim is

  

 50 

	 	 
frivolous, vexatious or that no reasonable cause of action is disclosed would succeed, such Claim shall be deemed to have been irrevocably withdrawn and lapsed and such Claim shall be deemed to
be “withdrawn” for the purposes of the provisions of this Clause 11. 

  

	11.8	Upon the release of any part of the Retention Amount to the Seller pursuant to this Clause 11, the Buyers agree to pay an amount to the Seller equal to 7% per annum on that
amount released for the period from Completion until the date of release to the Seller. 

  

	11.9	Prior to the date upon which the Retention Amount or part of it is to be released to the Seller pursuant to this Clause 11 the Seller shall not close the Retention Account,
finalise or conclude any dissolution, liquidation or winding up or enter into any agreement with its creditors or any class thereof or any other person in respect of the funds held in the Retention Account or take any other action which would
prejudice the ability of the Buyers to receive any payment from the Retention Account which they may become entitled to receive pursuant to this Clause 11, it being understood that nothing in this Agreement shall prevent the Seller from commencing
any dissolution, liquidation or winding up. 

  

	11.10	In addition to the Retention Amount, the Seller agrees that it shall not make any distribution of the Consideration prior to 1 January 2010. 

  

	12	Release of Claims Against the Group Companies 

  

	12.1	Subject to Clause 12.3, with effect from Completion, the Seller and the Covenantors release, relieve, waive and forever discharge each Group Company and any of their respective
officers, directors, employees, agents, successors and assigns from any and all claims, demands, actions, damages, liabilities, and causes of action, whether known or unknown, which such party may have had, may presently have, or in the future may
have that relate to or arise out of or are in connection with any circumstances, acts or omissions or contracts or agreements, including, without limitation, any agreements to indemnify such Seller, or Covenantor or otherwise hold such Seller or
Covenantor harmless, entered into prior to Completion, except for claims or demands that such Seller or Covenantor may have pursuant to this Agreement. 

  

	12.2	Mr McMahon’s right to receive remuneration (including bonuses) and expenses properly accrued shall be unaffected by and specifically excluded from the terms of the waiver
and release set out in Clause 12.1. 

  

	12.3	The Seller and the Covenantors agree to procure that at or before Completion each Group Company is released from any guarantees, security interests and indemnities given by it in
favour of that Seller, Covenantor or any of the Seller’s Affiliates. 

  

	12.4	The Seller shall ensure that at or before Completion all monies owing by the Seller or any Seller’s Affiliate to any Group Company are paid in full, whether or not then due
for payment. 

  

	12.5	 To the extent that they are not released on Completion, the Buyers shall procure that as soon as reasonably practicable following Completion the Seller be
released from the guarantees

  

 51 

	 	 
set out at Schedule 11 of this Agreement) and pending such release the Buyers shall indemnify and hold harmless the Seller and its Affiliates in respect of such guarantees.1 

  

	13	Announcements 

  

	13.1	Subject to Sub-Clause 13.2, no party shall issue any press release or other public document containing, or make any public statement containing, or otherwise disclose to any
person who is not a party, information which relates to or is connected with or arises out of this Agreement or the matters contained in it, without the prior written approval of the other party (such approval not to be unreasonably withheld or
delayed) as to its content and the manner and extent of its publication. The parties shall consult with each other prior to the issuance upon the form of any press release, document or statement any of them proposes to issue with respect to the
Transaction. 

  

	13.2	The provisions of Sub-Clause 13.1 shall not apply to disclosure of matters required to be made: 

  

	 	(a)	by virtue of the regulations of any securities exchange on which, in the case of the Seller, the securities of the Seller or, in the case of the Buyers, the securities of the
Guarantor, are listed or traded; 

  

	 	(b)	by any court or governmental or administrative authority competent to require the same; or 

  

	 	(c)	by any applicable law or regulation. 

  

	13.3	Prior to issuing a circular and notice of meeting to its shareholders in respect of the Transaction, the Seller shall provide substantially advanced drafts of these documents to
the Buyers at least two Business Days prior to the issuance of such documents. 

  

	14	Confidentiality 

  

	14.1	The Seller hereby undertakes with the Buyers and the Guarantor that it shall preserve the confidentiality of the Buyer Non-Disclosable Information, and except to the extent
otherwise expressly permitted by this Agreement, not directly or indirectly reveal, report, publish, disclose or transfer or use for its own or any other purposes such Buyer Non-Disclosable Information. 

  

	14.2	The Buyers and the Guarantor hereby undertake with the Seller that it shall preserve the confidentiality of the Seller Non-Disclosable Information, and except to the extent
otherwise expressly permitted by this Agreement, not directly or indirectly reveal, report, publish, disclose or transfer or use for its own or any other purposes such Seller Non-Disclosable Information. 

  

	14.3	Notwithstanding any other provision in this Agreement, the Buyers and Guarantor, after consultation with the Seller whenever practicable, may disclose Seller Non-Disclosable
Information and, notwithstanding any other provision in this Agreement, the Seller, after 

  

	1	Aramark to review guarantees when disclosed. 

  

 52 

	 	 
consultation with the Buyers and the Guarantor whenever practicable, may disclose Buyer Non-Disclosable Information if and to the extent: 

  

	 	(a)	required by any applicable law or regulation; 

  

	 	(b)	required by any securities exchange on which, in the case of the Seller, the securities of the Seller or, in the case of the Buyer, the securities of the Guarantor, are listed or
traded; 

  

	 	(c)	required by any court or governmental or administrative authority competent to require the same; 

  

	 	(d)	required to vest the full benefit of this Agreement in that party or to enforce any of the rights of that party in this Agreement; 

  

	 	(e)	required by its professional advisers, officers, employees, consultants, directors, subcontractors or agents to provide their services (and subject always to similar duties of
confidentiality); 

  

	 	(f)	that the information is in or has come into the public domain through no fault of that party or a breach of confidentiality obligation by that party; 

  

	 	(g)	that the information is or becomes available to the parties otherwise than in connection with entry into this Agreement and free of any restriction as to its use or disclosure;

  

	 	(h)	the other party has given prior written consent to the disclosure; or 

  

	 	(i)	it is necessary to obtain any relevant tax clearances from any appropriate tax authority. 

  

	14.4	The restrictions contained in this Clause 13.3 shall continue to apply after Completion or termination of this Agreement without limit in time. 

  

	15	Entire Agreement 

  

	15.1	This Agreement and the documents referred to or incorporated in this Agreement constitute the entire agreement between the parties relating to the subject matter of this
Agreement and supersede and extinguish any prior drafts, agreements, undertakings, representations, warranties and arrangements of any nature whatsoever, whether or not in writing, between the parties in relation to the subject matter of this
Agreement. 

  

	15.2	Each of the parties acknowledges and agrees that it has not entered into this Agreement in reliance on any statement or representation of any person (whether a party to this
Agreement or not) other than as expressly incorporated in this Agreement. 

  

 53 

	16	Assignment and Transfer 

 This Agreement shall
not be assignable in whole or in part by the Seller but each of the Buyers shall be entitled to assign and transfer all or any of its rights and obligations under this Agreement or any of the Transaction Documents to any member of the Buyers’
Group and any such assignee or transferee shall be entitled to enforce the same against the Seller as if it were named in this Agreement or the Transaction Documents as the Buyer acting as assignor or transferor for provided that where such assignee
ceases to be a member of the Buyers’ Group, such assignee shall immediately assign back all or any of its rights and obligations under this Agreement or any of the Transaction Documents to the relevant Buyer or any other member of that
Buyers’ Group. Subject to the foregoing, all of the terms and provisions of this Agreement shall be binding upon and shall inure to the benefit of and be enforceable by the successors and permitted assigns of the Seller and the Buyers.

  

	17	Exclusivity 

  

	17.1	The Seller and the Covenantors confirm that none of them are currently in discussions or negotiations with any other person concerning the sale of any of the Exclusive Assets.

  

	17.2	In further consideration and as a further inducement for the entry into this Agreement by the Buyers and subject to Clause 17.6 and 17.7 the Seller and the Covenantors agree not
to, and the Seller shall procure that no Group Director and no officer or employee of the Seller shall; 

  

	 	(a)	approach or solicit any person; or 

  

	 	(b)	enter into or recommence discussions or negotiations with any person or provide or make available information to any person (other than the Buyers and their professional
advisers) 

 in each case with a view to the acquisition or subscription by such person of or for any of the Exclusive Assets
until the earlier of: 
  

	 	(c)	if the Conditions are not satisfied prior to the date and time referred to in Clause 2.4, the date and time referred to in Clause 2.4; or 

  

	 	(d)	if this Agreement is rescinded pursuant to Clause 7.6, the date of such rescission. 

  

	17.3	The Seller agrees that, for the period referred to in Clause 17.2, it will not authorise or permit any adviser or agent acting on its behalf to do anything which it is prohibited
from doing by virtue of the provisions of Clause 17.2. 

  

	17.4	The Seller and the Covenantors acknowledge that any breach of this Clause 17 would result in serious damage being sustained by the Buyers and as a result the Seller and
Covenantors unconditionally agree that damages would not be an adequate remedy for any breach of the provisions of this Clause 17 and therefore further agree to waive any rights they may have to oppose the granting of any equitable relief (including
injunctive relief) sought by the Buyers in relation to any threatened or actual breach of the provisions of this Clause 17. 

  

	17.5	 Nothing in this Agreement shall prevent the directors of the Seller from deciding not to make, vary or withdraw a recommendation of the shareholders of the
Seller to vote in favour of the

  

 54 

	 	 
resolution required to satisfy the Condition set out at paragraph 1 of Schedule 2 if they are required to do by virtue of their legal obligations whether pursuant to their fiduciary duties as
directors of the Seller or any Group Company or pursuant to the Irish Takeover Panel Act 1997, Takeover Rules 2007 or otherwise. 

  

	17.6	Nothing in Clause 17.2(b) shall prevent the Covenantors from taking any action which they are required to do by virtue of their legal obligations whether pursuant to their
fiduciary duties as directors of the Seller or any Group Company or pursuant to the Irish Takeover Panel Act 1997, Takeover Rules 2007 or otherwise. 

  

	17.7	Nothing in Clause 17.2(b) shall prevent the Seller from taking any action or omitting to take any action which the directors of the Seller cause the Seller to take or omit to
take by virtue of their legal obligations whether pursuant to their fiduciary duties as directors of the Seller or pursuant to the Takeover Panel Act 1997, Takeover Rules 2007 or otherwise. 

  

	18	Costs and Expenses 

  

	18.1	Subject to the remainder of this Clause 18, each party hereto shall bear any costs, fees or expenses incurred by it in connection with negotiating, preparing and entering into
this Agreement. 

  

	18.2	In further consideration and as a further inducement for the entry into this Agreement by the Buyers, the Seller undertakes to pay to the Buyers the sum of €1,250,000, by way of compensation if the Condition set out at paragraph 1 of Schedule 2 is not satisfied, as a result of:

  

	 	(a)	a general meeting of the Seller not being held; or 

  

	 	(b)	the Seller’s directors recommendation to vote in favour of the resolution required to satisfy the Condition set out at clause 1 of Schedule 2 being withdrawn or adversely
modified AND the shareholders of the Seller not voting in the requisite majority in favour of the required resolution, or 

  

	 	(c)	the shareholders of the Seller not voting in the requisite majority in favour of the required resolution, whether or nor the Seller’s directors have recommended the
shareholders to vote in favour of such resolution or have withdrawn or varied their recommendation 

 AND, in all three
cases, within 6 months after the earlier of the meeting at which shareholders do not vote in the requisite majority in favour of the resolution or the termination of this Agreement, a sale (whether by way of an offer, scheme of arrangement,
recapitalisation, acquisition, purchase or other transaction) of all of the issued share capital or of all or substantially all of the assets of the Seller between the Seller and a third party is (i) consummated by the Seller or
(ii) announced or agreed and such sale is subsequently consummated whether during or subsequent to such six month period (with payment only to be made in the event such consummation occurs). 
  

	18.3	If the compensation amount becomes payable under Clause 18.2 above, it shall be paid into a bank account notified by the Buyers within ten (10) Business Days after the date
on which the conditions for payment set out in Clause 18.2 are satisfied. 

  

 55 

	18.4	Any bonuses and/or commissions payable as a result of the implementation of this Agreement and the sale of the Shares (including any PRSI or other tax or social security amounts
thereon payable by a Group Company) will be payable by the Seller. 

  

	19	Interest on Late Payments 

  

	19.1	If a party fails to pay any sum payable by it on the due date for payment under this Agreement, it shall pay interest on the overdue sum for the period from and including the due
date of payment up to the date of actual payment (after as well as before judgment) in accordance with Clause 19.2. 

  

	19.2	The interest referred to in Clause 19.1 shall accrue from day to day and shall be paid on demand at the rate of 6% above the base rate from time to time of AIB Bank plc. Unpaid
interest shall compound quarterly. 

  

	20	Payments under this Agreement 

  

	20.1	Any payment or delivery by or on behalf of the Buyers to the Seller’s Solicitors shall be an absolute discharge of any obligation to make such a payment or delivery to the
Seller. Any payment or delivery by or on behalf of the Seller to the Buyer’s Solicitors shall be an absolute discharge of any obligation to make such a payment or delivery to the Buyer. Any payments to be made by the Buyers to the Seller shall
be made after the deduction of any withholding tax required by law. The Buyers shall remit the amount of any required withholding to the relevant Tax Authority and the remainder amount shall be transferred to the Seller or the Seller’s
Solicitor as provided for in this Agreement. 

  

	20.2	All sums payable by the Seller under this Agreement shall be paid free and clear of all deductions or withholdings unless the deduction or withholding is required by law, in
which event the Seller shall pay such additional amount as shall be required to ensure that the net amount received by the relevant Buyer under this Agreement will equal the full amount which would have been received by it had no such deduction or
withholding been required to be made. 

  

	20.3	If any Tax Authority brings into charge to Tax any sum paid to any Buyer under this Agreement (including in circumstances where any relief is available in respect of such charge
to Tax), then the Seller shall pay such additional amount as shall be required to ensure that the total amount paid, less the Tax chargeable on such amount (or that would be so chargeable but for such relief), is equal to the amount that would
otherwise be payable under this Agreement. 

  

	20.4	Any assignee of a Buyer’s rights under this Agreement shall not be entitled to any additional amounts pursuant to Clauses 20.2 or 20.3 than the Buyer would have been
entitled had no such assignment taken place. 

  

	21	Effect of Completion 

 This Agreement shall,
to the extent that it remains to be performed, continue in full force and effect notwithstanding Completion. 
  

 56 

	22	Waiver and Remedies 

  

	22.1	The failure to exercise or delay in exercising a right or remedy provided by this Agreement or by law does not constitute a waiver of the right or remedy or a waiver of other
rights or remedies. A waiver of any right or remedy provided by this Agreement must be in writing and may be given subject to any conditions thought fit by the grantor. 

  

	22.2	A waiver of a breach of any of the terms of this Agreement or of a default under this Agreement does not constitute a waiver of any other breach or default and shall not affect
the other terms of this Agreement. A waiver of a breach of any of the terms of this Agreement or of a default under this Agreement will not prevent a party from subsequently requiring compliance with the waived obligation. Should any provision of
this Agreement transpire not to be enforceable against any of the parties hereto, such non-enforceability shall not render such provision unenforceable against any other Party hereto. 

  

	22.3	The rights and remedies provided by this Agreement are cumulative and (subject as otherwise provided in this Agreement) are not exclusive of any rights or remedies provided by
law. 

  

	22.4	No failure or delay by any party in exercising any claim, remedy, right, power or privilege under this Agreement shall operate as a waiver 

  

	22.5	Any single or partial exercise of any right or remedy arising under this Agreement shall not preclude or impair any other or further exercise of that or any other right, power,
privilege or remedy. 

  

	22.6	Nothing in this Agreement or in any other document referred to herein shall be read or construed as excluding any liability or remedy as a result of fraud.

  

	23	Variation 

 No variation of this Agreement or
of any of the documents referred to in it shall be valid unless it is in writing and signed by or on behalf of each of the parties. 
  

	24	No Benefit to Others 

 The representations,
warranties, covenants and agreements contained in this Agreement are for the sole benefit of the parties hereto and their heirs, executors, administrators, legal representatives, successors and assigns, and they shall not be construed as conferring
any third party beneficiary rights or any other rights on any other persons. 
  

	25	Severance 

  

	25.1	If any provision of this Agreement shall be found by any court or administrative body of competent jurisdiction to be invalid or unenforceable, such invalidity or
unenforceability shall not affect the other provisions of this Agreement which shall remain in full force and effect; and any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any
other jurisdiction. 

  

 57 

	25.2	If any provision of this Agreement is so found to be invalid or unenforceable but would be valid or enforceable if some part of the provision were deleted, the provision in
question shall apply with such modification(s) as may be necessary to make it valid. 

  

	26	Further Assurance 

  

	26.1	The Seller shall at the Buyers’ cost and expense use all reasonable endeavours from time to time on or following Completion, on being required to do so by a Buyer, to do or
procure to be done all such further acts and things and execute or procure the execution of all such other documents as a Buyer may from time to time reasonably require for the purpose of giving full effect to this Agreement and giving the Buyers
the full benefit of the rights, powers, privileges and remedies conferred upon the Buyers in this Agreement. 

  

	26.2	The Seller shall send to the Buyers after Completion (at the relevant Buyer’s registered office for the time being) at its own cost and expense all records, correspondence,
documents, files, memoranda and other papers belonging to the Group Companies not required to be delivered at Completion and which are not kept at any of the Properties; or procure to be given to the Buyers, their advisers and agents such access to
(including the right to take copies of) any documents belonging to the Group Companies in their possession or under their control containing such information as the Buyers may from time to time reasonably require. 

  

	27	Notices 

  

	27.1	Any notice or other communication given under this Agreement shall be in writing in English and may (at the option of the party giving the notice) be served by delivering it
personally or sending it by pre-paid recorded delivery or registered post (or registered airmail in the case of an address for service outside Ireland) or fax to the address and for the attention of the relevant party set out in Sub-Clause 27.2 (or
as otherwise notified by that party hereunder). Any such notice shall be deemed to have been received: 

  

	 	(a)	if delivered personally, at the time of delivery; 

  

	 	(b)	in the case of pre-paid recorded delivery or registered post, 48 hours from the date of posting; 

  

	 	(c)	in the case of registered airmail, five days from the date of posting; and 

  

	 	(d)	in the case of fax, at the time of transmission. 

  

	 	(e)	Provided that if deemed receipt occurs before 9.00 a.m. on a Business Day the notice shall be deemed to have been received at 9.00 a.m. on that day, and if deemed receipt occurs
after 5.00 p.m. on a Business Day, or on a day which is not a Business Day, the notice shall be deemed to have been received at 9.00 a.m. on the next Business Day. 

  

	27.2	The address and fax numbers of the parties for the purposes of Sub-Clause 27.1 are: 

 Seller 
  

 58 

			
	  Address:	  	 Fleming Court
  
 Flemings Place
  
 Dublin 4

		
	  For the attention of:	  	Declan Cassidy
		
	  Fax number:	  	+ 353 (0) 1 667 3749
		
	The Buyers	  	
		
	  Address:	  	 Northern Cross
  
 Malahide Road
  
 Dublin

		
	  For the attention of:	  	the Chief Financial Officer of the Irish Buyer
		
	  Fax number:	  	+ 353 (0) 1 816 0691
	
	with a copy to the Buyer’s Solicitors at:
		
	  Address:	  	70 Sir John Rogerson’s Quay Dublin 2 Ireland
		
	  For the attention of:	  	Tim Scanlon
		
	  Fax number:	  	+353 1 232 3333
		
	  Address	  	 Aramark Tower
  
 1101 Market Street
  
 Philadelphia
  
 Pennsylvania,
  
 19107, USA

		
	  For the attention of	  	the Senior Vice President and Treasurer
		
	  Fax number:	  	+ 1 215 238 3284

 or such other address or facsimile number as may be notified in writing from time to time by the
relevant party to the other party in accordance with Clause 27.4. 
  

	27.3	For the avoidance of doubt, notice given under this Agreement shall not be validly served if sent by e-mail. 

  

	27.4	A party may notify the other parties to this Agreement of a change to its name, relevant person, address or fax number for the purposes of Clause 27.2 provided that such
notification shall only be effective on: 

  

 59 

	 	(a)	the date specified in the notification as the date on which the change is to take place; or 

  

	 	(b)	if no date is specified or the date specified is less than five clear Business Days after the date on which notice is deemed to have been served, the date falling five clear
Business Days after notice of any such change is deemed to have been given. 

  

	28	Guarantee and indemnity 

  

	28.1	In consideration of the Seller entering into this agreement, the Guarantor unconditionally and irrevocably guarantees, as a primary obligation to the Seller, the due and punctual
payment by the Buyers of all monies payable under this Agreement. 

  

	28.2	If either of the Buyers defaults on the payment when due of any amount payable to the Seller under this Agreement, the Guarantor shall immediately on demand by the Seller pay
that amount to the Seller in the manner prescribed in this agreement as if it were such Buyer. 

  

	28.3	This guarantee is a continuing guarantee and shall extend to the ultimate balance of sums payable by the Buyers under this Agreement, regardless of any intermediate payment or
discharge in whole or in part. It shall not be affected by any act, omission, matter or thing which, but for this Clause 28.3, would reduce, release or prejudice any of the Guarantor’s obligations under this Clause 28.3 (without limitation and
whether or not known to it or the Seller). 

  

	28.4	If any payment by the Buyers, or any discharge given by the Seller, is avoided or reduced as a result of insolvency or any similar event, the liability of the Buyers and
Guarantor shall continue as if the payment, discharge, avoidance or reduction had not occurred and the Seller shall be entitled to recover the value or amount of that security or payment. The Guarantor waives any right it may have of first requiring
the Seller (or any trustee or agent on its behalf) to proceed against or enforce any other rights or security or claim payment from any person before claiming from the Guarantor under this Clause 28. 

  

	28.5	Until all amounts which may be or become payable by the Buyers under or in connection with this Agreement have been irrevocably paid in full, and unless the Seller otherwise
directs in writing, the Guarantor shall not exercise any rights which it may have by reason of performance by it of its obligations under this Clause 28. 

  

	28.6	The obligations of the Guarantor shall be in addition to and independent of all other security which the Buyers may at any time hold in respect of any of the obligations of the
Seller under this Agreement. 

  

	28.7	Without prejudice to Clause 28.1, the Guarantor unconditionally and irrevocably agrees to indemnify and keep indemnified the Seller from and against all and any losses, costs,
claims, liabilities, damages, demands and expenses suffered or incurred reasonably by the Seller and arising from failure of the Buyers to comply with any of its obligations, or discharge any of its liabilities, under this Agreement.

  

 60 

	29	Maintenance and availability of records 

  

	29.1	The Buyers shall promptly on demand by the Seller provide or procure the Group Companies to provide to the Seller or its duly authorised agents and the Seller shall promptly on
demand by the Buyer provide to the Buyers or their duly authorised agents, such working papers ledgers accounts records and other documents as the Seller or, as the case may be, the Buyers, may reasonably require to enable the Seller to prepare its
financial statement for the year ending after the date hereof, complete and file any tax or customs and excise or similar returns or reports, to carry out any tax audit or other proceeding or otherwise to fulfil any requirements of any law or
regulation binding on the Seller or as the case may be the Buyers. 

  

	29.2	The Buyers shall not be obliged to comply with the obligation set out in Clause 29.1 if compliance would result in a breach by the Buyers or the Group Companies of their legally
binding confidentiality obligations to third parties or any applicable law or regulation 

  

	29.3	The Seller shall not be obliged to comply with the obligation set out in Clause 29.1 if compliance would result in a breach by the Seller of its legally binding confidentiality
obligations to third parties. 

  

	30	Joint and several 

  

	30.1	The liabilities and obligations of the Buyers under this Agreement and all documents ancillary to this Agreement shall (unless specifically otherwise provided) be joint and
several. 

  

	30.2	In exercising any right, power or benefit under this Agreement and all documents ancillary to this Agreement, the Buyers shall at all times act jointly. The Seller shall, be
entitled to rely upon any notice, statement or document in writing (and where appropriate, orally) given, made or executed by any one of the Buyers and any Buyer shall have and shall be deemed to have power and authority to bind the others in
relation to any matter arising thereunder. 

  

	31	The Covenantors 

  

	31.1	The Covenantors are party to this Agreement solely for the purpose of providing for their agreement to comply with the provisions of Clauses 10, 12 and
17 of this Agreement. 

  

	31.2	For the avoidance of doubt, neither Covenantor shall be liable to the Buyers for any breach by the other Covenantor of any of the provisions of this Agreement.

  

	32	Counterparts 

 This Agreement may be executed
in any number of counterparts (by fax or otherwise), each of which, when executed and delivered, shall be an original, and all the counterparts together shall constitute one and the same instrument. This Agreement shall become effective and be dated
(and each counterpart shall be dated) on the date first written above between the Parties which have executed and delivered a counterpart. The original executed counterpart engrossment will be put in the post as soon as practicable thereafter.

  

 61 

	33	Language 

  

	33.1	This Agreement is drawn up in the English language. If this Agreement is translated into another language, the English language text shall in any event prevail.

  

	33.2	Each notice, instrument, certificate or other communication to be given by one party to another in this Agreement or in connection with this Agreement shall be in English (being
the language of negotiation of this Agreement) and in the event that such notice, instrument, certificate or other communication or this Agreement is translated into any other language, the English language text shall prevail.

  

	34	Governing Law and Jurisdiction 

  

	34.1	This Agreement shall be governed by, and construed in accordance with, the laws of Ireland. 

  

	34.2	Each party irrevocably agrees to submit to the exclusive jurisdiction of the courts of Ireland over any Claim or matter arising under or in connection with this Agreement or the
legal relationship established by this Agreement. 

  

	35	Acceptance of Service 

 The Buyers hereby
irrevocably authorise and appoint the Buyers’ Solicitors (or such other firm of solicitors resident in Ireland as it may by notice to the Seller substitute) to accept service of all legal process arising out of or in connection with this
Agreement and service on the Buyers’ Solicitors (or substitute as aforesaid) shall be deemed service on the Buyer. The Buyer agrees that failure by its process agent to notify it of the process will not invalidate the proceedings concerned.

  

 62 

 Schedule 1 
 Part 1: Particulars of the Irish Companies 
  

									
	Name:	 	Irish Estates (Management) Limited
		
	Number:	 	12850
		
	Date of registration:	 	01 April 1949 under the Companies Act 1963 to 2009
		
	Status:	 	Single member private company limited by shares
		
	Place of registration	 	Ireland
		
	Registered Office:	 	Ulysses House, 22-24 Foley Street, Dublin 1
		
	Authorised share capital:	 	€1,250,000 divided into 1,000,000 ordinary shares of €1.25 each
		
	Issued share capital:	 	260,100 ordinary shares
					
	Shareholder:	 	 Name
	  		  	Shares Held	  	
				
		 	Veris Public Limited Company	  	260,100	  	
					
		 	 Charge
  
	  	 Date Created
  
	  		  	Date Registered          

		 	 
				
	Charge 1 of 1:	 	Being a charge in favour of Anglo Irish Bank Corporation Plc (Including its successors and assigns) over the uncalled share capital of the company	  	22 December 2004	  	10 January 2005
					
		 	Name	  		  		  	
					
	Directors:	 	Bernard Patrick Farrell	  		  		  	
					
		 	Larry Kane	  		  		  	
					
		 	Martin Mc Mahon	  		  		  	
					
		 	Vincent Hickey	  		  		  	
			
	Secretary:	 	Declan Cassidy	  	
		
	Auditors:	 	KPMG, Chartered Accountants, 1 Stokes Place, St Stephen’s Green, Dublin 2.

  

 63 

									
	Name:	 	Vector Workplace and Facility Management Limited
		
	Number:	 	315777
		
	Date of registration:	 	25 November 1999 under the Companies Act 1963 to 2009
		
	Status:	 	Private limited by shares
		
	Place of registration	 	Ireland
		
	Registered Office:	 	Ulysses House, 22-24 Foley Street, Dublin 1
		
	Authorised share capital:	 	€100,000 divided into:-
		
		 	100,000 A ordinary shares of €0.01 each ;
		
		 	100,000 B ordinary shares of €0.01 each;
		
		 	100,000 C ordinary shares of €0.01 each;
		
		 	1,000,000 D ordinary shares of €0.01 each; and
		
		 	8,700,000 ordinary shares of €0.01 each.
		
	Issued share capital:	 	675,175 ordinary shares
			
	Shareholder:	 	Name	  	Shares Held
			
		 	Veris Public Limited Company	  	675,175
				
		 	 Charge
  
	  	 Date Created
  
	  	 Date Registered
  

		 	 
				
	Charge 1 of 2:	 	 Being a charge in favour of Anglo Irish Bank Corporation Limited over the uncalled share capital of the company.
  
	  	 22 December 2004
  
	  	 10 January 2005
  

		 	 
				
	Charge 2 of 2	 	Being a charge in favour of Anglo Irish Bank Corporation Limited over the book debts of the company.	  	22 December 2004	  	10 January 2005
			
		 	Name	  	
			
	Directors:	 	Bernard Patrick Farrell	  	
			
		 	Anne Ryan	  	
			
		 	Martin Mc Mahon	  	
			
		 	Vincent Hickey	  	
			
		 	Derry Robertson	  	

  

 64 

									
	 	 	Roger Brennan	  	 	  	 	  	 
					
	Secretary:	 	Anne Ryan	  		  		  	
		
	Auditors:	 	KPMG, Chartered Accountants, 1 Stokes Place, St. Stephen’s Green, Dublin 2.

  

 65 

									
	NAME:	  	PREMIER MANAGEMENT COMPANY (DUBLIN) LIMITED
		
	NUMBER:	  	121360
		
	DATE OF REGISTRATION:	  	14 APRIL 1987 UNDER THE COMPANIES ACT 1963 TO 2009
		
	STATUS:	  	SINGLE MEMBER PRIVATE COMPANY LIMITED BY SHARES
		
	PLACE OF REGISTRATION	  	IRELAND
		
	REGISTERED OFFICE:	  	ULYSSES HOUSE, 22-24 FOLEY STREET, DUBLIN 1
		
	AUTHORISED SHARE CAPITAL:	  	€126,973.80 DIVIDED INTO 100,000 ORDINARY SHARES OF €1.269738
		
	ISSUED SHARE CAPITAL:	  	3,000 ORDINARY SHARES
			
	SHAREHOLDER:	  	NAME	  	SHARES HELD
			
		  	VERIS PUBLIC LIMITED COMPANY	  	3,000
				
		  	CHARGE	  	DATE CREATED	  	DATE REGISTERED
				
	 CHARGE 1 OF 1:
	  	BEING A CHARGE IN FAVOUR OF ANGLO IRISH BANK CORPORATION PLC OVER THE UNCALLED SHARE CAPITAL OF THE COMPANY.	  	01 DECEMBER 2006	  	13 DECEMBER 2006
					
		  	NAME	  		  		  	
			
	DIRECTORS:	  	BERNARD PATRICK FARRELL	  	
					
		  	MARTIN MC MAHON	  		  		  	
			
	SECRETARY:	  	DECLAN CASSIDY	  	
		
	AUDITORS:	  	KPMG, CHARTERED ACCOUNTANTS, 1 STOKES PLACE, ST. STEPHEN’S GREEN, DUBLIN 2.

  

 66 

									
	NAME:	  	GLENRYE PROPERTIES SERVICES LIMITED
		
	NUMBER:	  	292811
		
	DATE OF REGISTRATION:	  	26 AUGUST 1998 UNDER THE COMPANIES ACT 1963 TO 2009
		
	STATUS:	  	SINGLE MEMBER PRIVATE COMPANY LIMITED BY SHARES
		
	PLACE OF REGISTRATION	  	IRELAND
		
	REGISTERED OFFICE:	  	ULYSSES HOUSE, 22-24 FOLEY STREET, DUBLIN 1
		
	AUTHORISED SHARE CAPITAL:	  	€126,973.80 DIVIDED INTO 100,000 ORDINARY SHARES OF €1.269738
		
	ISSUED SHARE CAPITAL:	  	1,052 ORDINARY SHARES
			
	SHAREHOLDER:	  	NAME	  	SHARES HELD
			
		  	VERIS PUBLIC LIMITED COMPANY	  	1,052
				
		  	CHARGE	  	DATE CREATED	  	DATE REGISTERED
				
	CHARGE 1 OF 1:	  	BEING A CHARGE IN FAVOUR OF ANGLO IRISH BANK CORPORATION PLC OVER THE UNCALLED SHARE CAPITAL OF THE COMPANY.	  	01 DECEMBER 2006	  	13 DECEMBER 2006
					
		  	NAME	  		  		  	
			
	DIRECTORS:	  	BERNARD PATRICK FARRELL	  	
					
		  	DOMINIC GLENNANE	  		  		  	
			
	SECRETARY:	  	DECLAN CASSIDY	  	
		
	AUDITORS:	  	KPMG, CHARTERED ACCOUNTANTS, 1 STOKES PLACE, ST. STEPHEN’S GREEN, DUBLIN 2.

  

 67 

 Schedule 1 
 Part 2: Particulars of VUKL 
  

									
	Name:	  	Veris UK Limited (“VUKL”)
		
	Number:	  	05920150
		
	Date of registration:	  	31 August 2006
		
	Status:	  	Private company limited by shares
		
	Place of registration	  	England and Wales
		
	Registered Office:	  	Principle house, 121-123 Fleet Road, Fleet, Hampshire, GU51 3PD
		
	Authorised share capital:	  	£1,000,000 divided into 1,000,000 ordinary shares of £1.00 each
		
	Issued share capital:	  	1 ordinary share
			
	Shareholder:	  	Name	  	Shares Held
			
		  	Veris Plc	  	1
				
		  	Charge	  	Date Created	  	Date Registered
				
	Charge 1 of 2:	  	Being a charge over shares in favour of Anglo Irish Bank Corporation Plc	  	29 November 2007	  	13 December 2007
				
	Charge 2 of 2:	  	Being a debenture in favour of Anglo Irish Bank Corporation Plc	  	29 November 2007	  	13 December 2007
					
		  	Name	  		  		  	
			
	Directors:	  	Bernard Farrell	  	
					
		  	Martin Mc Mahon	  		  		  	
			
	Secretary:	  	Declan Cassidy	  	
		
	Auditors:	  	KPMG, Chartered Accountants, 1 Stokes Place, St Stephen’s Green, Dublin 2

  

 68 

 Schedule 1 
 Part 3: Particulars of The Subsidiaries 
  

									
	Name:	  	Irish Estates (Facilities Management) Limited
		
	Number:	  	311486
		
	Date of registration:	  	26 August 1999 under the Companies Act 1963 to 2009
		
	Status:	  	Single member private company limited by shares
		
	Place of registration	  	Ireland
		
	Registered Office:	  	Ulysses House, 22-24 Foley Street, Dublin 1
		
	Authorised share capital:	  	€1,250,000 divided into 1,000,000 ordinary shares of €1.25 each
		
	Issued share capital:	  	10,000 ordinary shares
			
	Shareholder:	  	Name	  	Shares Held
			
		  	Irish Estates (Management) Limited	  	10,000
				
		  	 Charge
  
	  	 Date Created
  
	  	 Date Registered
  

		  	 
				
	Charge 1 of 1:	  	Being a charge in favour of Anglo Irish Bank Corporation Plc over the uncalled share capital of the company.	  	22 December 2004	  	10 January 2005
					
		  	Name	  		  		  	
			
	Directors:	  	Bernard Patrick Farrell	  	
					
		  	Larry Kane	  		  		  	
					
		  	Martin Mc Mahon	  		  		  	
					
		  	Vincent Hickey	  		  		  	
			
	Secretary:	  	Declan Cassidy	  	
		
	Auditors:	  	KPMG, Chartered Accountants, 1 Stokes Place, St. Stephen’s Green, Dublin 2

  

 69 

					
	NAME:	  	SPOKESOFT TECHNOLOGIES LIMITED
		
	NUMBER:	  	410970
		
	DATE OF REGISTRATION:	  	16 NOVEMBER 2005 UNDER THE COMPANIES ACT 1963 TO 2009
		
	STATUS:	  	SINGLE MEMBER PRIVATE COMPANY LIMITED BY SHARES
		
	PLACE OF REGISTRATION	  	IRELAND
		
	REGISTERED OFFICE:	  	ULYSSES HOUSE, 22-24 FOLEY STREET, DUBLIN 1
		
	AUTHORISED SHARE CAPITAL:	  	€100,000 DIVIDED INTO 100,000 ORDINARY SHARES OF €1.00
		
	ISSUED SHARE CAPITAL:	  	1 ORDINARY SHARE
			
	SHAREHOLDER:	  	NAME	  	SHARES HELD
			
		  	VECTOR WORKPLACE AND FACILITY MANAGEMENT LIMITED	  	1
		
	CHARGES:	  	NO CHARGES REGISTERED
			
		  	NAME	  	
			
	DIRECTORS:	  	BERNARD PATRICK FARRELL	  	
			
		  	MARTIN ANDREW MC MAHON	  	
			
		  	ANNE ITA RYAN	  	
			
	SECRETARY:	  	ANNE ITA RYAN	  	
		
	AUDITORS:	  	KPMG, CHARTERED ACCOUNTANTS, 1 STOKES PLACE, ST. STEPHEN’S GREEN, DUBLIN 2.

  

 70 

									
	NAME:	  	VERIS PROPERTY MANAGEMENT LIMITED
		
	NUMBER:	  	03462956
		
	DATE OF REGISTRATION:	  	10 NOVEMBER 1997
		
	STATUS:	  	PRIVATE COMPANY LIMITED BY SHARES
		
	PLACE OF REGISTRATION	  	ENGLAND AND WALES
		
	REGISTERED OFFICE:	  	PRINCIPLE HOUSE, 121-123 FLEET ROAD, FLEET, HAMPSHIRE, GU51 3PD
		
	AUTHORISED SHARE CAPITAL:	  	£1,000 DIVIDED INTO 1,000 ORDINARY SHARES OF £1.00 EACH
			
	ISSUED SHARE CAPITAL:	  	1,000 ORDINARY SHARES	  	
					
	SHAREHOLDER:	  	NAME	  		  		  	SHARES HELD
					
		  	ORANGE ENVIRONMENTAL BUILDING SERVICES LIMITED	  		  		  	1000
				
		  	CHARGE	  	DATE CREATED	  	DATE REGISTERED
				
	CHARGE 1 OF 1:	  	BEING A DEBENTURE IN FAVOUR OF ANGLO IRISH BANK CORPORATION PLC	  	21 DECEMBER 2007	  	10 JANUARY 2008
					
		  	NAME	  		  		  	
					
	DIRECTORS:	  	BERNARD FARRELL	  		  		  	
					
		  	MARTIN MCMAHON	  		  		  	
					
		  	DAVID MATHEWS	  		  		  	
					
	SECRETARY:	  	DAVID MATHEWS	  		  		  	
		
	AUDITORS:	  	KPMG, CHARTERED ACCOUNTANTS, 1 STOKES PLACE, ST. STEPHEN’S GREEN, DUBLIN 2.

  

 71 

									
	Name:	  	Orange Support Services Limited
		
	Number:	  	02949749
		
	Date of registration:	  	18 July 1994
		
	Status:	  	Private company limited by shares
		
	Place of registration	  	England and Wales
		
	Registered Office:	  	Principle House, 121-123 Fleet Road, Fleet, Hampshire, GU51 3PD
		
	Authorised share capital:	  	£1,000 divided into 1,000 ordinary shares of £1.00 each
		
	Issued share capital:	  	2 ordinary shares
			
	Shareholder:	  	Name	  	Shares Held
			
		  	Veris UK Limited	  	2
				
		  	 Charge
  
	  	 Date Created
  
	  	 Date Registered
  

		  	 
				
	Charge 1 of 1:	  	Being a debenture in favour of Anglo Irish Bank Corporation Plc	  	21 December 2007	  	10 January 2008
					
		  	Name	  		  		  	
			
	Directors:	  	Bernard Farrell	  	
					
		  	Martin McMahon	  		  		  	
					
		  	David Mathews	  		  		  	
			
	Secretary:	  	David Mathews	  	
		
	Auditors:	  	KPMG, Chartered Accountants, 1 Stokes Place, St Stephen’s Green, Dublin 2

  

 72 

									
	Name:	  	Orange Environmental Building Services Limited
		
	Number:	  	02949907
		
	Date of registration:	  	18 July 1994
		
	Status:	  	Private company limited by shares
		
	Place of registration	  	England and Wales
		
	Registered Office:	  	Principle House, 121-123 Fleet Road, Fleet, Hampshire, GU51 3PD
		
	Authorised share capital:	  	£1,000 divided into 1,000 ordinary shares of £1.00 each
		
	Issued share capital:	  	1,000 ordinary shares
			
	Shareholder:	  	Name	  	Shares Held
			
		  	Veris UK Limited	  	10,000
				
		  	 Charge
  
	  	 Date Created
  
	  	 Date Registered
  

		  	 
				
	Charge 1 of 2:	  	 Being a charge over shares in favour of Anglo Irish Bank Corporation Plc
  
	  	21 December 2007	  	10 January 2008
		  	 
				
	Charge 2 of 2:	  	Being a debenture in favour of Anglo Irish Bank Corporation Plc	  	21 December 2007	  	10 January 2008
					
		  	Name	  		  		  	
			
	Directors:	  	Bernard Farrell	  	
					
		  	Martin McMahon	  		  		  	
					
		  	David Mathews	  		  		  	
					
		  	William Astle	  		  		  	
					
		  	Dale Roy Vaughan	  		  		  	
			
	Secretary:	  	David Mathews	  	
		
	Auditors:	  	KPMG, Chartered Accountants, 1 Stokes Place, St Stephen’s Green, Dublin 2

  

 73 

							
	Name:	  	Vector Environmental Services Limited	  	
			
	Number:	  	NI 41888	  	
			
	Date of registration:	  	07 November 2001	  	
			
	Status:	  	Private company limited by shares	  	
			
	Place of registration	  	Northern Ireland	  	
		
	Registered Office:	  	Maneely McCann, Lamont Buildings, 44 Stranmillis Embankment, Belfast, BT9 5FL
		
	Authorised share capital:	  	£100,000 divided into 10,000,000 ordinary shares of £0.01 each
			
	Issued share capital:	  	95,000 ordinary shares	  	
				
	Shareholder:	  	Name	  		  	Shares Held
			
		  	Vector Workplace and Facility Management Limited	  	95,000
			
	Charges:	  	No charges registered	  	
				
		  	Name	  		  	
				
	Directors:	  	Bernard Farrell	  		  	
				
		  	Martin Mc Mahon	  		  	
				
		  	Michael Ferguson	  		  	
				
		  	Anne Ita Ryan	  		  	
				
	Secretary:	  	Anne Ita Ryan	  		  	
			
	Auditors:	  	KPMG	  	

  

 74 

 Schedule 1 
 Part 4: The Covenantors 
 The Covenantors are: 
 Mr Niall McFadden of 4 Avoca Wood, Avoca Park, Blackrock, County Dublin. 
 Mr Martin McMahon of 83
Kincora Road, Clontarf, Dublin 3. 
  

 75 

 Schedule 2 
 Conditions 
 The conditions referred to in Clause 2 are: 
  

	1	Shareholder Approval. 

 The passing at an
extraordinary general meeting of the Seller of the shareholder resolution attached as Annexure A hereto. 
  

	2	Competition Authority Approval. 

 One of the
following events having occurred: 
  

	 	(a)	the Competition Authority having informed the Buyer that it has determined, pursuant to Section 21 or 22(3)(a) of the Competition Act that the proposed acquisition of the
Shares by the Buyer hereunder may be put into effect; 

  

	 	(b)	the Competition Authority having made a conditional determination, pursuant to Section 22(3)(e) of the Companies Act, in relation to the proposed acquisition of the Shares
by the Buyer hereunder on terms acceptable to the Buyer; 

  

	 	(c)	the period specified in Section 19(1)(c) of the Competition Act having elapsed without the Competition Authority having informed the parties of the determination (if any) it
has made under Section 12(2) (a) or (b); or 

  

	 	(d)	the period specified in Section 19(1)(d) of the Competition Act having elapsed without the Competition Authority having made a determination under Section 22 in
relation to the proposed acquisition of the Shares by the Buyer. 

  

	3	Compliance with Schedule 3 Undertakings 

 The
Group Companies and the Seller shall have performed and complied in all material respects with all material undertakings and obligations required pursuant to Schedule 3 of this Agreement to be performed or complied with by them between the date
hereof and Completion Date. 
  

	4	No Litigation 

 No legal proceedings seeking
to materially restrain, prohibit or materially impede the consummation of the transactions contemplated by this Agreement in accordance with its terms or to obtain damages or compensation with respect thereto, having been instituted or are pending.

  

	5	No Legislation 

 No statute, rule, regulation,
executive order, decree, ruling or injunction having been enacted, entered, promulgated, or enforced by any court or government entity that prohibits, materially restrains, or materially restricts the consummation of the Transaction or any of the
other transactions contemplated by this Agreement. 
  

 76 

	6	No Material Adverse Changes 

 There shall not
have occurred in the period from the date of this Agreement to the Completion Date any event or circumstance which results in a Material Adverse Change or is likely to result in a Material Adverse Change excluding, in each case, any event,
circumstance or change resulting from: 
  

	 	(i)	changes affecting the industry in which the Group Companies or any of them operate which do not have a disproportionate effect on the Group Company compared to other companies
operating in such industry; 

  

	 	(ii)	changes in national or international political, economic or financial market conditions, stock markets, interest rates, exchange rates or other general economic conditions;

  

	 	(iii)	the announcement of the transactions contemplated by this Agreement or the change of control resulting from them; 

  

	 	(iv)	changes in law, regulations or generally accepted accounting principles; 

  

	 	(v)	acts of terrorism or war; 

  

	 	(vi)	any matter to the extent Disclosed; 

  

	 	(vii)	any other matters not directly relating to the assets or liabilities or conduct of the business of the Group Companies. 

  

	7	Representations and Warranties 

  

	7.1	The Warranties of the Seller given pursuant to paragraphs 1.1 to 1.5 (Share Capital) Part 1 of Schedule 5 (Title Warranties) and Warranty Clause 3.2 (Business
Conduct) and Warranty Clause 6 (Solvency) of Part 2 of Schedule 5 being accurate and correct in all material respects as at Completion; and 

  

	7.2	All other Warranties of the Seller given pursuant to Part 2 of Schedule 5 (other than those referred to at 7.1 above)(the “Other Warranties”) being accurate and
correct in all material respects as at Completion provided that this Condition 7.2 shall be deemed to be satisfied if the event or circumstance as a result of which the Other Warranties fail to be true and accurate in all material respects as at
Completion does not result in a Material Adverse Change or is not likely to result in a Material Adverse Change (excluding, in each case, any event, circumstance or change resulting from: 

  

	 	(i)	changes affecting the industry in which the Group Companies or any of them operate which do not have a disproportionate effect on the Group Company compared to other companies
operating in such industry; 

  

	 	(ii)	changes in national or international political, economic or financial market conditions, stock markets, interest rates, exchange rates or other general economic conditions;

  

	 	(iii)	the announcement of the transactions contemplated by this Agreement or the change of control resulting from them; 

  

	 	(iv)	changes in law, regulations or generally accepted accounting principles; 

  

 77 

	 	(v)	acts of terrorism or war; 

  

	 	(vi)	any matter to the extent Disclosed; 

  

	 	(vii)	any other matters not directly relating to the assets or liabilities or conduct of the business of the Group Companies. 

  

 78 

 Schedule 3 
 Conduct of Business between Exchange and Completion 
  

	1	The Seller hereby covenants with and undertakes to the Buyers that it will procure that between the date of this Agreement and Completion the Buyers and their advisers are given
promptly on request such reasonable facilities and information regarding and reasonable access to the business, premises, employees, assets, liabilities, contracts and affairs of the Group as the Buyers, representatives of the Buyers’ Group
and/or their advisers may reasonably require. 

  

	2	The Seller undertakes to procure that from the date of this Agreement until Completion, each Group Company shall not without the prior written consent of the Buyers:

  

	 	2.1	do anything outside the ordinary and usual course of its business either as regards the nature, scope or manner of conducting same; 

  

	 	2.2	dispose of, or grant any option in respect of, any part of any of its assets except in the ordinary and usual course of trading; 

  

	 	2.3	acquire any assets (other than stock in trade (including raw material and packaging) in the ordinary and usual course of trading and any debtors arising therefrom);

  

	 	2.4	enter into any transaction with any person which is otherwise than at arm’s length and for full value; 

  

	 	2.5	create or issue or allot or redeem or vary any share or loan capital or give any option in respect of any shares or loan capital; 

  

	 	2.6	save for the resolution referred to at clause 2.5 of this Agreement, pass any shareholder resolution; 

  

	 	2.7	enter into, modify or agree to terminate any material contract, customer or supplier which affects the revenue of Group Companies by more than €100,000 per contract per annum; 

  

	 	2.8	terminate or notify an intention to terminate any material contract to which it is a party; 

  

	 	2.9	make any increase in the remuneration or other emoluments or benefits of or provide any other benefits or privileges (of whatever nature) to its officers, employees or former
officers or former employees or make any change in the terms and conditions of employment of any of its officers or employees; 

  

	 	2.10	 establish or announce to or advise any person of any proposal to establish any new retirement, death or disability benefit scheme of or in respect of any of its
officers or employees or former officers or former employees (or any dependant of any such person) or grant or create or make or announce to any person any proposal to grant,

  

 79 

	 	 
create, make or agree any additional retirement, death or disability benefit or any changes to any existing benefits or agree any funding proposal with the trustees of an Irish Pension Scheme;

  

	 	2.11	dismiss any of its employees or employ or engage (or offer to employ or engage) any person on an annual remuneration of greater than €60,000; 

  

	 	2.12	create, extend, grant or issue any Encumbrance over any of its assets or undertaking or revenues or enter into any guarantee, indemnity or other assurance against loss in respect
of the liabilities of any person or enter into any similar arrangement otherwise than by operation of law; 

  

	 	2.13	grant, modify, agree to terminate or permit the lapse of any intellectual property rights or enter into any agreement relating to any such rights otherwise than by operation of
law; 

  

	 	2.14	enter into any (or modify any subsisting) agreement with any trade union or any agreement that relates to any works council or other employee representative body;

  

	 	2.15	enter into any tenancy, lease or licence agreement or arrangement in respect of any of the Properties or vary the terms on which it holds any Properties or settle any rent
review; 

  

	 	2.16	enter into any material hire purchase or lease or instalment purchase agreement or arrangement or other agreement or arrangement for payment on deferred terms;

  

	 	2.17	make any material change to the accounting procedures or principles by reference to which its accounts are drawn up; 

  

	 	2.18	permit any of its insurances to lapse or do or omit to do anything to make any policy of insurance void or voidable or the premiums thereunder likely to be increased;

  

	 	2.19	initiate any material litigation, arbitration or tribunal proceedings or compromise or settle any such proceedings or make any admission in relation to such proceedings other
than debt collection in the normal course of business; 

  

	 	2.20	enter into any capital commitment on any individual item in excess of €
100,000 or, which, together with all other capital commitments of the Group entered into after the date hereof exceeds EUR250,000 in the aggregate; 

  

	 	2.21	incur any liability to the Seller or a Covenantor other than trading liabilities incurred in the normal course of business; 

  

	 	2.22	attempt or agree, conditionally or otherwise, to do or permit (whether by omission or otherwise) to be done any of the foregoing 

 PROVIDED that nothing in Clause 2.1, 2.4, 2.21 shall prevent the Group Companies from declaring and paying lawful dividends, discharging lawful
management charges by way of set off or otherwise, lawfully lending or borrowing from another Group Company, if such steps

  

 80 

 
are, in the opinion of the Seller, necessary or desirable to reduce or eliminate on or before the Completion Date the intercompany balances existing between the Seller and the Group Companies.

  

	3	The Seller shall not induce, or attempt to induce, any employee of any Group Company, whether directly or indirectly, to terminate their employment before the Completion Date or
thereafter. 

  

	4	The Seller shall give to the Buyers as soon as reasonably practicable details of any Material Adverse Change arising between the date of this Agreement and the Completion date,
excluding, in each case, any event, circumstance or change resulting from: 

  

	 	(i)	changes affecting the industry in which the Group Companies or any of them operate which do not have a disproportionate effect on the Group Company compared to other companies
operating in such industry; 

  

	 	(ii)	changes in national or international political, economic or financial market conditions, stock markets, interest rates, exchange rates or other general economic conditions;

  

	 	(iii)	the announcement of the transactions contemplated by this Agreement or the change of control resulting from them; 

  

	 	(iv)	changes in law, regulations or generally accepted accounting principles; 

  

	 	(v)	acts of terrorism or war; 

  

	 	(vi)	any matter to the extent Disclosed; 

  

	 	(vii)	any other matters not directly relating to the assets or liabilities or conduct of the business of the Group Companies. 

  

 81 

 Schedule 4 
 Part 1: Documents which have been delivered prior to execution of this Agreement 
  

	1	A copy of the minutes of a meeting of the Directors of the Seller authorising the execution by the appropriate signatories on behalf of Seller of the Seller’s Completion
Documents (such copy minutes being certified as accurate by the company secretary of the Seller). 

  

	2	Disclosure Letter. 

  

	3	Irrevocable Undertakings in the agreed form from the directors of the Seller and Boundary Capital plc. 

  

 82 

 Schedule 4 
 Part 2: Documents which are to be delivered at Completion 
  

	1	At Completion the Seller shall deliver to the Buyers: 

  

	 	1.1	Minutes of the extraordinary general meeting of the Seller evidencing that the conditions referred to in section 2(1) has been complied with and evidence reasonably satisfactory
to the Buyers that the other conditions referred to in section 2 have been complied with and deliver to the Buyers all documents required in relation thereto, including any powers of attorney under which such documents have been executed;

  

	 	1.2	where any of the Seller is a corporate body, evidence of the authority of any person or persons executing or attesting the execution of this Agreement and any other document on
its behalf to do so; 

  

	 	1.3	duly executed share transfers in respect of the Shares together with the relevant certificates (or, in the case of any share certificates found to be missing, an indemnity, in a
form satisfactory to the Buyers); 

  

	 	1.4	irrevocable form of proxy in the agreed form executed by the Seller to enable the Buyers (during the period prior to the registration of the transfer of the Shares) to exercise
all voting and other rights attaching to the Shares; 

  

	 	1.5	written resolution of IEM executed by the Seller as sole shareholder providing for the amendment of the share capital clause in the Articles of Association of IEM and the related
executed Companies Registration Office documents (form G1, amended articles of association and copy written resolution) or evidence of the filing of same with the Companies Registration Office; 

  

	 	1.6	in relation to each Group Company, the statutory books, records and registers, the common seal, the certificate of incorporation, any certificates of incorporation on change of
name of each Group Company; 

  

	 	1.7	a written acknowledgement, in the agreed form, under seal from each of the Directors that he has no claim whatsoever against any of the Group Companies; 

 

	 	1.8	If requested by the Buyers at least 5 Business Days prior to the Completion Date, the resignation of the existing auditors of the Company confirming that they have no claims of
any kind against any of the Group Companies and that no fees are due (whether currently or in the future) to them by any of the Group Companies and containing a statement complying with the provisions of Section 185(2)(a) of the 1990 Act that
there are no circumstances connected with their resignation which they consider should be brought to the attention of the members or creditors of any Group Company; 

  

	 	1.9	a letter of resignation under seal from the secretary of each Group Company containing an acknowledgement, in the agreed form, that he has no claim whatsoever against any of the
Group Companies; 

  

 83 

	 	1.10	letters of resignation of such trustees of the Pension Schemes as the Buyers may require in such form as the Buyers may require and procure the appointment of one or more persons
as the Buyers may require in their place; 

  

	 	1.11	either a certificate of the kind described in Section 980 of the TCA or a letter from the auditors of the Group Companies (prior to the resignation referred to in paragraph
5.1.3) confirming that none is required 

  

	 	1.12	evidence, in the agreed form, of the release of each Group Company from all Encumbrances created or given by the such Group Company or to which any of its assets is subject,
including a release in the agreed form in respect of the Anglo Charges; 

  

	 	1.13	the Retention Charge, a form C1 for filing with the Companies Office in respect of the Retention Charge and a section 1001 notice for filing with the Revenue Commissioners in
respect of the Retention Charge, each in the agreed form, duly executed by the Seller; 

  

	 	1.14	copies of bank statements in relation to all bank accounts as at a date not earlier than the day immediately preceding the Completion Date and all cheque books of the Group in
use and the cash book balances of the Group as at the Completion Date with reconciliation statements reconciling such balances with the aforementioned bank statements; 

  

	 	1.15	appropriate forms to amend any mandates given by the Group Companies to their bankers or other financial institutions; 

  

	 	1.16	a release and deed of termination in the agreed form in respect of the Management Services Agreement between the Seller and the Group Companies; and 

  

	 	1.17	deeds of adherence for the Group Companies in respect of the Pension Schemes, where current participants in the Pension Schemes necessitate a deed of adherence, in the agreed
form. 

  

	2	At Completion the Seller shall: 

  

	 	2.1	procure that all of the Directors (other than the Continuing Directors) resign from their directorships in and offices of profit under and employment with each of the Group
Companies and deliver to the Buyers their written resignations under seal containing an acknowledgement that each has no claim against any Group Company in respect of breach of contract, compensation for loss of office or otherwise howsoever
arising; 

  

	 	2.2	discharge or procure the discharge of all monies owing to any Group Company (whether then due for payment or not) by the Sellers or the Directors or by any of them or by any
Connected Person of any of them; 

  

	 	2.3	procure that a meeting of the board of directors of each Group Company is held at which, inter alia: 

  

 84 

	 	(a)	the share transfers referred to in clause 1.2 (as appropriate) are approved (subject only to stamping) and in respect of VWFM the consent of the Seller to waive all pre-emption
rights is tabled, noted and approved by directors; 

  

	 	(b)	such persons as the Buyers may nominate are appointed as directors, as is secretary and auditors of such Group Company with immediate effect. 

  

	 	(c)	all existing mandates for the operation of bank accounts of such Group Company are revoked and new mandates are approved and adopted giving authority to such persons as the
Buyers may nominate; 

  

	 	(d)	the resignations referred to in clause paragraphs, 1.7, 1.8, 1.9 and 1.10 are accepted; 

  

	 	(e)	the registered office of such Group Company is changed to such address as is nominated by the Buyers before Completion; and 

  

 85 

 Schedule 5 
 Part 1: Title Warranties 
  

	1	Share Capital 

  

	1.1	Ownership of Shares 

 The Shares are
beneficially owned by the Seller free from any Encumbrances whatsoever and from any agreement, obligation or commitment to create, grant, give or permit to subsist any Encumbrances whatsoever and the Seller is entitled to sell and transfer to the
Buyers the full legal and beneficial ownership of the Shares free from any Encumbrance on the terms of the Agreement. 
  

	1.2	Shares Fully Paid Up 

 The Shares comprise the
whole of the allotted and issued share capital of the Irish Companies and VUKL and all of them are fully paid up. 
  

	1.3	Beneficial Ownership 

 The Seller or a Group
Company is the sole beneficial owner of all of the issued shares of the Subsidiaries. 
  

	1.4	Rights of Option 

 No person has the right
(whether actual or contingent) to call for the issue, allotment or transfer of any share or loan capital of any Group Company under any option or other agreement, arrangement or commitment and as far as the Seller is aware, no person has claimed to
be entitled to any of the foregoing. 
  

	1.5	Encumbrances 

 There is no Encumbrance over or
affecting any of the share capital of any Group Company and there is no agreement, arrangement or commitment whatsoever to give, grant or create such Encumbrance nor has any claim that such an Encumbrance exists been made or threatened by any
person. 
  

	2	Capacity and Authority of Seller 

  

	2.1	Power of Seller 

 The Seller has full power
and authority to enter into, perform and comply with its obligations under this Agreement and any other agreement which it is required to enter into hereunder and this Agreement constitutes and any such other agreements when executed will constitute
valid, legally binding and enforceable obligations on the Seller in accordance with its or their respective terms. The only approval required for the Seller to effect the transaction and carry out the acts contemplated by this Agreement is the
approval of its shareholders required to satisfy Clause 1 of Schedule 3 of this Agreement and the approval of the Competition Authority required to satisfy Clause 2 of Schedule 3 of this Agreement and the release of the Anglo Charges. 
  

 86 

	2.2	Seller is a Body Corporate 

  

	 	(a)	The Seller is duly incorporated and validly existing under the laws of the country of its incorporation; 

  

	 	(b)	all necessary actions, conditions and things actionable on or before the date hereof have been taken, fulfilled and done in order to enable it to enter into, perform and comply
with its obligations hereunder and those obligations are validly, and legally binding and enforceable upon it; and 

  

	 	(c)	the Seller’s entry into and performance of or compliance with its obligations hereunder does not violate or exceed any power or restriction granted or imposed by:

  

	 	(i)	any law to which it is subject; or 

  

	 	(ii)	any of its constituting documents. 

  

	2.3	Compliance by Seller 

 The entry into,
performance of or compliance by the Seller with its obligations under this Agreement and any document entered into pursuant to this Agreement will not: 
  

	 	(a)	constitute a breach of any agreement or instrument to which it is a party or which is binding on it or over its assets; nor 

  

	 	(b)	result in the existence of, or oblige it to create any security over those assets. 

  

	2.4	No Litigation Pending 

 No proceedings are
current, pending or as far as the Seller is aware, threatened to restrain (or which would have the effect of so restraining) the entry into, performance of, compliance with and enforcement of any of the obligations of the Seller hereunder and so far
as the Seller is aware there are no circumstances which might give rise to any such proceedings. 
  

	3	Commissions 

  

	3.1	No Commission Payable 

 No one is entitled to
receive from any Group Company any finder’s fee, brokerage or other commission in connection with the sale and purchase of the Shares under this Agreement. 
  

 87 

 Schedule 5 
 Part 2: General Warranties 
 Table of Contents 

					
	 	    	 	  	 
	 1
	    	 Information
	  	89
	 2
	    	 Constitution of the Company
	  	89
	 3
	    	 Companies Acts and International Law
	  	89
	 4
	    	 Accounts
	  	90
	 5
	    	 Transaction since the Accounts Date
	  	91
	 6
	    	 Solvency
	  	93
	 7
	    	 Information Technology and E-Commerce
	  	93
	 8
	    	 Intellectual Property, Confidential Information and Know-How
	  	94
	 9
	    	 Agreements and Arrangements
	  	95
	 10
	    	 Assets
	  	97
	 11
	    	 Directors and Employees
	  	97
	 12
	    	 Pensions
	  	100
	 13
	    	 Environment
	  	103
	 14
	    	 Properties
	  	104
	 15
	    	 Miscellaneous
	  	105
	 16
	    	 Litigation and Disputes
	  	106
	 17
	    	 Insurance
	  	107

  

 88 

 General Warranties2 
  

	1	Information 

  

	1.1	Completeness 

 The information set out in (A), (B),
(C), and (D) and in Schedule 1 is true and accurate in all material respects. 
  

	2	Constitution of the Company 

  

	2.1	Memorandum and Articles 

 The copy of the
memorandum and articles of association of each Group Company contained in the Disclosure Letter is true and accurate and complete in all respects and since the Accounts Date, no alteration has been made to the memorandum and articles of association
of any Group Company. 
  

	2.2	Conduct of Business 

 Each Group Company has,
at all times, carried on business and conducted its affairs in all material respects in accordance with its memorandum and articles of association for the time being in force. 
  

	2.3	Shares in other Companies and Joint Ventures and Partnership 

 No Group Company is or has agreed to become the holder or beneficial owner of any class of share or other capital (to include loan capital) of any company (wherever incorporated) other than the Subsidiaries and no
Group Company is or has agreed to become a member of any joint venture, partnership or consortium or other unincorporated association (other than trade associations) nor is it nor has it agreed to be or become a party to any agreement or arrangement
for sharing commissions or other income to include any profit sharing arrangement. 
  

	2.4	Branches 

 Other than those listed in the
Disclosure Letter, no Group Company has any branch, agency or place of business, or any permanent establishment outside Ireland or the United Kingdom. 
  

	2.5	Business Names 

 No Group Company uses any
name other than its full corporate name for any purpose. 
  

	3	Companies Acts and International Law 

  

	3.1	Compliance with Companies Acts 

  

	2	Subject to further review by Veris. In particular Veris to confirm proposed figures. 

  

 89 

 Each Group Company and its directors and company secretary has complied in all material respects with
the provisions of the Companies Acts in respect to the Group and the Business and there is not in existence, pending or, so far as the Seller is aware, threatened any investigation, enquiries, notification, court applications or court orders
pursuant to the Companies Acts in respect of any Group Company or its affairs or the Business and so far as the Seller is aware there are no facts likely to give rise to such an investigation, enquiry, notification, court application or court order.
No Group Company has been a party to any transaction to which any of the provisions of Part III of the 1990 Act apply. 
  

	3.2	Business Conduct 

 Neither the Seller, the
Irish Companies, VUKL or the Subsidiaries nor any of the Irish Companies, VUKL or the Subsidiaries respective, current shareholders, partners, directors, managing directors, trustees, officers, employees or authorised agents acting on behalf of the
Irish Companies, VUKL or the Subsidiaries has on behalf of the Irish Companies, VUKL or the Subsidiaries or in connection with the Business or the assets of the Seller, the Irish Companies, VUKL or the Subsidiaries: 
  

	 	(a)	used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; 

  

	 	(b)	made, offered, promised, or authorized any direct or indirect unlawful payments to (a) any foreign or domestic governmental officials or employees, including, without
limitation, employees of state-owned entities, or (b) any foreign political party, official thereof or candidate for foreign political office from corporate funds for the purpose of (1) influencing such person to take any action or
decision or to omit to take any action, in his or her official capacity, (2) inducing such person to use his or her influence with a government or instrumentality to affect any act or decision of the government or instrumentality, or
(3) securing any improper advantage in order to assist the Seller, the Irish Companies, VUKL or the Subsidiaries to obtain or retain business; 

  

	 	(c)	established or maintained any unlawful or unrecorded fund of corporate monies or other assets; 

  

	 	(d)	made any intentional false or fictitious entries on the books and records of a Group Company or intentionally failed to accurately record any transaction; or

  

	 	(e)	made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payments of any nature. 

  

	4	Accounts 

  

	4.1	Accounts True and Accurate 

 The Accounts have
been prepared in accordance with the requirements of the Companies Acts and all other applicable statutes and laws and in accordance with generally accepted accounting principles and all statements of standard accounting practice applicable in
Ireland and on a basis consistent with the audited accounts of the Group for the three financial years preceding the financial year ended on 31 December 2008, and give a true and fair view of the affairs of each Group Company as at the Accounts
Date and of the results of each Group Company for its financial period ending on the Accounts Date. 
  

 90 

	4.2	Management Accounts 

 The Management Accounts
have been prepared in accordance with the accounting policies of the Group Companies adopted in the Accounts and on a basis consistent with the previous monthly management accounts of the Group, and show a fair view of the assets and liabilities,
profits and losses of each of the Group Companies as at and to the Management Accounts Date. 
  

	4.3	Accounting Controls 

 So far as the Seller is
aware, the Group maintains in all material respects proper and adequate internal accounting controls which provide assurance (i) that all material Group transactions are executed with management’s authorisation; (ii) that Group
transactions are recorded as necessary to permit preparation of the consolidated financial statements of the Group Companies and to maintain accountability for the Group Company assets; (iii) that access to the Group Company assets is permitted
only in accordance with management’s authorisation; (iv) regarding prevention or timely detection of the unauthorised acquisition, use or disposition of the Group Company assets; and (v) that accounts, notes and other receivables are
recorded accurately in all material respects, and proper and adequate procedures are implemented in all material respects to effect the collection thereof on a current and timely basis. 
  

	5	Transaction since the Accounts Date 

  

	5.1	Transactions 

 Since the Accounts Date:

  

	 	(a)	each Group Company has carried on its business in the ordinary and usual course and without any alteration in the nature of its business; 

  

	 	(b)	no Group Company has paid or agreed to pay to any person any amount, sum or other compensation for loss of office, remuneration, emoluments, expenses or other payments or
benefits whatsoever (whether or not gratuitous) other than those which are deductible from the profits of such Group Company in computing its corporation tax. 

  

	 	(c)	no agreement (whether in respect of capital expenditure or otherwise) has been entered into by any Group Company which is of a long term nature or outside its ordinary course of
trade or which involved or could involve an obligation of a material nature or magnitude (a liability for expenditure in excess of €100,000 per annum being included as “material” for this purpose); 

  

	 	(d)	no Group Company has acquired or disposed of, or agreed to acquire or dispose of, any business or any asset, other than in the ordinary course of business, having a value in
excess of €100,000; 

  

	 	(e)	 no change has been made in terms of employment, including pension fund commitments, by any Group Company (other than those required by law) which could increase
the total staff costs of any Group Company by more than €2,500,000 per

  

 91 

	 	 
annum or the remuneration of any one director or employee by more than €25,000 per annum; 

  

	 	(f)	no share or loan capital has been allotted or issued or agreed to be allotted or issued by any Group Company; and 

  

	 	(g)	no dividend or other distribution has been declared, paid or made by any Group Company); 

  

	 	(h)	there has not occurred any event or circumstance which results in a Material Adverse Change or is likely to result in a Material Adverse Change excluding, in each case, any
event, circumstance or change resulting from: 

  

	 	(i)	changes affecting the industry in which the Group Companies or any of them operate which do not have a disproportionate effect on the Group Company compared to other companies
operating in such industry; 

  

	 	(ii)	changes in national or international political, economic or financial market conditions, stock markets, interest rates, exchange rates or other general economic conditions;

  

	 	(iii)	the announcement of the transactions contemplated by this Agreement or the change of control resulting from them; 

  

	 	(iv)	changes in law, regulations or generally accepted accounting principles; 

  

	 	(v)	acts of terrorism or war; 

  

	 	(vi)	any matter to the extent Disclosed; 

  

	 	(vii)	any other matters not directly relating to the conduct of the business of the Group Companies. 

  

	5.2	Accounts Receivable 

 All accounts
receivable of the Group Companies have arisen from bona fide transactions by the Group Companies in the ordinary course of their business. 
  

	5.3	Financial Liabilities and Loans 

 As at
Completion, the Facilities shall be paid out in full and no Group Company shall have any loans, borrowings or other indebtedness in the nature of borrowings other than loans, borrowings or other indebtedness in the nature of borrowings to other
Group Companies. 
  

	5.4	No Loans 

 No Group Company has made loans
(other than to another Group Company) which is outstanding and no Group Company has agreed to make any loans. 
  

 92 

	6	Solvency 

  

	6.1	Insolvency Proceedings 

 No order has been
made or petition presented or resolution passed or proceedings or action taken or ground arisen for the winding up of any Group Company or for or with a view to appointing an examiner, receiver, administrator, trustee or other similar officer to any
Group Company nor has any distress, execution, sequestration, attachment or other process been levied or entered upon or sued out in respect of any Group Company or against any property or asset of any Group Company nor is any of the foregoing in
the process of being so levied, entered upon or sued out, nor is there any unfulfilled or unsatisfied judgment, court order or award outstanding against any Group Company. 
  

	6.2	Solvency of Group Companies 

 No Group Company
has ceased payment of any debt nor is any Group Company insolvent or unable to pay its debts within the meaning of Section 214 of the Companies Act 1963 or Section 2 of the Companies (Amendment) Act 1990. No notice has been served on any
Group Company under Section 214(a) of the Companies Act 1963 and no arrangement has been or is about to be entered into by any Group Company under Section 201 or Section 279 of the Companies Act 1963 and no encumbrancer has taken
possession or attempted to take possession of or exercised or attempted to exercise any power of sale in respect of the whole or any part of the undertaking, property, assets or revenues of any Group Company and there exist no circumstances under
which a receiver may be appointed by any person over the whole or any part of the undertaking, property, assets or revenues of any Group Company and there is no unfulfilled or unsatisfied judgment, ruling, order, award, decree or directive
outstanding against any Group Company and there has been no delay by any Group Company in the payment of any obligation due for payment. 
  

	7	Information Technology and E-Commerce 

  

	7.1	Ownership and Licences 

 The Group Companies
are the sole, absolute and unencumbered legal and beneficial owner of all Computer Systems, or has all necessary rights and/or licenses from the owner of the Computer Systems to use the Computer Systems in the manner in which such Computer Systems
are used in carrying on the Business. 
  

	7.2	Breach of Rights or Licences 

 No Group
Company is in material breach of any rights, obligations and/or licenses pursuant to which the Group uses the Computer Systems and such rights and/or licenses are not restricted as to number of users (or, in the case of Software, to the processor on
which the Software runs). 
  

	7.3	Third Parties 

 No Group Company has granted
any rights and/or licences in respect of the Computer Systems to any third party and does not use the Computer Systems on behalf of any third party, save as Disclosed in the Disclosure Letter. 
  

 93 

	7.4	Source Code 

 The Group Companies are
in possession and control of, full and complete copies of all source code of all Software developed by Group Companies so as to enable them to modify and maintain or procure the maintenance and modification of such Software without undue expense,
delay or restriction. 
  

	7.5	Third Party Rights 

 So far as the Seller is
aware, the Group is not using any Computer Systems that infringe any rights of any third party and no Group Company has received notice and is not aware of any actual or threatened claim that its use of or benefit from any of the Computer Systems is
invalid or infringes any rights of any third party. 
  

	8	Intellectual Property, Confidential Information and Know-How 

  

	8.1	Ownership and Right to Use 

 All Corporate
Intellectual Property is: 
  

	 	(a)	legally, beneficially and exclusively owned by a Group Company and is free from all licences and Encumbrances except as set out in the Disclosure Letter; or

  

	 	(b)	lawfully used by the Group under a valid and subsisting licence from a third party in favour of the Group. 

  

	8.2	Validity, Renewals and Extensions 

  

	 	(a)	All Corporate Intellectual Property that is capable of registration in Ireland and the United Kingdom has been duly registered or is the subject of an application for
registration. Details of all registrations or applications for registration of Corporate Intellectual Property are set out in the Disclosure Letter. 

  

	 	(b)	In the case of registered Corporate Intellectual Property, all renewals and extensions have been made and all renewal and extension fees have been paid by their due date.

  

	8.3	Challenges and Infringement 

  

	 	(a)	No allegations, oppositions proceedings or, so far as the Seller is aware, any threat have been brought or made against any Group Company concerning any Corporate Intellectual
Property, nor have claims been made impugning the title, validity, application or enforceability of any Corporate Intellectual Property. 

  

	 	(b)	 All third party Computer Systems, Know How, processes employed, products made or services provided by the Group are so employed, made and provided in accordance
with any licensing agreements entered into by any of the Group Companies with such third parties and no allegation or claim or so far as the Seller is aware, threat has been

  

 94 

	 	 
made, or proceedings brought against any Group Company ascertaining that it infringes the Intellectual Property Rights of any third party. 

  

	 	(c)	No actual or threatened proceedings against any Group Company for infringement of Intellectual Property Rights have been settled by the giving of undertakings which are still
binding on the relevant Group Company; and 

  

	 	(d)	So far as the Seller is aware, no third party is infringing any Corporate Intellectual Property. 

  

	8.4	Licences and Agreements 

 Details of
all material licences, sub-licences and agreements in relation to the use by third parties of Corporate Intellectual Property owned by, or licensed to, the Group are set out in the Disclosure Letter and no Group Company has otherwise granted, nor
has it agreed to grant, any licence, sub-licence, assignment or other right in respect of Corporate Intellectual Property to any third party and no Group Company owes any amount in respect of licence fees or royalty payments relating to the use of
Corporate Intellectual Property or is in breach of any such licence, sub-licence, agreement or permission. 
  

	9	Agreements and Arrangements 

  

	9.1	Powers of Attorney and Agency 

 There are in
force no powers of attorney or other rights of representation given by any Group Company and no person, as agent or otherwise, is entitled or authorised to bind or commit any Group Company to any obligation not in the ordinary and usual course of
its business. 
  

	9.2	Contracts and Undertakings 

 No Group Company
is party to or bound by and no asset of any Group Company is affected by: 
  

	 	(a)	any contract of guarantee, agreement for indemnity or suretyship (whether given by or for the accommodation of such Group Company) other than the Anglo Other Charges;

  

	 	(b)	any agreement or arrangement which involves or is likely to involve the supply of goods to such Group Company the aggregate value of which would represent in excess of
10(ten) per cent of the total cost of supplies of the Group by reference to the Accounts; 

  

	 	(c)	any agreement or arrangement (including any agency, distributorship, marketing, purchasing, manufacturing or licensing agreement or arrangement) which in any way restricts the
ability or freedom of such Group Company to carry on the whole or any part of its business or engage in any other activities in any part of the world in such manner as it thinks fit; 

  

	 	(d)	 any material agreement or material arrangement which will or may by virtue of the acquisition of the Shares by the Buyers or other performance of the terms of
this Agreement, result in any other person who is party to such agreement or arrangement

  

 95 

	 	 
being relieved of any obligation (whether contractual or otherwise) or becoming entitled to exercise any right of termination of such agreement or arrangement or to determine any right or benefit
enjoyed by such Group Company or to exercise any right, whether under an agreement or arrangement with, or otherwise in respect of the Company; 

  

	 	(e)	any agreement or arrangement whereby such Group Company is, or has agreed to become, a party to any exclusive manufacturing, production, supply, distribution, agency or trading
rights or obligations; 

  

	 	(f)	any undertaking or assurances given to any court or governmental agency, which is still in force; 

  

	 	(g)	any agreement, contract or other arrangement for sub-contract services where the fees paid to the sub-contractor in the twelve (12) months prior to the date of this
Agreement exceed €200,000; 

  

	 	(h)	any agreement, contract or other arrangement for sub-contract services relating to the removal of waste or any services in respect of asbestos; or 

  

	 	(i)	any agreement, arrangement, contract or transaction with the Seller or any Seller’s Affiliate. 

 and the Disclosure Letter attaches copies of all the top fifteen contracts by 2009 revenue for Vector, VUKL and its Subsidiaries and IEFM and its
Subsidiaries and the top five property management contracts of the Group. 
  

	9.3	Breach of Agreement 

 No Group Company is in
material breach, nor as far as the Seller is aware are there any circumstances which with the giving of notice or the passing of time are likely to result in any Group Company being in material breach of any agreement, contract, arrangement,
commitment, obligation, covenant or understanding of the type referred to in Warranty 9.2 of this Schedule 5 (including the top fifteen contracts for various Group Companies and the top five property management contracts for the Group referred to at
paragraph 9.2) and each such contract, arrangement, commitment, obligation, covenant and understanding is valid and enforceable in accordance with its terms. 
  

	9.4	Termination or Rescission 

 No threat or claim
of default under any agreement of the type referred to in Warranty clause 9.2 of this Schedule 5 (including the top fifteen contracts for various Group Companies and the top five property management contracts for the Group referred to at paragraph
9.2) has been made to any of the Group Companies and is outstanding against such Group Company. 
  

	9.5	Default by Third Party 

 No person with
whom any Group Company has entered into any agreement or arrangement of the type referred to in Warranty paragraph 9.2 of this Schedule 5 (including the top fifteen contracts for various Group Companies and the top five property management contracts
for the Group referred to at paragraph 9.2) is in default thereunder or has not complied with its

  

 96 

 
obligations as stated therein, being a default or a non-compliance which would have an adverse effect on such Group Company and so far as the Seller is aware, there are no circumstances likely to
give rise to any such default or non-compliance. 
  

	9.6	Outstanding Offers 

 No offer, tender or the
like is outstanding which is capable of being converted into an obligation of a Group Company of the type set out in paragraph 9.2 of this Schedule 5 by acceptance, or other act, of some other person. 
  

	10	Assets 

  

	10.1	Ownership of Assets 

 The assets included in
the Accounts or acquired since the Accounts Date (other than trading stock subsequently disposed of in the ordinary and usual course of business or trading stock acquired subject to retention or reservation of title by the supplier or manufacturer
thereof and Disclosed in the Disclosure Letter) and all assets used by the Group: 
  

	 	(a)	are legally and beneficially owned by a Group Company free from any Encumbrance or any agreement or commitment to grant, give or create any Encumbrance and such Group Company has
good and marketable title to such assets; 

  

	 	(b)	are not the subject of any agreement for lease, hire, hire purchase, conditional purchase or sale on deferred terms save as Disclosed in the Accounts; 

 

	 	(c)	are situated in Ireland or the United Kingdom or any country where it has been disclosed that a Group Company has a branch pursuant to General Warranty 3.4 and are in the
possession and under the control of a Group Company; and 

  

	 	(d)	comprise all the assets necessary to enable the Group to carry on its business in the ordinary and usual course as at the date hereof. 

  

	11	Directors and Employees 

  

	11.1	Length of Directors’ Service Contracts 

 All contracts between any Group Company and all officers and employees employed comply with section 28 of 1990 Act, section 319 of the UK Companies Act 1985 and section 188 of the UK Companies Act 2006 (as applicable). 
  

	11.2	Schedule of Employees 

 The particulars shown
in the Schedule of Employees contained in the Disclosure Letter set out particulars of all remuneration payable (including any bonus or commission entitlements) and other benefits and privileges provided, for all of the employees and officers of
each Group Company who have an entitlement to annual remuneration and other benefits of at least €100,000 (together with any offer made to
employ or engage any such employee or officer that has not yet been accepted, or which has been accepted but where the employment or engagement has not yet commenced) at the date hereof. 
  

 97 

	11.3	Persons Providing Services to the Group Companies 

 The Disclosure Letter includes details of all persons who are providing services to any Group Company under an agreement which is not a contract of employment with any Group Company (including, in particular, where the individual acts as a
consultant or is on secondment from an employer which is not a member of the Group Companies) and the particulars of the terms on which the individual provides services, including: 
  

	 	(a)	the company which engages them; 

  

	 	(b)	the remuneration of each individual (including any bonus or commission entitlements, benefits and privileges provided or which any Group Company is bound to provide) to them or
their dependants, whether now or in the future; 

  

	 	(c)	the length of notice necessary to terminate each agreement, or if a fixed term, the expiry date of the fixed term and details of any previous renewals; 

 

	 	(d)	any country in which the individual provides services, if the individual provides services outside England and Wales or Ireland; and 

  

	 	(e)	the law governing the agreement, if the individual provides services wholly or mainly outside England and Wales or Ireland. 

  

	11.4	Changes in Remuneration 

 Since the Accounts
Date: 
  

	 	(a)	no change has been made in the rate of remuneration, or the emoluments or pension benefits, of any officer, former officer or senior executive of any Group Company (a senior
executive being a person in receipt of remuneration in excess of hundred thousand Euro (EUR100,000) per annum) and no material change has been made in respect of the same in relation to any other employee nor is any Group Company under any
obligation to make such a change nor has it made any provision to alter the same; and 

  

	 	(b)	no change has been made in any other terms of employment of any such officer or senior executive. 

  

	11.5	Termination of Contracts 

 All subsisting
contracts of service (or contracts for services) between each Group Company and any of its directors, officers or employees, are terminable at any time on 6 (six) months’ notice or less and no notice to terminate any such contract is pending,
outstanding or so far as the Seller is aware threatened. 
  

	11.6	Basis of Remuneration 

 No present or former
officer or employee of any Group Company is entitled to any remuneration, loan, commission or other emoluments of whatever nature calculated by reference to the whole or part of the turnover, the profits or sales of any Group Company or

  

 98 

 
which becomes payable in connection with the Transaction and no Group Company is party to or bound by or has proposed or required to introduce any share option, share, profit sharing, bonus or
commission scheme (whether discretionary or otherwise) in respect of any of its officers or employees. 
  

	11.7	Maximum Remuneration Owed 

 There are no
amounts owing to or accrued in respect of any present or former officers or employees of any Group Company (other than remuneration accrued due or for reimbursement of business expenses), the aggregate amount of which (when aggregated with
remuneration due and for reimbursement of business expenses of other Group Companies) exceeds ten thousand euro (EUR 10,000) per officer or employee. 
  

	11.8	Recognition of Trade Union 

 No Group Company
has entered into any recognition agreement with a trade union nor has it done any act which could reasonably be construed as recognition and there are no agreements or other arrangements (whether or not legally binding) between any Group Company and
any trade union or other body representing employees. 
  

	11.9	Industrial Disputes 

 No Group Company, and
none of its respective employees, is involved in any industrial or trade dispute, negotiation or claim with any trade union, group or organisation of employees or their representatives, and so far as the Seller is aware no circumstances exist which
might suggest that there will or may be any industrial dispute involving any Group Company. 
  

	11.10	Rights of Reinstatement 

 No past employee of
any Group Company has a right to return to work or has or may have a right to be reinstated or re-engaged under the Unfair Dismissals Acts 1977 and 1993, Maternity Protection Act 1994, Adoptive Leave Act 1995, Parental Leave Act 1998, Employment
Equality Act 1998, Carers Leave Act 2001 or Protection of Employees (Part-Time Work) Act 2001 or equivalent legislation anywhere in the world. 
  

	11.11	Redundancy Payments 

 No Group Company is
liable to make any payment to any person under the Redundancy Payments Acts 1967 to 1991 or the Protection of Employment Act 1977 or under the Employment Rights Act 1996, and no Group Company is a party to, bound by or is proposing to introduce any
redundancy payment scheme in addition to statutory redundancy pay, nor is there any agreed procedure for redundancy selection. 
  

	11.12	Liability to Employees 

 Since the Accounts
Date, no liability has been incurred by any Group Company in connection with the actual or proposed termination or suspension of employment or variation of any contract of employment of any present or former officer or employee which exceeds or is
likely to exceed €10,000. No claims have been made or are pending against a Group Company in respect of whistleblowing, equal pay,
discrimination, sexual or other harassment nor so far as the Seller is aware, are any such claims threatened. 
  

 99 

	11.13	Compliance with Obligations 

 Each Group
Company has in relation to each of its employees (and, so far as relevant, to each of its former employees): 
  

	 	(a)	complied in all material respects with all obligations imposed on it by, and all orders and awards made under all statutes and regulations relevant to the relations between it
and its employees or the conditions of service of its employees; and 

  

	 	(b)	complied with all recommendations of a binding nature made in any arbitrator, mediator or tribunal and all awards and declarations made by an arbitration, mediation or tribunal.

  

	11.14	Immigration Satisfaction 

 Every employee of,
or person engaged by, a Group Company has all necessary, current and appropriate permission to work in the jurisdiction in which they work and carry out the role for which they are engaged. 
  

	11.15	Consultation with Employees 

 No Group Company
has received a written request from at least 10 per cent of its employees or a direction from the Labour Court to establish information and consultation arrangements with its employees. 
  

	12	Pensions 

  

	12.1	Pension Schemes and PHI Schemes 

 The
Disclosure Letter contains a complete and accurate list of all retirement or death benefit schemes (each a “Pension Scheme” and collectively the “Pension Schemes”) and permanent health insurance schemes (each a “PHI
Scheme”) of the Group Companies. With the exception of the Pension Schemes and the PHI Schemes, there are not in existence nor has any proposal been announced or commitment given or promise made to establish any retirement, death or disability
benefit scheme for the benefit of any current or former officer or employee (or any dependant of any of them) of the Group Companies, nor is any such Group Company under any obligation (whether or not legally binding, established by custom or
Approved) to or in respect of any employee (or any dependant of any of them) of such company with regard to retirement, death or disability benefits pursuant to which the Group Companies are or may become liable to make payments. 
  

	12.2	Pension Scheme Documents 

 For each Pension
Scheme and PHI Scheme, true complete copies of all trust deeds, rules, explanatory booklets, annual reports and announcements relating to the schemes have been supplied to the Buyers together with details of the rate of contributions in respect of
each Pension Scheme, and none of the Group Companies have any obligation to any current or former employee or officer in relation to retirement, superannuation, pension, death or analogous benefits save as provided in the said deeds, rules,
booklets, reports and announcements disclosed prior to the date of this Agreement. 
  

 100 

	12.3	Seller’s Obligations and Compliance 

 In
relation to the Pension Schemes for officers, employees or former officers and employees, and their respective dependants of, the Irish Companies and its Subsidiaries (the “Irish Pension Schemes”), each Irish Pension Scheme is an
exempt approved scheme within the meaning of and for the purposes of Section 774 of the TCA and the Seller is not aware of any reason why such exempt status should or could be withdrawn. In relation to the Pension Schemes for officers,
employees or former officers and employees, and their respective dependants, of VUKL and its Subsidiaries (the “UK Pension Schemes”), each UK Pension Scheme is a registered pension scheme for the purposes of Chapter 2 of Part 4 of
the Finance Act 2004 and so far as the Seller is aware, there is no reason why HM Revenue & Customs might de-register the scheme. 
  

	12.4	Compliance 

  

	 	(a)	The Pension Schemes are managed and administered in accordance with, in all material respects, all applicable laws, regulations and requirements, including, without limitation,
the documentation by which the Pension Schemes are constituted and governed. 

  

	 	(b)	Each of the Group Companies have duly complied in all material respects with all of their obligations under the Pension Schemes and the PHI Schemes and under all applicable
legislation, regulations and requirements imposed on them by such provisions and in relation to such arrangements, including in respect of contributions, insurance premiums, tax and expenses due or in respect of any Pension Scheme.

  

	 	(c)	The UK Pension Schemes have not accepted any contributions from a European employer as defined for the purposes of Part 7 of the Pensions Act 2004. 

  

	 	(d)	Each of the Pension Schemes which is a Defined Contribution Scheme was established as such, was not established in succession to, and has not previously been converted from, a
Defined Benefit Scheme and no assurance, promise or guarantee (oral or written) has been made or given to any person entitled, or contingently entitled, to benefit under the Pension Schemes that any particular rate, level or amount of benefits
(other than insured lump sum death in service benefits) would be provided to or in respect of him under that scheme. 

  

	 	(e)	No UK Pension Scheme is a Defined Benefit Scheme and VUKL and/or its Subsidiaries do not and could not have a liability in respect of a Defined Benefit Scheme.

  

	 	(f)	In relation to each of the Pension Schemes which is a Defined Benefit Scheme: 

  

	 	(i)	the actuary who signed the report on the most recent actuarial valuation is the present actuary to the Pension Scheme; and 

  

	 	(ii)	the information supplied to the actuary for use in preparing the valuation and any supplementary actuarial advices was true, complete and accurate; and 

 

 101 

	 	(iii)	since the effective date of the most recent actuarial valuation contributions have been paid to the Pension Scheme at the rate and at the times recommended by the actuary in his
report and in all other material respects in accordance with the terms of the Pension Scheme; 

  

	 	(iv)	so far as the Seller is aware, as at the date hereof and, unless otherwise notified in writing to the Buyers, as at Completion, the Pension Deficit Amount in the Pension Scheme
is not greater than that which is disclosed in the Disclosure Letter; and 

  

	 	(v)	as at the date hereof or the Completion Date, none of the Group Companies have agreed to any funding proposal (as defined in section 49 of the Pensions Act).

  

	12.5	Discretionary Practices 

  

	 	(a)	Full details in writing are set out in the Disclosure Letter of all discretionary practices under each Pension Scheme which is a Defined Benefit Scheme and each Phi Scheme and
the current terms applicable on early retirement, late retirement, commutation, optional dependant’s pension and other optional arrangements under each Pension Scheme. 

  

	 	(b)	Save as disclosed in such written details in respect of each Pension Scheme or PHI Scheme, no power or discretion has been exercised and no intention to so exercise has been
communicated: 

  

	 	(i)	to admit to membership any employee or officer who would not otherwise have been eligible for membership; or 

  

	 	(ii)	to pay a contribution which would not otherwise have been paid or to augment or provide in respect of any past or present employee or officer of the Irish Companies or dependant
or beneficiary of any such person a benefit which would not otherwise have been paid. 

  

	12.6	Pension Scheme Insurance 

  

	 	(a)	All lump sum benefits and dependants’ pensions payable under the Pension Schemes on the death of a member thereof while in an employment to which the Pension Schemes relate
(other than a refund of contributions with interest where appropriate) and all benefits payable under the PHI Schemes during a period of sickness or disability of a member thereof are fully insured under policies effected with a life office
authorised under the terms of the European Communities (Life Assurance) Regulations 1984, to carry on life assurance business in Ireland at its normal rates and on its normal terms for persons in good health and all premia payable in the period up
to Completion have been paid. 

  

	 	(b)	All information which has been supplied to any life office which has issued or undertaken to issue policies for the purposes of the Pension Schemes and the PHI Schemes is true.

  

 102 

	 	(c)	Such policies are enforceable and there are no grounds on which the life office might avoid liability thereunder. 

  

	12.7	Claims and Disputes 

 So far as the Seller is
aware no litigation or arbitration proceedings or other claims (other than routine claims for benefits), complaints or disputes are outstanding, pending or threatened by or against the trustees or administrators of the Pension Schemes or the PHI
Schemes in respect of any act, event, omission or other matter arising out of or in connection with the Pension Schemes or the PHI Schemes or the provision of pension, death, sickness, disability or related benefits generally and so far as the
Seller is aware there are no facts, or circumstances likely to give rise to any such litigation or arbitration proceedings, claims, complaints or disputes. 
  

	13	Environment 

  

	13.1	Compliance with Legislation 

 Each Group
Company and each of its operations is and has at all times been in compliance with all applicable Environmental Laws in all material respects and has obtained all requisite Environmental Licences and is and has at all time been in compliance with
all such Environmental Licences and so far as the Seller is aware there are no circumstances which may give rise to the suspension, cancellation, revocation or non-renewal of any such Environmental Licences. 
  

	13.2	Investigations and Notices 

 No Group Company
and none of its present or past operations or properties is the subject of any outstanding or anticipated investigation, inquiry, dispute, claim, demand, action, suit, proceeding, litigation, notice, order, judgment, ruling, decree, citation or
award of whatever nature in relation to any (i) alleged violation of any Environmental Laws or Environmental Licences; (ii) with respect to any alleged failure to have or obtain any permits required under any Environmental Law; and
(iii) with respect to any Hazardous Materials Activity in connection with the operation of the Business, and so far as the Seller is aware there are no circumstances which may give rise to any of the foregoing. 
  

	13.3	No Hazardous Material Activities 

 With
respect to the Group Companies and the Business and all real property currently or previously owned, leased or otherwise used by a Group Company, there are no and, with respect to the Group Companies and the Business and all real property, there
have been no Hazardous Materials Activities (as hereinafter defined) other than such activities incidental to the normal operation of the Business and the Assets which (i) are described in reasonable detail in the Disclosure Letter and
(ii) have been conducted in compliance with Environmental Laws. Neither the Company nor any other Person has conducted any dry cleaning business or operations on the Properties or any real property owned, leased or used by a Group Company in
the past. 
  

	13.4	No Environmental Information Request 

 No
Group Company nor any current shareholder of a Group Company has received from any Governmental Authority or any other person any request for information, notice of claim,

  

 103 

 
demand letter, subpoena or other notification that it is or may be potentially responsible with respect to any investigation or clean up of any threatened or actual release of any Hazardous
Materials at any facility or on any real property currently or formerly owned, leased, operated or otherwise used by a Group Company in connection with the Business or at any other site. 
  

	13.5	No Treatment Notice 

 No Group Company has
filed any notice under any Environmental Law indicating past or present treatment of Hazardous Materials at any of the facilities or real property currently or formerly owned, leased, operated, or otherwise used by the Company, and none of the Group
Company’s operations involves or has involved the generation, transportation, treatment, storage or disposal of Hazardous Materials. 
  

	13.6	Environmental Release 

 No Group Company has
caused or contributed to any Environmental Release and there are no circumstances which may give rise to any Environmental Release by any Group Company. “Environmental Release” means the spilling, leaking, pumping, pouring, emitting,
releasing, emptying, discharging, injecting, escaping, leaching, dumping, leaving, discarding or disposing of any Hazardous Materials into or upon the environment. 
  

	13.7	Storage Tanks 

 So far as the Seller is aware,
no Hazardous Materials are stored or contained on or under any real property currently or previously owned, leased or otherwise used by a Group Company or the Business whether in storage tanks, land fills, pits, ponds, lagoons or otherwise.

  

	13.8	Environmental Studies 

 There have been
no material environmental investigations, studies, audits, tests, reviews or other analyses, reports or correspondence conducted in the last 10 years by, on behalf of, or which are in the possession of the Group Company with respect to any Property
which have not been Disclosed. 
  

	14	Properties 

  

	14.1	General 

 The Properties comprise all the
lands and buildings owned, occupied or used by the Group Companies or in which the Group Companies have any interest and Schedule 9 contains full and accurate particulars of the title of the Group Companies thereto. 
  

	14.2	Details of Properties 

 Each relevant Group
Company is the legal and beneficial owner(s) of a lessee’s or licensee’s (as the case may be) interest in the Properties and each lease or license is valid and in force. The Disclosure Letter sets out true details of the leases and
licenses pursuant to which the relevant Group Companies occupy the Properties (including, without limitation, details of the term of each lease or license, the initial rent payable by each relevant Group Company under each lease or license, the
current rent payable by each relevant Group Company under each lease or license and details of any landlord and tenant break options). The said leases and

  

 104 

 
licenses represent the entire relationship between the Group and each relevant lessor or licensor in respect of the Properties. 
  

	14.3	Previous Properties 

 So far as the Seller is
aware, no Group Company has any actual or contingent liability in respect of any property previously owned, used or occupied by it. 
  

	14.4	Compliance with Terms of Leases 

 Each
relevant Group Company has paid all rent and other charges and performed and observed in all material respects all covenants and conditions on the part of the lessee or licensor contained in the relevant lease or licence under which each Property is
held and is not in a material breach of any covenant or condition on the part of the lessee or licensor thereto. There are no rent reviews currently in progress and there is not outstanding and unobserved or unperformed any obligation on the part of
any Group Company necessary to comply with any notice or other written requirement given by any landlords thereunder. 
  

	14.5	Other Material Matters 

 There is no other
matter of which the relevant Group Companies are aware which may affect the right or title of the relevant Group Companies to any of the Properties thereto or which could materially restrict the use thereof for the purposes for which they or any of
them are now used 
  

	15	Miscellaneous 

  

	15.1	Books of Account and Records 

 All necessary
books of account, minute books, registers and records and insurance policies and records have been maintained (from the date on which such Group Company was acquired by the Seller) by each Group Company and are in its possession and all such books,
registers and records are in all material respects duly written up to date and do not contain any material inaccuracies. 
  

	15.2	Rectification of Register 

 No Group Company
has received any notice of any intended application or proceedings to rectify its register of members. 
  

	15.3	Licences, Consents and Authorisations 

 All
necessary licences, consents, permits and authorisations (public and private) have been obtained by or on behalf of each Group Company to enable such Group Company to properly and effectively carry on the Business in all material respects in the
places and in the manner in which such business is now carried on or has been carried on in three (3) years prior to the date of this Agreement and short particulars of such licences and consents are contained in the Disclosure Letter.

  

	15.4	Validity and Currency 

  

 105 

 So far as the Seller is aware, all of the licences, consents, permits and authorisation referred to in
paragraph 15.2 are valid and subsisting. No Group Company is in breach of any of the terms or conditions of any such licence, consent, permit or authorisation and so far as the Seller is aware there is no reason or circumstance why any of them
should be suspended, cancelled or revoked or not renewed on the same or substantially similar terms. 
  

	15.5	Compliance with Laws 

 Each Group Company has
complied in all material respects with and continues to comply in all material respects with all the applicable laws (including common law) and with all applicable bye-laws, statutes, regulations, orders, instruments, decrees, directives, notices,
certificates, awards and judgements of any government, local government, supranational, executive, administrative, judicial or regulatory authority or agency in relation to or affecting the assets or business of each Group Company whether in Ireland
or elsewhere. 
  

	15.6	Orders or Judgments 

 No Group Company is and
neither the Business nor the Assets are, subject to any order or judgement given by any court or governmental or other official authority, department, board, body or agency nor has it been a party to any undertaking or assurance given to any court
or governmental or other official authority, department, board, body or agency which is still in force, nor so far as the Seller is aware are there any facts or circumstances likely to give rise to it becoming subject to such an order or judgement
or to be a party to any such undertaking or assurance. 
  

	15.7	Grants 

 No Group Company has applied for, or
received, or is or will be entitled to or is or will be the beneficiary of any grant, subsidy or financial assistance from any government department or agency, any local or other authority or any supranational agency, or is a party to any agreement
with such department, agency or authority. 
  

	15.8	Conflict or Future Indebtedness 

 Compliance
with the terms of this Agreement does not and will not: 
  

	 	(a)	conflict with, or result in the breach of, or constitute a default under, any of the terms, conditions or provisions of any material agreement, arrangement or instrument to which
any Group Company is a party, or any provision of the memorandum or articles of association of any Group Company, or any Encumbrance, lease, contract, order, judgement, award, injunction, regulation or other restriction or obligation by which or to
which any asset of any Group Company is bound or subject, which conflict, breach or default has not been waived by the relevant counterparty; or 

  

	 	(b)	result in any present or future indebtedness of any Group Company, other than the VUKL Facility, becoming due, or capable of being declared due and payable prior to its stated
maturity. 

  

	16	Litigation and Disputes 

  

	16.1	Engagement in Litigation 

  

 106 

 No Group Company or the Business is engaged in any litigation, arbitration, prosecution, investigation
or other legal, administrative or disciplinary proceedings (whether as plaintiff or defendant or in whatever capacity) or any dispute or claims, whether or not with a Government Authority, or has been served with any notice making it a party to any
litigation, arbitration, prosecution or other legal, administrative or disciplinary proceedings or to any dispute or claim save debt collection (not exceeding an aggregate of one hundred and fifty thousand Euro (EUR150,000) by or on behalf of such
Group Company in the ordinary and usual course of its business, and so far as the Seller is aware, no such litigation, arbitration, prosecution or other legal, administrative or disciplinary proceedings or disputes are threatened either by or
against such Group Company and so far as the Seller is aware there are no facts or circumstances which might give rise to any such proceedings or dispute. 
  

	17	Insurance 

  

	17.1	Disclosure of Insurance Details 

 The
Disclosure Letter: 
  

	 	(a)	lists all policies of property and liability insurance and surety bonds currently in effect for the Group Companies or the Business and confirmation that such will remain in full
force and effect following Completion; 

  

	 	(b)	lists all policies of insurance covering employee injury claims and all forms of liability insurance covering the Group Companies or the Business currently in effect and in
effect during the period five (5) years prior to Completion and each insurance policy that relates to any current or pending litigation or prosecution of the type referred to in warranty Clause 17.5 of this Schedule 5, including insurance for
entities and material assets acquired by the Seller during this period; and 

  

	 	(c)	specifies with respect to each policy the type of insurance, insurer, limits, policy period and policy number; and 

 All such policies of insurance are and have been in the past in full force and effect and, so far as the Seller is aware, there are no circumstances
which might lead to any material liability under such insurance being avoided by the insurers or the premiums being or likely to be increased and Completion will not have the affect of terminating, or entitling any insurer to terminate, cover under
any such insurance. 
  

	17.2	Full Disclosure of Insurance Details 

 The
Seller has delivered true copies of all policies referenced in the Disclosure Letter which are currently in effect. 
  

	17.3	Unpaid Premiums 

 Except as specified in the
Disclosure Letter, (i) there are no outstanding unpaid premiums under any Disclosed policies of insurance; (ii) no Disclosed policies of insurance are subject to retrospective or retroactive premiums; (iii) none of the Seller’s
current or historical insurance program aggregate limits have been impaired or eroded or no insurers are insolvent; (iv) so far as the Seller is aware, there is no default or failure to give any notice or present any incident, claim, fact or
circumstance in a timely fashion or in the manner or detail

  

 107 

 
required by any of the Disclosed insurance policies; and (v) there is no disallowance, denial or declination of coverage for any claim presented under the Disclosed insurance policies.

  

	17.4	The Group Companies have insurance coverage that is not limited or adversely affected in any material way (other than by way of a requirement to pay a commercially reasonable
excess) in respect to all existing or pending litigation, prosecution or claim made against the Group Companies. 

  

 108 

 Schedule 5 
 Part 3: Tax Warranties 
  

	1	The Accounts make full provision in respect of Tax (whether actual or contingent) assessable or payable in respect of any period ended on or before the Accounts Date. The
amount of any provision for deferred Tax contained in the Accounts was, at the Accounts Date, adequate and fully in accordance with generally accepted accounting principles. 

  

	2	Each Group Company has filed or caused to be filed in a timely manner all material Tax returns required to be filed and such Tax returns are correct in all material respects, and
all material Taxes shown due on any such Tax return have been paid. Each Group Company has complied in all material respects with its obligations to deduct withhold or retain amounts of or an account of Tax, including any system for the deduction of
payroll Taxes at source, and has duly accounted to the relevant Tax Authority for such Tax, and has complied in all material respects with its reporting obligations in respect of such payments. 

  

	3	There is no dispute, action, inquiry, investigation or audit current, completed within the last twelve (12) months, or currently proposed, threatened or pending against, or
with respect to, the Group Companies in respect of Taxes. 

  

	4	Each Group Company is resident in its country of incorporation for Tax purposes and has not been treated as resident for Tax purposes, carried on any business through a branch or
agency or paid tax on income, profits or gains to any Tax Authority in any other jurisdiction. No Group Company constitutes a permanent establishment of any other person or business for Tax purposes. 

  

	5	Each Group Company has obtained, kept and given in all material respects complete and correct records, invoices and other documents appropriate or required for Tax purposes,
including any claims or elections made to calculate the Tax liability or relief which would arise on any disposal or on the realisation of any asset owned by such Group Company at the date of this Agreement or acquired by such Group Company since
the date of this Agreement but before Completion. 

  

	6	In the five years prior to the date of this Agreement, the amount of any Tax liability of any Group Company has not, to any material extent, depended on any arrangement or
concession (in either case whether formal or informal) with any Tax Authority. 

  

	7	Each Group Company is separately registered for VAT solely in its country of incorporation. No Group Company has ever been treated, nor has applied to be treated, as a member of
a VAT group. No Group Company engages in (nor has engaged in) the letting of immovable goods for periods of less than ten years or any other exempt or part-exempt activity. 

  

	8	In the past 11 years, no Group Company has acquired from any other company any asset in circumstances where the companies were, at the time of the acquisition, members of the
same group of companies for Tax purposes. 

  

	9	No Group Company has repaid any share capital. No Group Company has issued any share capital or security as paid-up otherwise than by the receipt of new consideration. No
distribution will arise, for Tax purposes, on the redemption of any share capital or security at par. 

  

 109 

	10	All material documents to which any Group Company is a party and under which such Group Company has any rights or in respect of which a Group Company is an accountable person or
which form part of a Group Company’s title to any asset owned by it have been duly stamped with the correct amount of stamp duty, stamp duty reserve tax or stamp duty land tax, paid within the applicable time limits. No Group Company has, in
the past six years, been involved in any transaction involving the submission of a claim to a Tax Authority for a reduction of or relief from stamp duty, stamp duty reserve tax or stamp duty land tax or capital duty and a material document for the
purposes of this paragraph shall mean a document in respect of which the duty owing is greater than €37,500. 

  

	11	No Group Company is (nor has at any time since acquisition by the Seller or by any member of the Seller’s Group been) a close company for Tax purposes.

  

	12	No Group Company has been involved in any tax avoidance transaction within the meaning of section 811 TCA (Transactions to avoid liability to tax) on which any Tax
Authority has, or could have, formed an opinion that the transaction in question was a Tax avoidance transaction, nor has any Group Company been party to any scheme, transaction or arrangement, a main purpose of which is securing or achieving a Tax
advantage or the avoidance of Tax or which is disclosable to a Tax Authority. 

  

 110 

 Schedule 6 
 [Intentionally left blank] 
  

 111 

 Schedule 7 
 Agreed Treatments 
  

	1	Post Completion Events 

 Post completion
events and circumstances which arise from any voluntary acts, omissions or defaults of any of the Group Companies or the Buyers after Completion otherwise than in pursuance of commitments which are legally binding on any of the Group Companies at
Completion are to be ignored. 
  

	2	Accounting Standards 

  

	 	2.1	No adjustments are to be made for the effect of any changes in accountancy standards effective for periods ending after Completion and in this respect no prior year adjustments
are to be made. 

  

	 	2.2	No changes to the Group Companies normal policies in making provisions are to be made after Completion which would have the effect of reducing the Completion Profit.

  

	3	Fixed Assets 

  

	 	3.1	Tangible and intangible fixed assets are to be valued at their net book value in the Accounts adjusted to reflect acquisitions at cost, additions at cost, and disposals at net
book value and depreciation charges at rates applied in the year ended on the Accounts Date arising in the period from the day after the Accounts Date to Completion. 

  

	 	3.2	The accounting polices are to be applied on the same basis as at the Accounts Date and accordingly no depreciation is to be charged in respect of assets acquired after the
Accounts Date. 

  

	 	3.3	Fixed assets are not to be revalued from the position reported in the Accounts. 

  

	4	Trade and other Creditors 

  

	 	4.1	No provision is to be made for dilapidation costs or any vacant properties. 

  

	 	4.2	No provision is to be made in respect of holiday pay liabilities 

  

	 	4.3	No provision is to be made for audit and accountancy fees for periods after the Accounts Date. 

  

	5	Taxation 

  

	12	 Please detail these commitments. 

  

 112 

 Taxation for the period from the day after the Accounts Date to Completion is to be provided for by
adopting the same accounting policies and practices that were used in calculating the provision for Taxation in the Accounts. 
  

	6	No Double Counting 

 No item is to be included
more than once in the Consideration Statement. 
  

 113 

 Schedule 8 
 Working Capital – Worked example of calculations based of the combined management 
 accounts of the Group Companies as at the Management Accounts Date 
  

 114 

 Schedule 9 
 Properties 
 Irish Estates (Management) Limited 
 Lease of portion of premises at First Floor and Second Floor, Ulysses House, 22 - 23 Foley Street, Dublin 1 together with 1 car space 
 Vector Workplace and Facility Management Limited 
 Lease of part
of First Floor, Novum Facility, Clonshaugh Industrial Estate, Dublin 17 
 Premier Management Company (Dublin) Limited 
 Occupies portion of premises at first and second floor, Ulysses House, 22-23 Foley Street, Dublin 1 
 Glenrye Properties Services Limited 
 Lease of First Floor of the building comprising 66, 66a and 67 Park
Street, Dundalk 
 Occupies space in Heather House 
 Veris UK Limited 
 No physical presence 
 Irish Estates (Facilities Management) Limited 
 Occupies part of First Floor, Novum Facility, Clonshaugh Industrial Estate, Dublin 17

 Spokesoft Technologies Limited 
 Licence at
National Software Centre, Cork 
 Veris Property Management Limited 
 Occupies part of premises at Building C, Principle House, Fleet Road, Fleet, Hampshire 
 Orange Support Services
Limited 
 Occupies part of premises at Building C, Principle House, Fleet Road, Fleet, Hampshire 
 Orange Environmental Building Services Limited 
 Lease of
Building C, Principle House, 121-123 Fleet Road, Fleet Hampshire. 
 Lease of Unit A, 6 Elms Road, Adlershot, Hampshire, GU11 1LJ. 
 Vector Environmental Services Limited 
 Lease of Unit 5A CIDO
Business Complex, Carn Industrial Area, Craigavon, Co. Armagh. 
  

 115 

 Schedule 10 
 Anglo Other Charges 
  

	1.	Composite Debenture dated 22 December 2004 made between the Bank, Boundary Outsourced Services Limited, Irish Estates (Management) Limited, Vector Workplace and Facility
Management Limited and Irish Estates (Facilities Management) Limited; 

  

	2.	Composite Debenture dated 1 December 2006 made between the Bank, Veris plc, Glenrye Properties Services Limited and Premier Management Company (Dublin) Limited;

  

	3.	Composite Debenture dated 11 July 2006 made between the Bank, A.G. Doree (Ireland) Limited, Bond Business Support Limited, Hire A Crate Limited, Nat Ross Limited, Oman
Transport Limited and the Seller; 

  

	4.	Guarantee and Indemnity dated 22 December 2004 made between the Bank, Boundary Outsourced Services Limited, Irish Estates (Management) Limited, Vector Workplace and Facility
Management Limited and Irish Estates (Facilities Management) Limited, as guarantors 

  

	5.	Guarantee and Indemnity dated 11 July 2006 made between, inter alios, the Bank and , Irish Estates plc and Vector Workplace and Facility Management Limited, as guarantors;

  

	6.	Guarantee and Indemnity dated 1 December 2006 made between the Bank and the Seller, Glenrye Properties Services Limited and Premier Management Company (Dublin) Limited, as
guarantors; 

  

	7.	Guarantee and Indemnity dated 11 January 2007 made between, inter alios, the Bank and Glenrye Properties Services Limited, Irish Estates (Facilities Management) Limited,
Irish Estates (Management) Limited, Premier Management Company (Dublin) Limited, the Seller, and Vector Workplace and Facility Management Limited, as guarantors; 

  

	8.	Guarantee and Indemnity dated 29 November 2007 made between the Bank and the Seller and VUKL, as guarantors; 

  

	9.	Deed of Accession dated 21 December 2007 supplemental to a Guarantee and Indemnity dated 21 December 2007 made between the Bank and the Seller, VUKL, as existing
guarantors, and Orange Environmental Building Services Limited, Orange Support Services Limited and Orange Fabric Services Limited (now known as Veris Property Management Limited), as acceding guarantors; 

  

	10.	Charge on Account dated 22 December 2004 made between the Bank and Vector Workplace and Facility Management Limited in respect of the account held by Vector Workplace and
Facility Management Limited with the Bank having account number 1403/216084/01; 

  

	11.	Debenture dated 29 November 2007 made between the Bank and Veris UK Limited; 

  

	12.	Debenture dated 21 December 2007 made between the Bank and Orange Fabric Services Limited (now known as Veris Property Management Limited); 

  

	13.	Debenture dated 21 December 2007 made between the Bank and Orange Support Services Limited; 

  

	14.	Debenture dated 21 December 2007 made between the Bank and Orange Environmental Building Services Limited; 

  

 116 

	15.	Deed of Confirmation between the Seller and the Bank dated 29 November 2007; 

  

	16.	Counter-Indemnity from VUKL to the Bank dated 29 November 2007; and 

  

	17.	Counter-Indemnity from the Seller to the Bank dated 29 November 2007. 

  

 117 

 Schedule 11 
 Guarantees 
  

	1.	Performance Bond Guarantee provided by the Seller in respect of work carried out under an agreement entered into between VWFM and Arup Consulting Engineers on 13 September
2008. 

  

	2.	Performance Bond Guarantee provided by the Seller in respect of a tender given by VWFM to Arup Consulting Engineers regarding the mechanical and electrical maintaining of the
motor tax office in Cork. Guarantee will commence on the date that the tender is awarded to VWFM. 

  

 118 

 Annexure A 
 Resolution 
 Ordinary Resolution 
 “That the transaction comprising the disposal of the Business as described in the circular to Shareholders dated — October 2009 is hereby approved for the purposes of Rule 15 of the AIM Rules for Companies as issued by the London Stock Exchange plc and for
the purposes of Rule 15 of the IEX Rules for Companies as issued by the Irish Stock Exchange and that the Board of the Company is hereby empowered to do all such acts and take all such steps as are required to give effect to the Proposed
Disposal”. 
 it being understood that the “transaction comprising the disposal of the Business as described in the circular to
Shareholders dated — October 2009” and “the Proposed
Disposal” refers to the Transaction. 
  

 119 

 In witness whereof the parties hereto have executed this Agreement on the date written at the head of this
Agreement. 
  

 120 

									
	SIGNED	 		 		 		 	
	 For and on behalf of
 VERIS
PLC
	 		 		 		 	
	in the presence of:	 		 		 		 	
					
	Witness signature:	 	  
	 		 	  
	 	
		 		 		 	Authorised signatory	 	
	Witness address:	 	  
	 		 		 	
					
		 	  
	 		 		 	
					
	Witness occupation:	 	  
	 		 		 	

  

 121 

									
	SIGNED	 		 		 		 	
	 For and on behalf of
 ARAMARK IRELAND HOLDINGS
	 		 		 	
	in the presence of:	 		 		 		 	
		 		 		 		 	
					
	Witness signature:	 	  
	 		 	  
	 	
		 		 		 	Authorised signatory	 	
	Witness address:	 	  
	 		 		 	
					
		 	  
	 		 		 	
					
	Witness occupation:	 	  
	 		 		 	
				
	 SIGNED
 For and on behalf of

 ARAMARK INVESTMENTS LIMITED
 in the presence of:

	 		 		 	
					
	Witness signature:	 	  
	 		 	  
	 	
		 		 		 	Authorised signatory	 	
	Witness address:	 	  
	 		 		 	
					
		 	  
	 		 		 	
					
	Witness occupation:	 	  
	 		 		 	
				
	 SIGNED
 For and on behalf of

 ARAMARK CORPORATION
 in the presence
of:
	 		 		 	
					
	Witness signature:	 	  
	 		 	  
	 	
		 		 		 	Authorised signatory	 	
	Witness address:	 	  
	 		 		 	
					
		 	  
	 		 		 	
					
	Witness occupation:	 	  
	 		 		 	

  

 122 

									
	SIGNED by	 		 		 		 	
	 Niall McFadden
 in the presence
of:
	 		 		 	
					
	 Witness signature:
	 	  
	 		 	  
	 	
		 		 		 	Signature	 	
					
	 Witness address:
	 	  
	 		 		 	
					
		 	  
	 		 		 	
					
	 Witness occupation:
	 	  
	 		 		 	

  

 123 

									
	SIGNED by	 		 		 		 	
	 Martin McMahon
 in the presence
of:
	 		 		 		 	
					
	 Witness signature:
	 	  
	 		 	  
	 	
		 		 		 	Signature	 	
					
	 Witness address:
	 	  
	 		 		 	
					
		 	  
	 		 		 	
					
	 Witness occupation:
	 	  
	 		 		 	

  

 124

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]